Antibody-multidrug conjugate

Abstract

Provided is a more useful antitumor drug that is the result of further advancing conventional antibody-drug conjugates. An antibody-multidrug conjugate represented by general formula (I): [in the formula, the symbols have the meanings set forth in the description of the present application] or a pharmacologically acceptable salt thereof.

Description

Antibody / multi-drug conjugate The present invention describes a novel "antibody-multidrug conjugate" useful as an antitumor drug, in which an "antibody" that can target tumor cells and "multiple antitumor drugs" are linked via a linker. -Drugs Conjugate; AMDC). Antibody Drug Conjugate (ADC) is a drug that binds a cytotoxic drug (payload) to an antibody that binds to an antigen that is expressed on the surface of cancer cells and can be internalized into the cell. It can be expected to selectively deliver drugs to cells, release and accumulate drugs within cancer cells, and kill cancer cells (Non-Patent Documents 1 to 3). As an ADC, for example, Adcetris (brentuximab vedotin) (Patent Document 1), which is an anti-CD30 antibody conjugated with monomethyl auristatin E, is a therapeutic drug for Hodgkin's lymphoma and anaplastic large cell lymphoma, which is an anti-HER2 antibody conjugated with emtansine. Kadcyla (trastuzumab emtansine) is used as a therapeutic drug for HER2-positive metastatic breast cancer, and Enhertu (trastuzumab deruxtecan), which is a combination of anti-HER2 antibody and deruxtecan, is used as a therapeutic drug for HER2-positive metastatic breast cancer (Patent Document 2). Trodelvy (sacituzumab govitecan), which is an anti-TROP-2 antibody conjugated to SN-38, is used as a treatment for TROP-2-positive metastatic breast cancer, and Blenrep (belantamab mafodotin), which is an anti-CD269 (BCMA) antibody conjugated to MMAF, is a treatment for TROP-2-positive metastatic breast cancer. As a therapeutic drug for multiple myeloma, Tivdak (tisotumab vedotin), which is an anti-CD142 antibody conjugated with monomethyl auristatin E, is used as a therapeutic drug for metastatic cervical cancer, and a pyrrolobenzodiazepine dimer is combined with an anti-CD19 antibody. Conjugated Zynlonta (loncastuximab tesirin) has been approved as a treatment for B-cell lymphoma (Non-patent Documents 4 to 10), and many other new ADCs are under clinical development as anti-tumor drugs (Non-Patent Documents 4-10). Patent Documents 11 to 14). On the other hand, almost all effective cancer chemotherapy is designed to overcome differences in drug sensitivity within heterogeneous tumor cell populations, and treatment with combinations of multiple drugs is widely practiced (non-patent Reference 15). This strategy has also been applied to ADCs, and clinical trials are currently being conducted combining ADCs with approved unconjugated anticancer drugs (Non-Patent Document 16). Based on these facts, if multiple anti-tumor drugs with different mechanisms of action are linked to a single antibody via a linker in an ADC, qualitatively superior drug efficacy will be exhibited, resulting in a more useful anti-tumor drug. It is expected that this will happen. Furthermore, when multiple antitumor compounds having the same mechanism of action are linked to one antibody via a linker, it is expected that the compound will exhibit stronger efficacy and become a more useful antitumor drug. WO2003 / 043583 JP2016-196484 WO2022 / 022649CN113941007WO2021 / 148500WO2021 / 209007WO2021 / 212638WO2022 / 199429 Bioconjugate Chem. , 2010, 21, 5-13 Current Open. Chem. Biol. , 2010, 14, 529-537 Expert Opin. Biol. Ther. , 2004, 4, 1445-1452Biotechnol Lett. , 2016, 38, 1655-1664. Chem Pharm Bull. , 2019, 67, 173-185. N Engl J Med. , 2012, 367, 1783-1791 Expert Opin. Biol. Ther. , 2020, 8, 871-875 Drugs Today, 2021, 57, 653-663 Drugs, 2021, 81, 2141-2147 Drugs, 2021, 81, 1229-1233 Clin Cancer Res. , 2019, 25, 5441-5448. Molecules. 2020, 25, 4764 Methods Mol Biol. , 2020, 2078, 1-22 Nat. Rev. Drug Discov. , 2017, 16, 315 Nat. Biotechnol. , 2015, 33, 733-736N Engl J Med. , 2018, 378, 331-344. Bioconjugate Chem. 2016, 27, 1030-1039Org. Biomol. Chem. 2016, 14, 6165-6178 Nat. Commun. 2015, 6, 6645 Angew. Chem. Int. Ed. , 2017, 56, 733-737Bioorg. Med. Chem. Lett. , 2018, 28, 3617-3621 Data in Brief, 2018, 21, 2208-2220 Antib. Ther. 2019 Oct; 2 (4): 71-78 Nat. Commun. 2018, 9, 2512 The present invention provides an ADC having a linker modified with at least one modifying group such as a lactonyl group and a phosphoryl group and connected to two or more drugs. The present inventors conducted extensive studies to develop a useful antitumor drug. As a result, the antibody and multiple anti-tumor drugs are linked via a branched (e.g., biantennary or Y-shaped) linker, where the linker or the anti-tumor drug has a lactonyl group and a phosphoryl group. We have devised and successfully synthesized an Antibody multi-drug conjugate (AMDC), which is characterized by the fact that It was revealed that the drug showed high stability in the blood. Furthermore, the present invention was completed by confirming that the AMDC is effective in in vitro and in vivo tests and exhibits antitumor effects. That is, in the antibody / multiple drug conjugate of the present invention, the linker extending from the antibody branches in two directions to form a Y-shape, and the first antitumor drug is bound to the end of one branched linker. , a second anti-tumor drug is attached to the end of the other branched linker, and either the Y-shaped linker or the anti-tumor drug has a lactonyl group and / or a phosphoryl group (preferably both). . AMDCs in which multiple drugs are bound to one antibody via linkers are disclosed in Patent Documents 3 to 8 and Non-Patent Documents 17 to 24, some of which have Y-shaped linkers (Patent Document 3 ), but none have both a lactonyl group and a phosphoryl group in the linker or antitumor drug. The present invention provides the following [1] to

[24] . [1] The following general formula (I): [In the formula, A is an antibody residue obtained by removing the sulfhydryl group or amino group present in the antibody (for example, an antibody that can target tumor cells), B is -S- or -NH- derived from the sulfhydryl group or amino group present in the antibody, G is the formula or It is a group represented by, and in these formulas, R is a hydrogen atom, hydroxyl group, amino group, alkyl group, or alkyloxy group, Cy is a cycloalkyl ring, cycloalkenyl ring, aryl ring, heteroaryl ring, or heterocyclyl ring, a is an integer from 1 to 10, D １ and D ２ is a residue obtained by removing one hydrogen atom or one hydroxyl group from any position of an antitumor drug molecule, its analog, or its derivative, and they may be the same or different. It's okay, L １ is G and D １ It is a linker that connects L ２ is G and D ２ It is a linker that connects L ３ is a linker that connects G and B, L １ , L ２ , and L ３ may be the same or different, D １ ,D ２ , L １ , L ２ , and L ３ At least one of them has one or more phosphoryl groups (-P(=O)(OH)) as a substituent or protecting group. ２ ), The total number of the phosphoryl groups is 1 to 10, L １ , L ２ , and L ３ At least one of them has one or more lactonyl groups as a substituent, The total number of the lactonyl groups is 1 to 10, and when the total number is 2 or more, the lactonyl groups may be the same or different. An antibody / multi-drug conjugate (hereinafter also referred to as antibody / multi-drug conjugate (I) or conjugate of the present invention) represented by the above, or a pharmacologically acceptable salt thereof. [2] A is an antibody residue derived from an antibody having one or more properties selected from the following: a property capable of binding to a target cell, a property capable of being internalized by a target cell, and a property capable of damaging a target cell; [1] or a pharmacologically acceptable salt thereof. [3] A is an antibody residue obtained by removing a sulfhydryl group or an amino group present in an antibody that can target tumor cells, and the sulfhydryl group is a sulfhydryl group generated by a reduction reaction of a disulfide bond in the antibody. The antibody / multi-drug conjugate according to [1] or [2], or a pharmacologically acceptable salt thereof. [4] A is anti-HER2 antibody, anti-EGFR antibody, anti-Lymphocyte Antigen 6E (Ly-6E) antibody, anti-Hepatocyte Growth Factor Receptor (HGFR) antibody, anti-CD22 antibody, anti-Folate Rec. ptor alpha (FRα) antibody, anti-PSMA (FOLH1) Antibodies, anti-CD30 (TNFRSF8) antibodies, anti-TROP-2 antibodies, anti-CD19 antibodies, anti-5T4 antibodies, anti-Mesothelin antibodies, anti-CD20 antibodies, anti-CD33 antibodies, anti-CDB7-H3 antibodies, anti-CD269 (BCMA) antibodies, anti-CD142 Antibodies, anti-CD70 antibodies, anti-CD123 antibodies, anti-TAG-72 antibodies, anti-TFRC antibodies, anti-EPHA2 antibodies, anti-c-KIT antibodies, anti-PD-L1 antibodies, anti-Epithelial Cell Adhesion Molecule (EPCAM) antibodies, anti-AXL antibodies, Anti-Interleukin-1 Receptor Accessory Protein antibody, anti-Mucin-16 (CA125) antibody, anti-MUC1 antibody, anti-GPC3 antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-Sodium -Dependent Phosphate Transport Protein 2B ( SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-TweakR antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-CD147 antibody, anti-Sialyl-Tn antibody, anti-GCC antibody, anti-HER3 antibody, Anti-Integrin antibody, anti-EGFR variant III antibody, anti-Claudin 6 antibody, anti-Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 antibody, anti- PTK7 antibody, anti-LYPD3 antibody, anti-ASCT2 antibody, anti-ASPH antibody, anti-GPC1 antibody, Anti-CD174 antibody, anti-CD38 antibody, anti-ANGPT2 antibody, anti-CD44 antibody, anti-DDL3 antibody, anti-FGFR2 antibody, anti-KAAG1 antibody, anti-CD73 antibody, anti-CLDN18.2 antibody, anti-PRLR antibody, anti-SEZ6 antibody, anti-Neprilysin antibody, Anti-Neural Cell Adhesion Molecule 1 antibody, anti-CD166 (ALCAM) antibody, anti-CD24 antibody, anti-CD27 antibody, anti-CDH3 antibody, anti-EPHA4 antibody, anti-FGFR3 antibody, anti-GFRAL antibody, anti-Globo H antibody, anti-IL-13R a2 antibody, Anti-STEAP-1 antibody, anti-TMCC3 antibody, anti-CD209 antibody, anti-CD37, anti-CD48 antibody, anti-CDCP1 antibody, anti-CD46 antibody, anti-CD200 antibody, anti-CTLA4 antibody, anti-CXCR5 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) Antibodies, anti-CLDN6 / 9 antibody, anti-CEACAM6 antibody, anti-CA9 antibody, anti-EDNRB antibody, anti-GD3 Ganglioside antibody, anti-MICA / B antibody, anti-JAG1 / 2 antibody, anti-TM4SF1 antibody, anti-uPAR antibody, anti-Carbonic anhydrase IX antibody , anti-ALK1 antibody, anti-IGF-1R antibody, anti-KDR antibody, anti-CEACAM8 antibody, anti-IL5R antibody, anti-CD205 (Ly75) antibody, anti-MSR1 antibody, anti-KREMEN2 antibody, anti-SSEA-4 antibody, anti-CD228 antibody, anti-CD5 Antibodies, anti-DLL4 antibodies, anti-FAP antibodies, anti-Notch3 antibodies, anti-AG7 antibodies, anti-Guanylate Cyclases antibodies, anti-Nectin-4 antibodies, anti-CD226 (DNAM-1) antibodies, anti-FcRL5 antibodies, anti-HLA-DR antibodies, anti-ITGB3 Antibodies, anti-DLK1 antibodies, anti-CD157 (BST1) antibodies, anti-CD56 (NCAM1) antibodies, anti-MICA (MHC class I Polypeptide-Related Sequence A) antibodies, anti-SSEA-1 antibodies, anti-TRAIL-R2 (DR 5) Antibody, anti GPNMB antibody, anti-CCR5 antibody, anti-LAMP1 antibody, anti-LGALS3BP antibody, anti-ROR2 antibody, anti-DLL3 antibody, anti-ETBR antibody, anti-LIV-1 antibody, anti-Integrin αvβ6 antibody, anti-TIM-1 antibody, anti-AGS-16 (ENPP3 ) Antibody, anti-SLITRK6 antibody, anti-GD2 antibody, anti-CD52 antibody, anti-CCR4 antibody, anti-VEGFR2 antibody, anti-PDGFR antibody, anti-FGFR antibody, anti-SLAMF7 antibody, anti-GD2 Ganglioside antibody, anti-EPHA3 antibody, anti-Integrin αvβ3 antibody, anti- AGS-5 antibody, anti-CA19-9 antibody, anti-PSA antibody, anti-MAGE3 antibody, anti-Transferrin receptor 1 (CD71) antibody, or anti-CEACAM1 antibody, anti-SLC3A2 (CD98) antibody, anti-ACVR1 antibody, anti-AG-7 antibody, Anti-AMHR2 antibody, anti-ABCB1 antibody, anti-C16orf54 antibody, anti-CathepsinD antibody, anti-CCR7 antibody, anti-SLC44A4 antibody, anti-CD300LF antibody, anti-DPEP3 antibody, anti-FucGM1 antibody, anti-GPR20 antibody, anti-ITGB6 antibody, anti-Lewis-A-like Carbohydrate antibody, anti-prolactin receptor antibody, anti-Sialyl Tn antibody, anti-SLAMF6 antibody, anti-SLAMF7 antibody, anti-TRA-1-60 antibody, anti-matriptase antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-Can Ag antibody , the antibody / multiple drug according to any one of [1] to [3], which is an antibody residue derived from an anti-A33 antibody, an anti-α10β1 integrin antibody, an anti-ALPP antibody, an anti-CD248 antibody, or an anti-GPRC5D antibody. Conjugate, or a pharmacologically acceptable salt thereof. [5] A is anti-HER2 antibody, anti-EGFR antibody, anti-Lymphocyte Antigen 6E (Ly-6E) antibody, anti-Hepatocyte Growth Factor Receptor (HGFR) antibody, anti-CD22 antibody, anti-Folate Rec. ptor alpha (FRα) antibody, anti-PSMA (FOLH1) Antibodies, anti-CD30 (TNFRSF8) antibodies, anti-TROP-2 antibodies, anti-CD19 antibodies, anti-5T4 antibodies, anti-Mesothelin antibodies, anti-CD20 antibodies, anti-CD269 (BCMA) antibodies, anti-CD142 antibodies, anti-CD123 antibodies, anti-TAG-72 Antibodies, anti-TFRC antibodies, anti-c-KIT antibodies, anti-Epithelial Cell Adhesion Molecule (EPCAM) antibodies, anti-AXL antibodies, anti-Mucin-16 (CA125) antibodies, anti-CLEC12A (CLL1) antibodies, anti-LRRC15 antibodies, anti-ADAM9 antibodies, Anti-Sodium-Dependent Phosphate Transport Protein 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-HER3 antibody , anti-EGFR variant III antibody, anti-PTK7 antibody , anti-GPC1 antibody, anti-CD38 antibody, anti-DDL3 antibody, anti-SEZ6 antibody, anti-CD166 (ALCAM) antibody, anti-CDH3 antibody, anti-FGFR3 antibody, anti-Globo H antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CD46 antibody, anti- FLT3 antibody, anti-SDC1 (CD138) antibody, anti-TM4SF1 antibody, anti-IGF-1R antibody, anti-CEACAM8 antibody, anti-CD205 (Ly75) antibody, anti-CD228 antibody, anti-FAP antibody, anti-AG7 antibody, anti-Nectin-4 antibody, anti- CD226 (DNAM-1) antibody, anti-HLA-DR antibody, anti-DLK1 antibody, anti-CD157 (BST1) antibody, anti-CD56 (NCAM1) antibody, anti-CCR5 antibody, anti-ROR2 antibody, anti-LIV-1 antibody, anti-TIM-1 antibody, anti-CA19-9 antibody, or anti-CEACAM1 antibody, anti-SLC3A2 (CD98) antibody, anti-ACVR1 antibody, anti-AG-7 antibody, anti-AMHR2 antibody, anti-ABCB1 antibody, anti-C16orf54 antibody, anti-CathepsinD antibody, anti-CCR7 antibody, Anti-SLC44A4 antibody, anti-CD300LF antibody, anti-DPEP3 antibody, anti-FucGM1 antibody, anti-GPR20 antibody, anti-ITGB6 antibody, anti-Lewis-A-like carbohydrate antibody, anti-prolactin receptor antibody, anti-Sialyl Tn antibody, anti- SLAMF6 antibody, anti-SLAMF7 antibody , derived from anti-TRA-1-60 antibody, anti-matriptase antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-CanAg antibody, anti-α10β1 integrin antibody, anti-ALPP antibody, anti-CD248 antibody, or anti-GPRC5D antibody The antibody / multi-drug conjugate according to any one of [1] to [4], or a pharmacologically acceptable salt thereof, which is an antibody residue that acts as an antibody residue. [6] A is anti-HER2 antibody, anti-EGFR antibody, anti-Lymphocyte Antigen 6E (Ly-6E) antibody, anti-CD22 antibody, anti-Folate Receptor alpha (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody , anti TROP-2 antibody, anti-CD19 antibody, anti-Mesothelin antibody, anti-CD20 antibody, anti-CD269 (BCMA) antibody, anti-CD123 antibody, anti-TFRC antibody, anti-c-KIT antibody, anti-Epithelial Cell Adhesion Molecule (EPCAM) antibody, anti-AXL Antibody, anti-Mucin-16 (CA125) antibody, anti-Sodium-Dependent Phosphate Transport Protein 2B (SLC34A2) antibody, anti-CD25 antibody, anti-CEACAM5 antibody, anti-CD79b antibody, anti-HER3 antibody, anti-P TK7 antibody, anti-CD38 antibody, anti-CD37 Antibodies, anti-FLT3 antibodies, anti-IGF-1R antibodies, anti-FAP antibodies, anti-Nectin-4 antibodies, or anti-CD56 (NCAM1) antibodies, anti-AG-7 antibodies, anti-CCR7 antibodies, anti-DPEP3 antibodies, anti-ITGB6 antibodies, anti-matriptase The antibody / multi-drug conjugate according to any one of [1] to [5], which is an antibody residue derived from an antibody, an anti-Cripto antibody, an anti-ALPP antibody, or an anti-GPRC5D antibody, or a pharmacologically acceptable one thereof. salt. [7] The antibody / multi-drug conjugate according to any one of [1] to [6], or a pharmacologically acceptable salt thereof, wherein a is an integer of 1 to 8. [8] The antibody / multi-drug conjugate according to any one of [1] to [7], or a pharmacologically acceptable salt thereof, wherein a is an integer of 1 to 7. [9] The antibody / multi-drug conjugate according to any one of [1] to [8], wherein G is a group represented by formula (i), formula (ii), or formula (iii), or the Pharmacologically acceptable salts.

[10] The antibody / multi-drug conjugate according to any one of [1] to [9], or a pharmacologically acceptable salt thereof, wherein G is a group represented by formula (i).

[11] D １ and D ２ but camptothecin; MMAE; maytansine; PBD (parabenzodiazepine) dimer; eribulin; 5-fluorouracil (5-FU); 5-bromo-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2 -[(2-fluoro-4-iodophenyl)amino]-benzamide (PD-318088); Pimasertib (AS-703026); 3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5- (2-Fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione (TAK-733); Samotrisib (LY-3023414); Calicheamicin; Paclitaxel; Docetaxel; Mitomycin C ; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; dolastatin 10; superdox; ciprofloxacin; cardofloxacin (CS-940); or analogs or derivatives thereof; or derivatives of the above analogs. residues of an anti-tumor drug molecule independently selected from the group; The antibody / multi-drug conjugate according to any one of [1] to

[10] , or a pharmacologically acceptable salt thereof.

[12] D １ and D ２ However, camptothecin; MMAE; maytansine; PBD (parabenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; or an analog or derivative thereof; or a residue of an anti-tumor drug molecule independently selected from the group consisting of: bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; dolastatin 10; superdox; or an analog or derivative thereof; is, The antibody / multi-drug conjugate according to any one of [1] to

[11] , or a pharmacologically acceptable salt thereof.

[13] D １ and D ２ or the remainder of an anti-tumor drug molecule independently selected from the group consisting of: camptothecin; MMAE; maytansine; PBD (parabenzodiazepine) dimer; eribulin; or an analog or derivative thereof; is the basis, The antibody / multi-drug conjugate according to any one of [1] to

[12] , or a pharmacologically acceptable salt thereof.

[14] D １ and D ２ are residues of the same anti-tumor drug or an analog or derivative of those anti-tumor drugs; or a derivative of said analog; The antibody / multi-drug conjugate according to any one of [1] to

[13] , or a pharmacologically acceptable salt thereof.

[15] D １ and D ２ is a residue of a different anti-tumor drug or an analog or derivative of these anti-tumor drugs; or a derivative of said analog; The antibody / multi-drug conjugate according to any one of [1] to

[13] , or a pharmacologically acceptable salt thereof.

[16] D １ ,D ２ , L １ , L ２ , and L ３ At least one of them has one or more phosphoryl groups (-P(=O)(OH)) as a substituent or protecting group. ２ ), The total number of the phosphoryl groups is 1 to 4, L １ , L ２ , and L ３ At least one of them has one or more lactonyl groups as a substituent, The total number of lactonyl groups is 1 to 8, If the total number is 2 or more, the lactonyl groups may be the same or different, The antibody / multi-drug conjugate according to any one of [1] to

[15] , or a pharmacologically acceptable salt thereof.

[17] L １ , L ２ , and L ３ are each independently an optionally substituted alkylene group; One or more methylene groups in the chain of the alkylene group, -C(R １ )(R ２ )-;-O-;-N(R ３ )-;-N(R ３ )-N(R ３ )-;-S-;-Se-;-Si(R ４ )(R ５ )-;-S-S-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R ６ )(R ７ ))-;-C(=O)-;-C(=S)-;-C(=N(R ８ ))-;-C(=N-OR ９ )-;-C(=N-N(R １０ )(R １１ ))-;-P(=O)(R １２ )-;-P(=O)(OR １３ )-;-O-P(=O)(R １２ )-O-;-O-P(=O)(OR １３ )-O-;-C(R １４ )=;=C(R １４ )-;-C(R １４ )=C(R １４ )−;−N=;=N−;−C≡C−;−(O−C(R １ )(R ２ )-C(R １ )(R ２ )) １−３０ -;-(C(R １ )(R ２ )-C(R １ )(R ２ )−0) １−３０ -; optionally substituted alkenylene group; optionally substituted alkynylene group; optionally substituted cycloalkylene group; optionally substituted cycloalkenylene group; optionally substituted arylene group; and optionally substituted heteroarylene groups; and one or more divalent groups independently selected from the group consisting of optionally substituted heterocyclylene groups; R １ ,R ２ ,R ３ ,R ４ ,R ５ ,R ６ ,R ７ ,R ８ ,R ９ ,R １０ ,R １１ ,R １２ ,R １３ , and R １４ each independently represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, and an optionally substituted cycloalkyl group. a group selected from the group consisting of an optionally substituted cycloalkenyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclyl group, and R ３ is an alkyl group, the alkyl group may form a cyclic structure together with the alkyl group in the adjacent methylene group, m and n are each independently an integer of 0 to 2, The antibody / multi-drug conjugate according to any one of [1] to

[16] , or a pharmacologically acceptable salt thereof.

[18] L １ , L ２ , and L ３ are each independently optionally substituted alkylene groups; one or more methylene groups in the chain of the alkylene group are replaced with one or more divalent groups independently selected from the following formula group, The antibody / multi-drug conjugate according to

[17] , or a pharmacologically acceptable salt thereof expression group -C(R １ )(alkyl)−; -C(R １４ )=; -O-; -N(R ３ )−; −N=; -N(R ３ )-C(R １ )(R ２ )-(wherein, R ３ , and R １ or R ２ is an alkyl group, R ３ and R １ or R ２ may form a cyclic structure together); -N(R ３ )-C(R １)(R ２ )-C(=O)-(wherein, R ３ , and R １ or R ２ is an alkyl group, R ３ and R １ or R ２ may form a cyclic structure together); -O-C(R １ )(R ２ )−; -S-C(R １ )(R ２ )−; -N(R ３ )-N(R ３ )−; -N(R ３ )-O-C(R １ )(R ２ )−; -S-; -Si(R ４ )(R ５ )−; -S-S-; -SOm-; -C(=O)-; -C(R １ )(R ２ )-C(=O)-; −C(=C(R ６ )(R ７ ))−; −C(=N(R ８ ))−; -C(=N-OR ９ )−; −C(=N−N(R １０ )(R １１ )−; −P(=O)(R １２ )− −P(=O)(R １２ )-O-; -O-P(=O)(R １２ )-O-; −P(=O)(OR １３ )-O-; −P(=O)(OR １３ )-N(R ３ )−; -O-P(=O)(OR １３ )-O-; -C(R １４ )=C(R １４ )−; -C(R １４ )=C(R １４ )-P(=O)(OR １３ )-N(R ３ )−; -C(R １４ )=N−; -C(R １４ )=N-N(R ３ )−; -C≡C-; -O-C(R １ )(R ２ )-C(R １ )(R ２ )−; -O-C(R １ )(R ２ )-C(R １ )(R ２ )-O-; -(O-C(R １ )(R ２ )-C(R １ )(R ２ )) １−３０ −; -C(=O)-O-; -C(=O)-S-; -C(=O)-N(R ３ )−; -C(=O)-N(R ３ )-O-; -C(=O)-N(R ３ )-C(R １ )(R ２ )-(wherein, R ３ , and R １ or R ２ is an alkyl group, R ３ and R １ or R ２ may form a cyclic structure together); -C(=S)-O-; -C(=S)-S-; -O-C(=O)-O-; -O-C(=O)-N(R ３ )−; -S-C(=O)-N(R ３ )−; -N(R ３ )-C(=O)-N(R ３ )−; an optionally substituted arylene group; an optionally substituted heteroarylene group; and An optionally substituted heterocyclylene group.

[19] L １ , L ２ , and L ３ are each independently optionally substituted alkylene groups; one or more methylene groups in the chain of the alkylene group are replaced with one or more divalent groups independently selected from the following formula group, The antibody / multi-drug conjugate according to

[17] or a pharmacologically acceptable salt group thereof -C(R １４ )=; -O-; -N(R ３ )−; −N=; -S-; -C(=O)-; -O-Si(CH ３ )(CH ３ )-O-; -CH ２ -C(=O)-; -C(=O)-NH-; -C(=O)-O-; -C(=O)-S-; -O-C(=O)-O-; -N(H or CH ３ )-C(=O)-O-; -NH-NH-; -N(CH ３ )-O-CH ２ −; -C(=O)-(CH ２ ) １−２０ -C(=O)-; -C(=O)-(CH ２ ) １−１０ -O-(CH ２ ) １−１０ -C(=O)-; -C(=O)-CH ２ -(O-CH ２ CH ２ ) １−２０ -O-CH ２ -C(=O)-; -(O-CH ２ CH ２ ) １−２０ −; -C(=O)-N(H or CH ３ )-CH ２ CH ２ -N(H or CH ３ )-C(=O)-; [In the formula, * is the bonding point with the adjacent group] -C(=O)-N(H or CH ３ )-CH ２ −; -P(=O)(OH)-O-; -O-P(=O)(OH)-O-; -O-P(=O)(OH)-O-P(=O)(OH)-O-; -O-P(=O)(OH)-O-P(=O)(OH)-O-P(=O)(OH)-O-; -CH(CH ２ -NH ２ )−; -CH(CH ２ -NH-C(=O)-; -CH(CH ２ -NH-C(=O)-(CH ２ CH ２ -O-) １−２０ -CH ３ )−; -CH(CH ２ -NH-C(=O)-(CH ２ ) ０−２０ -lactonyl)-; -CH(CH ２ -NH-C(=O)-(CH ２ CH ２ -O-) １−２０ -CH ２ -lactonyl)-; -CH(CH ２ -NH-C(=O)-(CH ２ ) １−２０ -phosphoryl)-; -CH(CH ２ -NH-C(=O)-(CH ２ CH ２ -O-) １−２０ -CH ２ -phosphoryl)-; -CH(CH ２ -NH-(CH ２ ) １−２０ -phosphoryl)-; -(cis)-CH=CH-P(=O)(O-CH ２ CH ３ or O-CH ２ CH ２ -OH)-NH-(phenylene)-C(=O)-; -C(=O)-(cyclohexylene)-; −(succinimidylene)−; -Gly-; -Ala-; -Val-; -Leu-; -Ile-; -Phe-; -Ser-; -Cys-; -Asp-; -Glu-; -Orn-; -Lys-; -Cit-; -Arg-; -His-; -Pro-; -GlyGly-; -PheLys-; -ValLys-; -ValCit-; -ValAla-; -AspValCit-; -GluValCit-; -LysValCit-; -SerValCit-; -AspValAla-; -GluValAla-; -LysValAla-; -SerValAla-; -GlyGlyPheGly-; -AspGlyGlyPheGly-; -GluGlyGlyPheGly-; -LysGlyGlyPheGly-; -SerGlyGlyPheGly-; -AspAspAspAspAsp-; (In the above amino acids and amino acid residues in the peptide, The side chain carboxy groups of Asp and Glu may be lactonyl esters, lactonyl alkyl esters, or phosphorylalkyl esters; they may also be unsubstituted amides, monoalkylamides, or dialkylamides. , the amino group of the amide moiety may have a lactonyl group, lactonylalkyl group, or phosphorylalkyl group as a substituent: The amino group of the side chain of Lys and Orn has a lactonyl group, a lactonylalkyl group, a lactonylcarbonyl group, a lactonylalkylcarbonyl group, a phosphoryl group, a phosphorylalkyl group, or a phosphorylalkylcarbonyl group as a substituent. Also: The hydroxyl group on the side chain of Ser and the sulfhydryl group on the side chain of Cys are substituents such as lactonyl group, lactonylalkyl group, lactonylcarbonyl group, lactonylalkylcarbonyl group, phosphoryl group, phosphorylalkyl group, or phosphorylalkylcarbonyl group. (may have a group) -N(H or CH ３ )-(optionally substituted phenylene)-CH ２ -O-C(=O)-; -O-(optionally substituted phenylene)-CH ２ -O-C(=O)-; -N(H or CH ３ )-(optionally substituted pyridylene)-CH ２ -O-C(=O)-; and [In the formula, * is the point of attachment to the adjacent group].

[20] Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 and Example 7 [In the formula, A ＨＥＲ２ is an antibody residue obtained by removing the sulfhydryl group present in the anti-HER2 antibody, and a has the same meaning as above] The antibody / multi-drug conjugate according to [1], or a pharmacologically acceptable salt thereof, selected from the group consisting of:

[21] Example 2 and Example 3 [In the formula, A ＨＥＲ２ is an antibody residue obtained by removing the sulfhydryl group present in the anti-HER2 antibody, and a has the same meaning as above] The antibody / multi-drug conjugate according to [1], or a pharmacologically acceptable salt thereof, selected from the group consisting of:

[22] Example 2 [In the formula, A ＨＥＲ２ is an antibody residue obtained by removing the sulfhydryl group present in the anti-HER2 antibody, and a has the same meaning as above] The antibody / multi-drug conjugate according to [1], or a pharmacologically acceptable salt thereof, represented by:

[23] Example 3 [In the formula, A ＨＥＲ２ is an antibody residue obtained by removing the sulfhydryl group present in the anti-HER2 antibody, and a has the same meaning as above] The antibody / multi-drug conjugate according to [1], or a pharmacologically acceptable salt thereof, represented by:

[24] A pharmaceutical composition comprising one or more antibody / multi-drug conjugate according to any one of [1] to

[23] , or a pharmacologically acceptable salt thereof.

[25] Example A. “Specific example of ADC manufactured using conjugate precursor (Example A3)” Example A1 Example A2 Example A3 Example A3b Example A3c Example A4 Example A5 Example A6 Example A7 Example A8 Example A9 Example A10 Example A11 Example A12 Example A13 Example A14 Example A15 Example A16 Example A17 Example A18 Example A19 Example A20 Example A21 Example A22 Example A23 Example A24 Aspects of the present invention will be described below. Note that the present invention also includes embodiments in which the following embodiments are arbitrarily selected and combined, and embodiments in which the following embodiments are arbitrarily combined with any of the embodiments or embodiments described in this specification. [Aspect A1] An antibody / multidrug conjugate (I), or a pharmacologically acceptable salt thereof, wherein A is an antibody residue obtained by removing a sulfhydryl group or an amino group present in an antibody capable of targeting tumor cells. . [Aspect A2] antibodies, wherein A is an antibody residue derived from an antibody having one or more properties selected from the following: a property capable of binding to a target cell, a property capable of being internalized by a target cell, and a property capable of damaging a target cell; Drug conjugate (I) or a pharmacologically acceptable salt thereof. [Aspect A3] A is an antibody residue obtained by removing a sulfhydryl group or an amino group present in an antibody capable of targeting tumor cells, and the sulfhydryl group is a sulfhydryl group generated by a reduction reaction of a disulfide bond in the antibody. ”, or a pharmacologically acceptable salt thereof. [Aspect A4] A is anti-HER2 antibody, anti-EGFR antibody, anti-Lymphocyte Antigen 6E (Ly-6E) antibody, anti-Hepatocyte Growth Factor Receptor (HGFR) antibody, anti-CD22 antibody, anti-Folate Rec. ptor alpha (FRα) antibody, anti-PSMA (FOLH1) Antibodies, anti-CD30 (TNFRSF8) antibodies, anti-TROP-2 antibodies, anti-CD19 antibodies, anti-5T4 antibodies, anti-Mesothelin antibodies, anti-CD20 antibodies, anti-CD33 antibodies, anti-CDB7-H3 antibodies, anti-CD269 (BCMA) antibodies, anti-CD142 Antibodies, anti-CD70 antibodies, anti-CD123 antibodies, anti-TAG-72 antibodies, anti-TFRC antibodies, anti-EPHA2 antibodies, anti-c-KIT antibodies, anti-PD-L1 antibodies, anti-Epithelial Cell Adhesion Molecule (EPCAM) antibodies, anti-AXL antibodies, Anti-Interleukin-1 Receptor Accessory Protein antibody, anti-Mucin-16 (CA125) antibody, anti-MUC1 antibody, anti-GPC3 antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-Sodium -Dependent Phosphate Transport Protein 2B ( SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-TweakR antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-CD147 antibody, anti-Sialyl-Tn antibody, anti-GCC antibody, anti-HER3 antibody, Anti-Integrin antibody, anti-EGFR variant III antibody, anti-Claudin 6 antibody, anti-Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 antibody, anti- PTK7 antibody, anti-LYPD3 antibody, anti-ASCT2 antibody, anti-ASPH antibody, anti-GPC1 antibody, Anti-CD174 antibody, anti-CD38 antibody, anti-ANGPT2 antibody, anti-CD44 antibody, anti-DDL3 antibody, anti-FGFR2 antibody, anti-KAAG1 antibody, anti-CD73 antibody, anti-CLDN18.2 antibody, anti-PRLR antibody, anti-SEZ6 antibody, anti-Neprilysin antibody, Anti-Neural Cell Adhesion Molecule 1 antibody, anti-CD166 (ALCAM) antibody, anti-CD24 antibody, anti-CD27 antibody, anti-CDH3 antibody, anti-EPHA4 antibody, anti-FGFR3 antibody, anti-GFRAL antibody, anti-Globo H antibody, anti-IL-13R a2 antibody, Anti-STEAP-1 antibody, anti-TMCC3 antibody, anti-CD209 antibody, anti-CD37, anti-CD48 antibody, anti-CDCP1 antibody, anti-CD46 antibody, anti-CD200 antibody, anti-CTLA4 antibody, anti-CXCR5 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) Antibodies, anti-CLDN6 / 9 antibody, anti-CEACAM6 antibody, anti-CA9 antibody, anti-EDNRB antibody, anti-GD3 Ganglioside antibody, anti-MICA / B antibody, anti-JAG1 / 2 antibody, anti-TM4SF1 antibody, anti-uPAR antibody, anti-Carbonic anhydrase IX antibody , anti-ALK1 antibody, anti-IGF-1R antibody, anti-KDR antibody, anti-CEACAM8 antibody, anti-IL5R antibody, anti-CD205 (Ly75) antibody, anti-MSR1 antibody, anti-KREMEN2 antibody, anti-SSEA-4 antibody, anti-CD228 antibody, anti-CD5 Antibodies, anti-DLL4 antibodies, anti-FAP antibodies, anti-Notch3 antibodies, anti-AG7 antibodies, anti-Guanylate Cyclases antibodies, anti-Nectin-4 antibodies, anti-CD226 (DNAM-1) antibodies, anti-FcRL5 antibodies, anti-HLA-DR antibodies, anti-ITGB3 Antibodies, anti-DLK1 antibodies, anti-CD157 (BST1) antibodies, anti-CD56 (NCAM1) antibodies, anti-MICA (MHC class I Polypeptide-Related Sequence A) antibodies, anti-SSEA-1 antibodies, anti-TRAIL-R2 (DR 5) Antibody, anti GPNMB antibody, anti-CCR5 antibody, anti-LAMP1 antibody, anti-LGALS3BP antibody, anti-ROR2 antibody, anti-DLL3 antibody, anti-ETBR antibody, anti-LIV-1 antibody, anti-Integrin αvβ6 antibody, anti-TIM-1 antibody, anti-AGS-16 (ENPP3 ) Antibody, anti-SLITRK6 antibody, anti-GD2 antibody, anti-CD52 antibody, anti-CCR4 antibody, anti-VEGFR2 antibody, anti-PDGFR antibody, anti-FGFR antibody, anti-SLAMF7 antibody, anti-GD2 Ganglioside antibody, anti-EPHA3 antibody, anti-Integrin αvβ3 antibody, anti- AGS-5 antibody, anti-CA19-9 antibody, anti-PSA antibody, anti-MAGE3 antibody, anti-Transferrin receptor 1 (CD71) antibody, anti-CEACAM1 antibody, anti-SLC3A2 (CD98) antibody, anti-ACVR1 antibody, anti-AG-7 antibody, anti- AMHR2 antibody, anti-ABCB1 antibody, anti-C16orf54 antibody, anti-CathepsinD antibody, anti-CCR7 antibody, anti-SLC44A4 antibody, anti-CD300LF antibody, anti-DPEP3 antibody, anti-FucGM1 antibody, anti-GPR20 antibody, anti-ITGB6 antibody, anti-Lewis-A-like carboh ydrate Antibodies, anti-prolactin receptor antibodies, anti-Sialyl Tn antibodies, anti-SLAMF6 antibodies, anti-SLAMF7 antibodies, anti-TRA-1-60 antibodies, anti-matriptase antibodies, anti-B7-H4 antibodies, anti-Cripto antibodies, anti-CD99 antibodies, anti-CanAg antibodies, An antibody / multi-drug conjugate (I), which is an antibody residue derived from an anti-A33 antibody, an anti-α10β1 integrin antibody, an anti-ALPP antibody, an anti-CD248 antibody, or an anti-GPRC5D antibody, or a pharmacologically acceptable salt thereof. [Aspect A5] A is anti-HER2 antibody, anti-EGFR antibody, anti-Lymphocyte Antigen 6E (Ly-6E) antibody, anti-Hepatocyte Growth Factor Receptor (HGFR) antibody, anti-CD22 antibody, anti-Folate Rec. ptor alpha (FRα) antibody, anti-PSMA (FOLH1) Antibodies, anti-CD30 (TNFRSF8) antibodies, anti-TROP-2 antibodies, anti-CD19 antibodies, anti-5T4 antibodies, anti-Mesothelin antibodies, anti-CD20 antibodies, anti-CD269 (BCMA) antibodies, anti-CD142 antibodies, anti-CD123 antibodies, anti-TAG-72 Antibodies, anti-TFRC antibodies, anti-c-KIT antibodies, anti-Epithelial Cell Adhesion Molecule (EPCAM) antibodies, anti-AXL antibodies, anti-Mucin-16 (CA125) antibodies, anti-CLEC12A (CLL1) antibodies, anti-LRRC15 antibodies, anti-ADAM9 antibodies, Anti-Sodium-Dependent Phosphate Transport Protein 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-HER3 antibody , anti-EGFR variant III antibody, anti-PTK7 antibody , anti-GPC1 antibody, anti-CD38 antibody, anti-DDL3 antibody, anti-SEZ6 antibody, anti-CD166 (ALCAM) antibody, anti-CDH3 antibody, anti-FGFR3 antibody, anti-Globo H antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CD46 antibody, anti- FLT3 antibody, anti-SDC1 (CD138) antibody, anti-TM4SF1 antibody, anti-IGF-1R antibody, anti-CEACAM8 antibody, anti-CD205 (Ly75) antibody, anti-CD228 antibody, anti-FAP antibody, anti-AG7 antibody, anti-Nectin-4 antibody, anti- CD226 (DNAM-1) antibody, anti-HLA-DR antibody, anti-DLK1 antibody, anti-CD157 (BST1) antibody, anti-CD56 (NCAM1) antibody, anti-CCR5 antibody, anti-ROR2 antibody, anti-LIV-1 antibody, anti-TIM-1 Antibodies, anti-CA19-9 antibodies, anti-CEACAM1 antibodies, anti-SLC3A2 (CD98) antibodies, anti-ACVR1 antibodies, anti-AG-7 antibodies, anti-AMHR2 antibodies, anti-ABCB1 antibodies, anti-C16orf54 antibodies, anti-CathepsinD antibodies, anti-CCR7 antibodies, anti- SLC44A4 antibody, anti-CD300LF antibody, anti-DPEP3 antibody, anti-FucGM1 antibody, anti-GPR20 antibody, anti-ITGB6 antibody, anti-Lewis-A-like carbohydrate antibody, anti-prolactin receptor antibody, anti-Sialyl Tn antibody, anti-S LAMF6 antibody, anti-SLAMF7 antibody, Derived from anti-TRA-1-60 antibody, anti-matriptase antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-CanAg antibody, anti-α10β1 integrin antibody, anti-ALPP antibody, anti-CD248 antibody, or anti-GPRC5D antibody Antibody / multi-drug conjugate (I), which is an antibody residue, or a pharmacologically acceptable salt thereof. [Aspect A6] A is anti-HER2 antibody, anti-EGFR antibody, anti-Lymphocyte Antigen 6E (Ly-6E) antibody, anti-CD22 antibody, anti-Folate Receptor alpha (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody , anti TROP-2 antibody, anti-CD19 antibody, anti-Mesothelin antibody, anti-CD20 antibody, anti-CD269 (BCMA) antibody, anti-CD123 antibody, anti-TFRC antibody, anti-c-KIT antibody, anti-Epithelial Cell Adhesion Molecule (EPCAM) antibody, anti-AXL Antibody, anti-Mucin-16 (CA125) antibody, anti-Sodium-Dependent Phosphate Transport Protein 2B (SLC34A2) antibody, anti-CD25 antibody, anti-CEACAM5 antibody, anti-CD79b antibody, anti-HER3 antibody, anti-P TK7 antibody, anti-CD38 antibody, anti-CD37 Antibodies, anti-FLT3 antibodies, anti-IGF-1R antibodies, anti-FAP antibodies, anti-Nectin-4 antibodies, or anti-CD56 (NCAM1) antibodies, anti-AG-7 antibodies, anti-CCR7 antibodies, anti-DPEP3 antibodies, anti-ITGB6 antibodies, anti-matriptase An antibody / multidrug conjugate (I), which is an antibody residue derived from an antibody, an anti-Cripto antibody, an anti-ALPP antibody, or an anti-GPRC5D antibody, or a pharmacologically acceptable salt thereof. [Aspect A7] An antibody / multidrug conjugate (I), in which A is an antibody residue derived from an anti-HER2 antibody, an anti-CD20 antibody, or an anti-EGFR antibody, or a pharmacologically acceptable salt thereof. [Aspect A8] A is trastuzumab, rituximab, palivizumab, infliximab, basiliximab, tocilizumab, bevacizumab, adalimumab, cetuximab, ranibizumab, omalizumab, eculizumab, ustekinumab, golimumab, canakinumab, denosumab, mogamulizumab, natalizumab, nivolumab, secukinumab, ipilimumab, evolocumab, mepolizumab, aliro Kumabu , ixekizumab, brodalumab, idarucizumab, pembrolizumab, sarilumab, bezlotoxumab, belimumab, avelumab, dupilumab, atezolizumab, benralizumab, emicizumab, guselkumab, durvalumab, vedolizumab, romosozumab, risankizumab, lavulizumab, burosumab, brolcizumab, tildrakizumab, satralizumab, galcanezumab, fremanezumab, erenumab , dinutuximab, anifrolumab, sotrovimab, bimekizumab, faricimab, nemolizumab, lanadelumab, ibritumomab, brentuximab, inotuzumab, polatuzumab, enfortumab, panitumumab, ofatumumab, pertuzumab, alemtuzumab, ramucirumab, elotuzumab, daratumumab, obinutuzumab, blinatumomab, necitumab Mab, Isatuximab, Inebilizumab , dinutuximab, gemtuzumab, lorbotuzumab, promiximab, tamlintamab, tarquetamab, cofetuzumab, belantamab, tarquetamab, erlanatamab, felzaltamab, mezazitamab, naratuximab, otlertuzumab, rilotumab, teprotumumab, ganitumab, dalotuzumab ( Dalotuzumab), Sixtumumab, Robatumumab, Istiratumab, figitumumab, sibrotuzumab, mekbotamab, tilvestamab, mipacetamab, enapotamab, oregovomab, avagovomab, ubamatamab, sofituzumab, upifitamab, rifastuzumab, dacriximab (Dacliximab), Daclizumab, Inolimomab, Camidanlumab, Alsitumomab, artumomab, tusamitamab, labetuzumab, sibisatamab, patritumab, duligotumab, zenocutuzumab, ceribantumab, barecetamab, rumletuzumab, ergemtumab, dicitamab, margetuximab, zanidatamab, coprerotamab, inetetamab, gancota Mab, ambenitamab, xenocutuzumab, ertumaxomab, lunimotamab, amivantamab, Nimotuzumab, zaltumumab, futuximab, modotuximab, depatuxizumab, durigotumab, tomzotuximab, imgatuzumab, matuzumab, cercultamab, petosemtamab, rosatuxizumab, etebritamab, scillaslimab, eplatuzumab, bectumomab, pinatuzumab, mirvetuximab, farletuzumab, rosopatamab, capro Mab, Iratumumab, Sacituzumab, Datopotamab, Cortuximab ( Coltuximab), Denintuzumab, Duvortuxizumab, Roncastuximab, Obexelimab, Tafasitamab, Taplitumomab, Ubrituximab, Tositumomab, Ocrelizumab, Ocalatuzumab (O caratuzumab), Zuberitamab (Zuberitamab), Divozilimab ( Divozilimab, Imvotamab, Epcoritamab, Glofitamab, Odronextamab, Plamotamab, Mosunetu zumab), Amatuximab, Anetumab, Belantamab, Alnuctamab, Elranatamab, Linboseltamab, Pacanalotamab, Pavurutamab, Teclistamab, Vibecotamab ecotamab), talacotuzumab, pivekimab, flotetuzumab, tucotuzumab, katumaxomab (Catumaxomab), Solitomab, Oportuzumab, Edrecolomab, Citatuzumab, or Adecatumumab, and one to six antibodies of any of these (preferably 6) complements An antibody / multi-drug conjugate (I), which is an antibody having a sex-determining region (CDR), or a pharmacologically acceptable salt thereof. [Aspect A9] A is lorbotuzumab, promiximab, tamlintamab, talquetamab, cofetuzumab, belantamab, isatuximab, daratumumab, talquetamab, erlanatamab, felzaltamab, mezazitamab, naratuximab, otlertuzumab, rilotumab, teprotumumab, ganitumab, Dalotuzumab , Sixutumumab, Robatumumab, Istiratumab, Figitumumab, Sibrotuzumab, Enfortumab , mekubotamab, tilvestamab, mipacetamab, enapotamab, oregovomab, avagovomab, ubamatamab, sofituzumab, Upfitamab, rifastuzumab, basiliximab, Dacliximab, daclizumab, inolimomab, camidanlumab, alsitumomab, altumomab, tusamitamab, Labetuzumab, Sibisatamab, Polatuzumab, Patritumab, Duligotumab, Zenocutuzumab, Seribantumab , Barecetamab, rumletuzumab, ergemtumab, trastuzumab, dicitamab, margetuximab, pertuzumab, zanidatamab, coprerotamab, inetetamab, gancotamab, anbenitamab, zenocutuzumab, ertumaxomab, lunimotamab, cetuximab, amivantamab, necitumumab, nimotuzumab, panizumab Mumab, zaltumumab, futuximab, modotuximab, depatuxizumab, durigotumab , tomzotuximab, imgatuzumab, matuzumab, cercultamab, petosemtamab, rosatuxizumab, etebritamab, inotuzumab, scillaslimab, epratuzumab, bectumomab, pinatuzumab, mirvetuximab, farletuzumab, rosopatamab, capromab, brentuximab, iratumumab, sacituzumab, datopotamab, Co ltuximab, Denintuzumab, Duvortuxizumab, Ron Castuximab, obexelimab, tafasitamab, Taplitumomab, ibritumomab, rituximab, polatuzumab, ofatumumab, obinutuzumab, ublituximab, tositumomab, ocrelizumab, Ocaratuzumab, Zuberitamab, Divozilimab, Imvotamab, Epcoritamab, Glofitamab, Odronextamab, Plamotamab, Mosunetuzumab, Amatuximab, Anetumab, Belantamab , Alnuctamab, Elranatamab, Linvoseltamab, Pacanalotamab, Pavurutamab, Teclistamab, Vibecotamab, Talacotuzumab, Pibequimab, Flotetuzumab, Tucotu zumab, Catumaxomab, Solitomab, Oportuzumab, Edrecolomab, Citatuzumab, or Adecatumumab and one to six antibodies (preferably An antibody / multiple drug conjugate (I), which is an antibody having six complementarity determining regions (CDRs), or a pharmacologically acceptable salt thereof. [Aspect A10] An antibody / multiple drug conjugate (I), in which A is an antibody having trastuzumab, rituximab, and cetuximab and one to six (preferably six) complementarity determining regions (CDRs) thereof, or the pharmacologically effective Acceptable salt. [Aspect B1] The antibody / multi-drug conjugate according to any one of [Aspect A1] to [Aspect A10], wherein B is an -S- or -NH- group derived from a sulfhydryl group or an amino group present in the antibody. (I), or a pharmacologically acceptable salt thereof. [Aspect B2] In any one of [Aspect A1] to [Aspect A10], B is -S-; or -NH- group produced by a reduction reaction of a disulfide bond (-S-S-) present in the antibody. The antibody / multi-drug conjugate (I) described above, or a pharmacologically acceptable salt thereof. [Aspect B3] The antibody / multi-drug conjugate (I) according to any one of [Aspect A1] to [Aspect A10], or a pharmacologically acceptable salt thereof, wherein B is -S-. [Aspect B4] The antibody / multi-drug conjugate (I) according to any one of [Aspect A1] to [Aspect A10], or a pharmacologically acceptable salt thereof, wherein B is -NH-. [Aspect C1] The antibody / multi-drug conjugate (I) according to any one of [Aspect A1] to [Aspect A10] and [Aspect B1] to [Aspect B4], where a is an integer of 1 to 10, or its pharmacology Salt allowed on top. [Aspect C2] The antibody / multi-drug conjugate (I) according to any one of [Aspect A1] to [Aspect A10] and [Aspect B1] to [Aspect B4], where a is an integer of 1 to 8, or the Pharmacologically acceptable salts. [Aspect C3] The antibody / multi-drug conjugate (I) according to any one of [Aspect A1] to [Aspect A10] and [Aspect B1] to [Aspect B4], where a is an integer of 2 to 8, or the Pharmacologically acceptable salts. [Aspect C4] The antibody / multiple drug conjugate (I) according to any one of [Aspect A1] to [Aspect A10] and [Aspect B1] to [Aspect B4], wherein a is an integer of 3 to 8, or the Pharmacologically acceptable salts. [Aspect C5] The antibody / multi-drug conjugate (I) according to any one of [Aspect A1] to [Aspect A10] and [Aspect B1] to [Aspect B4], wherein a is an integer of 4 to 8, or the Pharmacologically acceptable salts. [Aspect C6] The antibody / multi-drug conjugate (I) according to any one of [Aspect A1] to [Aspect A10] and [Aspect B1] to [Aspect B4], where a is an integer of 1 to 7, or the Pharmacologically acceptable salts. [Aspect D1] [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], wherein G is a group represented by formula (i), formula (ii), formula (iii), or formula (iv) and the antibody / multi-drug conjugate (I) according to any one of [Aspect C1] to [Aspect C6], or a pharmacologically acceptable salt thereof. [Aspect D2] [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], and [Aspect C1], wherein G is a group represented by formula (i), formula (ii), or formula (iii) ~Antibody / multi-drug conjugate (I) according to any one of [Aspect C6], or a pharmacologically acceptable salt thereof. [Aspect D3] In any one of [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], and [Aspect C1] to [Aspect C6], where G is a group represented by formula (i) The antibody / multi-drug conjugate (I) described above, or a pharmacologically acceptable salt thereof. [Aspect E1] D １ and D ２ is a residue obtained by removing one hydrogen atom or one hydroxyl group from any position of an antitumor drug molecule, an analog thereof, or a derivative thereof, [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], [Aspect C1] to [Aspect C6], and [Aspect D1] to [Aspect D3]. Drug conjugate (I) or a pharmacologically acceptable salt thereof. [Aspect E2] D １ and D ２ But each independently, camptothecin; MMAE; maytansine; PBD (parabenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; dolastatin 10; superdox;; ciprofloxacin; cardofloxacin (CS-940); is a residue of an antitumor drug molecule independently selected from the group consisting of derivatives of [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], [Aspect C1] to [Aspect C6], and [Aspect D1] to [Aspect D3]. Drug conjugate (I) or a pharmacologically acceptable salt thereof. [Aspect E3] D １ and D ２ However, camptothecin; MMAE; maytansine; PBD (parabenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin; paclitaxel; docetaxel; mitomycin C; or an analog or derivative thereof; or a residue of an anti-tumor drug molecule independently selected from the group consisting of: bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; dolastatin 10; superdox; or an analog or derivative thereof; is, [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], [Aspect C1] to [Aspect C6], and [Aspect D1] to [Aspect D3]. Drug conjugate (I) or a pharmacologically acceptable salt thereof. [Aspect E4] D １ and D ２ or the remainder of an anti-tumor drug molecule independently selected from the group consisting of: camptothecin; MMAE; maytansine; PBD (parabenzodiazepine) dimer; eribulin; or an analog or derivative thereof; is the basis, [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], [Aspect C1] to [Aspect C6], and [Aspect D1] to [Aspect D3]. Drug conjugate (I) or a pharmacologically acceptable salt thereof. [Aspect E5] D １ and D ２ are residues of the same anti-tumor drug or an analog or derivative of those anti-tumor drugs; or a derivative of said analog; [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], [Aspect C1] to [Aspect C6], and [Aspect D1] to [Aspect D3]. Drug conjugates, or pharmacologically acceptable salts thereof. [Aspect E6] D １ and D ２ is a residue of a different anti-tumor drug or an analog or derivative of these anti-tumor drugs; or a derivative of said analog; [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], [Aspect C1] to [Aspect C6], and [Aspect D1] to [Aspect D3]. Drug conjugates, or pharmacologically acceptable salts thereof. [Aspect F1] D １ ,D ２ , L １ , L ２ , and L ３ At least one of them has one or more phosphoryl groups (-P(=O)(OH)) as a substituent or protecting group. ２ ), The total number of the phosphoryl groups is 1 to 10, L １ , L ２ , and L ３ At least one of them has one or more lactonyl groups as a substituent, The total number of the lactonyl groups is 1 to 10, If the total number is 2 or more, the lactonyl groups may be the same or different, [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], [Aspect C1] to [Aspect C6], [Aspect D1] to [Aspect D3], and [Aspect E1] to [Aspect E6] The antibody / multi-drug conjugate according to any one of the above, or a pharmacologically acceptable salt thereof. [Aspect F2] D １ ,D ２ , L １ , L ２ , and L ３ At least one of them has one or more phosphoryl groups (-P(=O)(OH)) as a substituent or protecting group. ２ ), The total number of the phosphoryl groups is 1 to 4, L １ , L ２ , and L ３ At least one of them has one or more lactonyl groups as a substituent, The total number of lactonyl groups is 1 to 8, If the total number is 2 or more, the lactonyl groups may be the same or different, [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], [Aspect C1] to [Aspect C6], [Aspect D1] to [Aspect D3], and [Aspect E1] to [Aspect E6] The antibody / multi-drug conjugate according to any one of the above, or a pharmacologically acceptable salt thereof. [Aspect G1] L １ , L ２ , and L ３ are each independently an optionally substituted alkylene group; One or more methylene groups in the chain of the alkylene group, -C(R １ )(R ２ )-;-O-;-N(R ３ )-;-N(R ３ )-N(R ３ )-;-S-;-Se-;-Si(R ４ )(R ５ )-;-S-S-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R ６ )(R ７ ))-;-C(=O)-;-C(=S)-;-C(=N(R ８ ))-;-C(=N-OR ９ )-;-C(=N-N(R １０ )(R １１ ))-;-P(=O)(R １２ )-;-P(=O)(OR １３ )-;-O-P(=O)(R １２ )-O-;-O-P(=O)(OR １３ )-O-;-C(R １４ )=;=C(R １４ )-;-C(R １４ )=C(R １４ )−;−N=;=N−;−C≡C−;−(O−C(R １ )(R ２ )-C(R １ )(R ２ )) １−３０ -;-(C(R１ )(R ２ )-C(R １ )(R ２ )−0) １−３０ -; optionally substituted alkenylene group, optionally substituted alkynylene group, optionally substituted cycloalkylene group; optionally substituted cycloalkenylene group; optionally substituted arylene group; and optionally substituted heteroarylene groups; and one or more divalent groups independently selected from the group consisting of optionally substituted heterocyclylene groups; R １ ,R ２ ,R ３ ,R ４ ,R ５ ,R ６ ,R ７ ,R ８ ,R ９ ,R １０ ,R １１ ,R １２ ,R １３ , and R １４ each independently represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, and an optionally substituted cycloalkyl group. a group selected from the group consisting of an optionally substituted cycloalkenyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclyl group, and R ３ is an alkyl group, the alkyl group may form a cyclic structure together with the alkyl group on the adjacent methylene group, m and n are each independently an integer of 0 to 2, [Aspect A1] to [Aspect A10], [Aspect B1] to [Aspect B4], [Aspect C1] to [Aspect C6], [Aspect D1] to [Aspect D3], [Aspect E1] to [Aspect E6], and The antibody / multi-drug conjugate (I) according to any one of [Aspect F1] to [Aspect F2], or a pharmacologically acceptable salt thereof. [Aspect G2] L １ , L ２ , and L ３ are each independently an optionally substituted alkylene group; one or more methylene groups in the chain of the alkylene group are replaced with one or more divalent groups independently selected from the group of formulas below, Antibody / multi-drug conjugate (I) according to [Aspect G1] or a pharmacologically acceptable salt thereof expression group -C(R １ )(alkyl)−; -C(R １４ )=; -O-; -N(R ３ )−; −N=; -N(R ３ )-C(R １ )(R ２ )-(wherein, R ３ , and R １ or R ２ is an alkyl group, R ３ and R １ or R ２ may form a cyclic structure together); -N(R ３ )-C(R １ )(R ２ )-C(=O)-(wherein, R ３ , and R １ or R ２ is an alkyl group, R ３ and R １ or R ２ may form a cyclic structure together); -O-C(R １ )(R ２ )−; -S-C(R １ )(R ２ )−; -N(R ３ )-N(R ３ )−; -N(R ３ )-O-C(R １ )(R ２ )−; -S-; -Si(R ４ )(R ５ )−; -S-S-; -SOm-; -C(=O)-; -C(R １ )(R ２ )-C(=O)-; −C(=C(R ６ )(R ７ ))−; −C(=N(R ８ ))−; -C(=N-OR ９ )−; −C(=N−N(R １０ )(R １１ )−; −P(=O)(R １２ )−; −P(=O)(R １２ )-O-; -O-P(=O)(R １２ )-O-; −P(=O)(OR １３ )-O-; −P(=O)(OR １３ )-N(R ３ )−; -O-P(=O)(OR １３ )-O-; -C(R １４ )-C(R １４ )−; -C(R １４ )=C(R １４ )-P(=O)(OR １３ )-N(R ３ )−; -C(R １４ )=N−; -C(R １４ )=N-N(R ３ )−; -C≡C-; -O-C(R １ )(R ２ )-C(R １ )(R ２ )−; -O-C(R １ )(R ２ )-C(R １ )(R ２ )-O-; -(O-C(R １ )(R ２ )-C(R １ )(R ２ )) １−３０ −; -C(=O)-O-; -C(=O)-S-; -C(=O)-N(R ３ )−; -C(=O)-N(R ３ )-O-; -C(=O)-N(R ３ )-C(R １ )(R ２ )-(wherein, R ３ , and R １ or R ２ is an alkyl group, R ３ and R １ or R ２ may form a cyclic structure together); -C(=S)-O-; -C(=S)-S-; -O-C(=O)-O-; -O-C(=O)-N(R ３ )−; -S-C(=O)-N(R ３ )−; -N(R ３ )-C(=O)-N(R ３ )−; an optionally substituted arylene group; an optionally substituted heteroarylene group; and An optionally substituted heterocyclylene group. [Aspect G3] L １ , L ２ , and L ３ are each independently an optionally substituted alkylene group; one or more methylene groups in the chain of the alkylene group are replaced with one or more divalent groups independently selected from the group of formulas below, Antibody / multi-drug conjugate (I) according to [Aspect G1] or a pharmacologically acceptable salt thereof expression group -C(R １４ )=; -O-; -N(R ３ )−; −N=; -S-; -C(=O)-; -O-Si(CH ３ )(CH ３ )-O-; -CH ２ -C(=O)-; -C(=O)-NH-; -C(=O)-O-; -C(=O)-S-; -O-C(=O)-O-: -N(H or CH ３ )-C(=O)-O-; -NH-NH-; -N(CH ３ )-O-CH ２ −; -C(=O)-(CH ２ ) １−２０ -C(=O)-; -C(=O)-(CH２ ) １−１０ -O-(CH ２ ) １−１０ -C(=O)-; -C(=O)-CH ２ -(O-CH ２ CH ２ ) １−２０ -O-CH ２ -C(=O)-; -(O-CH ２ CH ２ ) １−２０ −; -C(=O)-N(H or CH ３ )-CH ２ CH ２ -N(H or CH ３ )-C(=O)-; [In the formula, * is the bonding point with the adjacent group] -C(=O)-N(H or CH ３ )-CH ２ −; -P(=O)(OH)-O-; -O-P(=O)(OH)-O-; -O-P(=O)(OH)-O-P(=O)(OH)-O-; -O-P(=O)(OH)-O-P(=O)(OH)-O-P(=O)(OH)-O-; -CH(CH ２ -NH ２ )−; -CH(CH ２ -NH-C(=O)-; -CH(CH ２ -NH-C(=O)-(CH ２ CH ２ -O-) １−２０ -CH ３ )−; -CH(CH ２ -NH-C(=O)-(CH ２ ) ０−２０ -lactonyl)-; -CH(CH ２ -NH-C(=O)-(CH ２ CH ２ -O-) １−２０ -CH ２ -lactonyl)-; -CH(CH ２ -NH-C(=O)-(CH ２ ) １−２０ -phosphoryl)-; -CH(CH ２ -NH-C(=O)-(CH ２ CH ２ -O-) １−２０ -CH ２ -phosphoryl)-; -CH(CH ２ -NH-(CH ２ ) １−２０ -phosphoryl)-; -(cis)-CH=CH-P(=O)(O-CH ２ CH ３ or O-CH ２ CH ２ -OH)-NH-(phenylene)-C(=O)-; -C(=O)-(cyclohexylene)-; -(succinimidylene)-; -Gly-; -Ala-; -Val-; -Leu-; -Ile-; -Phe-; -Ser-; -Cys-; -Asp-; -Glu-; -Orn-; -Lys-; -Cit-; -Arg-; -His-; -Pro-; -GlyGly-; -PheLys-; -ValLys-; -ValCit-; -ValAla-; -AspValCit-; -GluValCit-; -LysValCit-; -SerValCit-; -AspValAla-; -GluValAla-; -LysValAla-; -SerValAla-; -GlyGlyPheGly-; -AspGlyGlyPheGly-; -GluGlyGlyPheGly-; -LysGlyGlyPheGly-; -SerGlyGlyPheGly-; -AspAspAspAspAsp-; (In the above amino acid residues and amino acid residues in the peptide, The side chain carboxy group of Asp and Glu may be a lactonyl ester, a lactonyl alkyl ester, or a phosphorylalkyl ester, or may be an unsubstituted amide, monoalkyl amide, or dialkyl amide. , the amino group of the amide moiety may have a lactonyl group, lactonylalkyl group, or phosphorylalkyl group as a substituent, The amino group of the side chain of Lys and Orn has a lactonyl group, a lactonylalkyl group, a lactonylcarbonyl group, a lactonylalkylcarbonyl group, a phosphoryl group, a phosphorylalkyl group, or a phosphorylalkylcarbonyl group as a substituent. Good too, The hydroxyl group on the side chain of Ser and the sulfhydryl group on the side chain of Cys are substituents such as lactonyl group, lactonylalkyl group, lactonylcarbonyl group, lactonylalkylcarbonyl group, phosphoryl group, phosphorylalkyl group, or phosphorylalkylcarbonyl group. (may have a group) -N(H or CH ３ )-(optionally substituted phenylene)-CH ２ -O-C(=O)-; -O-(optionally substituted phenylene)-CH ２ -O-C(=O)-; -N(H or CH ３ )-(optionally substituted pyridylene)-CH ２ -O-C(=O)-; -2, 3 or 4 cyclic (1,2,3-triazolylene)-; and [In the formula, * is the bonding point with the adjacent group] [Aspect G4] L １ , L ２ , and L ３ One or more methylene groups in the chain of the optionally substituted alkylene group in at least one of are replaced with any of the following divalent groups, Antibody / multi-drug conjugate (I) according to [Aspect G1], or a pharmacologically acceptable salt thereof: [Aspect G5] L １ , L ２ , and L ３ One or more methylene groups in the chain of the optionally substituted alkylene group in at least one of are replaced with any of the following divalent groups, Antibody / multi-drug conjugate (I) according to [Aspect G1], or a pharmacologically acceptable salt thereof: Among the above divalent groups, those that are left-right asymmetric and those that can be left-right asymmetric are L in general formula (I). １ and L ２ When present as a part of the divalent group, the divalent group may be oriented in any of the left, right, top, and bottom directions on the page. For example, −N(R ３ )-C(R １ )(R ２ )-but, L １ -N(R ３ )- is on the B side, -C(R １ )(R ２ )-is D １ It may be on the side, or -C(R １ )(R ２ )- is on the B side, -N(R ３ )-is D １ It can be on the side. In addition, the "three-letter alphabet" is a symbol representing the following amino acids, and in particular, in this specification, the divalent residue of each amino acid (-NH-CH(R １５ )-C(=O)-). Here, R １５ are hydrogen atom (Gly), methyl group (Ala), isopropyl group (Val), isobutyl group (Leu), (butan-2-yl) group (Ile), phenylmethyl group (Phe), hydroxymethyl group (Ser). ), sulfhydrylmethyl group (Cys), carboxymethyl group (Asp), 2-carboxyethyl group (Glu), 3-aminopropyl group (Orn), 4-aminobutyl group (Lys), 3-(ureido)propyl group (Cit), 3-guanidinopropyl group (Arg), or (1H-imidazol-4-yl)methyl group (His) (corresponding amino acids are shown in parentheses). In addition, the above formula (-NH-CH(R １５ )-C(=O)-), R １５ is a propyl group, and when the propyl group forms a 5-membered ring together with the nitrogen atom of "-NH-" in the formula, it becomes a cyclic amino acid (Pro; proline). Gly; glycine Ala; alanine Val; Valin Leu; Leucine Ile; isoleucine Phe; phenylalanine Ser; Serin Cys; cysteine Asp; aspartic acid Glu; glutamic acid Ornithine Lys; lysine Cit; citrulline Arg; arginine His; histidine Pro; Proline In addition, amino acid residues having an asymmetric center in the "linker" or "antitumor drug molecules or analogs thereof, or derivatives thereof" of the antibody / multiple drug conjugate represented by the general formula (I) of the present invention is included and optical isomerism can occur, both optical isomers are included in the present invention. [Aspect H1] An antibody-drug conjugate (ADC) comprising an antibody and a drug, wherein the antibody and drug are linked directly or indirectly via a linker, the linker having a solubilizing group, such as a lactonyl group and An ADC modified with a group selected from the group consisting of phosphoryl groups, especially solubilizing groups. [Aspect H2] The ADC according to [Aspect H1], wherein the linker is modified with a lactonyl group and a phosphoryl group. [Aspect H3] The linker is a branched linker, A branched linker has at least one branch and at least a first linker portion, a second linker portion and a third linker portion, the third linker being interposed between the antibody and the branch; and a second linker moiety are each covalently linked at one end to said branch and at the other end to each of the first anti-tumor drug molecule or an analog or derivative thereof; The ADC according to [Aspect H1] or [Aspect H2], wherein the derivative and the second antitumor drug molecule or an analog or derivative thereof; or a derivative of the analog are linked by a covalent bond; The first linker moiety and the second linker moiety may be the same or different, and the first anti-tumor drug molecule and the second anti-tumor drug molecule may be the same or different}. [Aspect H4] The first linker portion, the second linker portion and the third linker portion each contain a polyalkylene glycol (preferably polyethylene glycol) block, according to any one of [Aspect H1] to [Aspect H3] above. ADC. [Aspect H5] The ADC according to any one of [Aspect H1] to [Aspect H4], wherein the third linker moiety is modified with a lactonyl group and / or a phosphoryl group. [Aspect H6] The ADC according to any one of [Aspect H1] to [Aspect H5], wherein one or both of the first linker moiety and the second linker moiety is modified with a lactonyl group and / or a phosphoryl group. [Aspect H7] The ADC according to any one of [Aspect H1] to [Aspect H5], wherein the first linker portion and the second linker portion are modified with a lactonyl group and a phosphoryl group. [Aspect H8] the first linker moiety or the second linker moiety and the anti-tumor drug molecule or an analog or derivative thereof; or a derivative of said analog covalently linked via -O-P(=O)(OH)-O- The ADC according to any one of [Aspect H1] to [Aspect H7], which are connected by a bond. [Aspect H9] the first linker moiety and the second linker moiety and the anti-tumor drug molecule or analog or derivative thereof bound to each; or a derivative of the analog; -O-P(=O)(OH)- The ADC according to any one of [Aspect H1] to [Aspect H8] above, which are covalently linked via O-. [Aspect H10] The anti-tumor drug molecule or an analog or derivative thereof; or a derivative of said analog has a secondary amine, said secondary amine is linked to a second linker moiety -O-P(=O)(OH)- The ADC according to [Aspect H8] or [Aspect H9] above, which is covalently linked via O-. [Aspect H11] The ADC according to any one of [Aspect H1] to [Aspect H10], wherein the second linker portion and the third linker portion have an oligopeptide portion that is cleaved within the tumor tissue. [Aspect H12] The ADC according to [Aspect H11] above, wherein the oligopeptide portion includes a valine-citrulline (Val-Cit) dipeptide. [Aspect H13] one, two, or all selected from the group consisting of the first linker moiety, the second linker moiety, and the third linker moiety comprise a polyalkylene glycol block (preferably a polyethylene glycol block); The second linker portion and the third linker portion include a valine-citrulline (Val-Cit) dipeptide, one, two, or all selected from the group consisting of the first linker moiety, the second linker moiety, and the third linker moiety are modified with a phosphoryl group and / or a lactonyl group, The ADC according to any one of [Aspect H1] to [Aspect H12]. [Aspect H14] [Aspect H1] to [Aspect H13] above, wherein the antitumor drug molecule or its analog or derivative or the derivative of the analog is modified with a phosphoryl group or a phosphate group, or has a phosphoryl group or a phosphate group. ] The ADC according to any one of. [Aspect H15] [Embodiment H1] above, which exhibits superior long-term blood retention compared to ADC having maleimidocaproyl-valine-citrulline-p-aminobenzyl alcohol-MMAE (MC-Val-Cit-PAB-MMAE) The ADC according to any one of [Aspect H114]. [Aspect H16] The ADC or conjugate according to any of the above, wherein the blood concentration 3 days after administration is 10% or more of the blood concentration 5 minutes after administration. [Aspect H17] The ADC or conjugate according to any of the above, wherein the blood concentration 3 days after administration is 20% or more of the blood concentration 5 minutes after administration. [Aspect H18] The ADC or conjugate according to any of the above, wherein the blood concentration 3 days after administration is 25% or more of the blood concentration 5 minutes after administration. [Aspect H19] The ADC or conjugate according to any of the above, wherein the blood concentration 3 days after administration is 30% or more of the blood concentration 5 minutes after administration. [Aspect H20] The ADC or conjugate according to any of the above, wherein the blood concentration 3 days after administration is 14% or more of the blood concentration 5 minutes after administration. [Aspect H21] The ADC or conjugate according to any of the above, wherein the linker includes a linking portion with an antibody, a polyethylene glycol portion, a cleavable portion, a portion connecting the cleavable portion and a drug portion, and a drug. [Aspect H22] The ADC or conjugate according to any of the above, wherein the linking portion with the antibody contains a succinimide group and is linked to a sulfur atom of a cysteine ​​residue of the antibody. [Aspect H23] The ADC or conjugate according to any of the above, wherein the polyethylene glycol portion contains 3 to 20 (preferably 3 to 10, for example 3 to 6) ethylene glycol units. [Aspect H24] The ADC or conjugate according to any of the above, wherein the cleavable moiety comprises a valine-citrulline dipeptide. [Aspect H25] The linking part with the antibody contains a succinimide group and is linked to the sulfur atom of the cysteine ​​residue of the antibody, The polyethylene glycol block contains 3 to 20 (preferably 3 to 10, e.g. 3 to 6) ethylene glycol units, and The ADC or conjugate according to any of the above, wherein the cleavable moiety comprises a valine-citrulline dipeptide. [Aspect H26] The ADC or conjugate according to any of the above, wherein the antibody-linking portion has an additional solubilizing group. [Aspect H27] The ADC or conjugate according to any of the above, wherein the cleavable moiety has a solubilizing group in its side chain. [Aspect H28] The ADC or conjugate according to any of the above, wherein the moiety connecting the cleavable moiety and the drug has an additional solubilizing group. [Aspect H29] An ADC or conjugate according to any of the above, wherein the drug moiety has an additional solubilizing group. [Aspect H30] The ADC or conjugate according to [Aspect H25] above, wherein the additional solubilizing group is a group having a phosphonic acid in its side chain. [Aspect H31] The ADC or conjugate according to [Aspect H26] above, wherein the solubilizing group is an amino group, phosphonic acid, or lactonyl group. [Aspect H32] The ADC or conjugate according to [Aspect H27] above, wherein the additional solubilizing group is a phosphoric acid ester (including a phosphoric diester). [Aspect H33] Use of each moiety defined in [Aspect H21] to [Aspect H32] above (particularly a moiety having a solubilizing group) in the production of any of the above ADCs or conjugates. [Aspect I1] An ADC with a linker represented by the following formula. {wherein the succinimidyl group is linked at the asterisk symbol to the S or N atom of the antibody side chain, and the phosphonic acid group is linked at the asterisk symbol to the antitumor drug molecule, its analogs, derivatives, or said analogs. conjugated with a derivative of } [Aspect I2] An ADC with a linker represented by the following formula. {wherein the succinimidyl group is linked at the asterisk symbol to the S or N atom of the antibody side chain, and the carboxy group is linked to the antitumor drug molecule, its analogue, derivative, or said analogue at the asterisk symbol. Connect with derivatives. } [Aspect I3] An ADC with a linker represented by the following formula. {wherein the succinimidyl group is linked to the S or N atom of the antibody side chain at the asterisk symbol, and the phosphonic acid group is linked to the antitumor drug molecule, its analogue, derivative, or said analogue at the asterisk symbol. and the carboxy group is linked at the asterisk symbol to the anti-tumor drug molecule, its analogue, derivative, or derivative of said analogue. } [Aspect I4] An ADC with a linker represented by the following formula. {wherein the succinimidyl group is linked at the asterisk symbol to the S or N atom of the antibody side chain, and the phosphonic acid group is linked at the asterisk symbol to the antitumor drug molecule, its analogs, derivatives, or said analogs. conjugated with a derivative of } [Aspect I5] An ADC with a linker represented by the following formula. {wherein the succinimidyl group is linked at the asterisk symbol to the S or N atom of the antibody side chain, and the carboxy group is linked to the antitumor drug molecule, its analogue, derivative, or said analogue at the asterisk symbol. Connect with derivatives. } [Aspect I6] An ADC with a linker represented by the following formula. {wherein the succinimidyl group is linked at the asterisk symbol to the S or N atom of the antibody side chain, and the phosphonic acid group is linked at the asterisk symbol to the antitumor drug molecule, its analogs, derivatives, or said analogs. and the carboxy group is linked at the asterisk symbol to the anti-tumor drug molecule, its analogue, derivative, or derivative of said analogue. } The antibody-drug conjugate modified according to the group of the present invention has higher stability in blood compared to the antibody-drug conjugate without the modification, and is therefore expected to have a sustained antitumor effect. It is preferable. The antibody / multi-drug conjugate represented by general formula (I) of the present invention or a pharmacologically acceptable salt thereof is administered in vivo and then selectively delivered to the target tumor cells and intracellularly. Since the multiple antitumor drugs released in this method exhibit their respective functions, it is useful as a cancer treatment drug with excellent antitumor effects and safety. The antitumor effect of AMDC (1 mg / kg body weight) in Example 2 is shown. The antitumor effect of AMDC (1 mg / kg body weight) in Example 3 is shown. The antitumor effect of AMDC (1 mg / kg body weight) in Example 4 is shown. The antitumor effect of AMDC (1 mg / kg body weight) in Example 5 is shown. The antitumor effect of AMDC (1 mg / kg body weight) in Example 6 is shown. The antitumor effect of AMDC (3 mg / kg body weight) in Example 4 is shown. The antitumor effect of AMDC (3 mg / kg body weight) in Example 5 is shown. 2 shows a SEC analysis HPLC chart of AMDC of Example 2. Below, the definitions of terms used in this specification are described, and specific examples are illustrated for each, but the present invention is not limited thereto. In addition, various antibodies, drug molecules, compounds, and substituents defined or exemplified below can be arbitrarily selected, and by combining them, the antibody / multiple drug conjugate of the present invention or a pharmacologically acceptable salt thereof is manufactured. definition Unless otherwise specified, the following terms and phrases used herein have the meanings set forth below. Additionally, when trade names are used herein, unless otherwise indicated, trade names include product formulations, generic drugs, and active pharmaceutical ingredients of the trade name product. Also, terms written in the singular do not exclude the plural. Furthermore, "comprising" has the meaning of both "consisting of" and "including." As used herein, "antibody" refers to complete monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments that exhibit the desired biological activity. (For example, antigen-binding fragments of antibodies, including but not limited to Fab, Fab', F(ab') ２ , and scFv. However, an antibody fragment refers to an antibody fragment (having the necessary number of binding sites for a linker attached to a drug), and the antibody may be any antibody that can target tumor cells. Antibodies, for example, can bind to antigens that are expressed on the surface of cancer cells and can be internalized by the cells, ie, can be targeted to tumor cells. That is, in the antibody / multi-drug conjugate of the present invention, since the antibody is bound to a cytotoxic agent (for example, an antitumor active drug) via a linker, the antibody has the property of being able to recognize tumor cells, It is preferable to have one or more of the following characteristics: ability to specifically bind to tumor cells, ability to be taken up and internalized within tumor cells, and further characteristics to damage tumor cells. Native antibodies are tetramers, consisting of two identical pairs of immunoglobulin chains, each pair having one light chain and one heavy chain. In each pair, the light and heavy chain variable regions (VL and VH) together are primarily responsible for binding to the antigen. Light and heavy chain variable domains consist of three hypervariable regions called "complementarity determining regions" or "CDRs" and a framework region interrupted by four hypervariable regions. Constant regions are capable of being recognized by and interacting with the immune system. The antibodies can be of any type (e.g. IgG, IgE, IgM, IgD, IgY and IgA), class (e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass, especially IgG1, IgG2 , IgG3, IgG4. Antibodies can be derived from any suitable species. In some embodiments, the antibody is of human or murine origin. The antibody can be, for example, human, humanized or chimeric. The term "monoclonal antibody" as used herein means an antibody obtained from a substantially homogeneous population of antibodies. That is, the individual antibodies within a population are identical except for the possibility of slight naturally occurring mutations. Monoclonal antibodies are highly specific, targeting a single antigenic site. The term "monoclonal" indicates the character of the antibody as "obtained from a substantially homogeneous population of antibodies" and does not imply that the antibody must be produced by any particular method. An "intact antibody" is one that contains an antigen-binding variable region and the appropriate light chain (CL) and heavy chain constant domains CH1, CH2, CH3, and CH4 for the antibody class. The constant domain can be a native sequence constant domain (eg, a human native sequence constant domain) or an amino acid sequence variant thereof. "Antibody fragment" includes its antigen-binding region or variable region, and includes a portion of a complete antibody. Antibody fragments may be antigen-binding fragments of antibodies, such as, but not limited to, Fab, Fab', F(ab') ２ , and scFv. For use in the present invention, antibody fragments may have functional groups (e.g., sulfhydryl groups, amino groups, etc.) so that they can be attached to multiple drug moieties via linkers, or disulfide groups from which sulfhydryl groups can be generated upon reduction. Must have a bond. An "antigen" is a substance to which an antibody specifically binds (eg, a cell surface antigen, particularly a cell surface protein, a cell surface glycoprotein, or a cell surface sugar chain). "Specific binding" and "specifically binds" mean that an antibody or antibody derivative binds to its corresponding target antigen in a highly selective manner and does not bind to a large number of other antigens. means. Typically, antibodies and antibody derivatives will have at least about 1 x 10 −７ M, preferably 10 −８ ~10 −９ M, 10 −１０ M, 10 −１１ M or 10 −１２ binds to a given antigen with an affinity of M and at least two times higher than its affinity for non-specific antigens other than the given antigen or closely related antigens (e.g., bovine serum albumin (BSA), casein). Join. "Therapeutically effective amount" means an amount of drug effective to treat a disease or disorder in a mammal. A therapeutically effective amount of a drug reduces the number of cancer cells, reduces tumor size, inhibits cancer cell invasion into surrounding organs, inhibits tumor metastasis, inhibits tumor growth to some extent, and / or inhibits cancer cell growth. One or more of the associated symptoms can be alleviated to some extent. To the extent that the drug can inhibit proliferation and / or kill existing cancer cells, the drug may be cytostatic and / or cytotoxic. For cancer treatment, efficacy can be determined, for example, by assessing time to disease progression (TTP) and / or response rate (RR). "Intracellular cleavage" refers to the cleavage by which the drug moiety (D １ or D ２ ) and linker (L １ , L ２ or L ３ ) or antibody (A) is cleaved, thereby generating metabolic decomposition products including drugs from the antibody / multiple drug conjugate within the cell. Refers to a metabolic process or reaction of the conjugate. "Cytotoxic activity" refers to the cell-killing effect of intracellular metabolites of a drug or antibody / multidrug conjugate. Cytotoxic activity is the concentration per unit volume (molar or mass concentration) at which half of the cells survive when exposed to a cytotoxic agent; ５０ It can be expressed by a value. "Cytostatic activity" refers to the antiproliferative effect of the antibody / multiple drug conjugate other than cell killing. The term "cytotoxic agent" as used herein refers to a substance that has cytotoxic activity and causes destruction of cells, and includes radioactive isotopes (e.g., 211At, 131I, 125I, 90Y, 186Re, 188Re, 153Sm , 212Bi, 32P, 60C, and Lu radioisotopes), chemotherapeutic agents, and derivatives thereof, small molecule toxins or toxins of bacterial, fungal, plant, or animal origin. The term "cytostatic agent" as used herein refers to a substance that has cytostatic activity and, for example, inhibits cell functions that are responsible for or contribute to cell growth or proliferation. Cytostatic agents include inhibitors such as protein inhibitors, such as enzyme inhibitors. "Cancer" and "cancerous" as used herein refer to the physiological condition or disorder in mammals that is typically characterized by uncontrolled cell growth. A "tumor" includes one or more cancerous cells. As used herein, "patient" refers to a subject to whom an antibody / multidrug conjugate is administered. Examples of "patients" include, but are not limited to, humans, rats, mice, guinea pigs, non-human primates, pigs, goats, cows, horses, dogs, cats, birds, and poultry. Typically, the patient is a rat, mouse, dog, non-human primate or human. In some embodiments, the patient is a human in need of an effective amount of an antibody-multidrug conjugate. "Treating" or "therapy" as used herein, unless otherwise indicated, refers to, for example, inhibiting or slowing down (reducing) undesirable physiological changes or disorders, such as the development or spread of cancer; It means therapeutic treatment and prophylactic treatment to prevent recurrence. Beneficial or desirable clinical outcomes of Treatment include, for example, alleviation of symptoms, reduction in disease severity, stabilization of disease state, delay or deceleration of disease progression, improvement or alleviation of disease state, and remission (partial remission or complete remission), but are not limited to these. "Treating cancer" includes any or all of the following actions: i.e., inhibiting the growth of tumor cells, cancer cells, or tumors, inhibiting the replication of tumor cells or cancer cells, reducing overall tumor burden, or reducing the number of cancerous cells; and improving one or more symptoms associated with the disease. Useful polyclonal antibodies are heterogeneous populations of antibody molecules derived from the serum of immunized animals. Useful monoclonal antibodies are homogeneous populations of antibodies directed against specific antigenic determinants (eg, cancer cell antigens, viral antigens, microbial antigens, proteins, peptides, carbohydrates, compounds, nucleic acids, or fragments thereof). Monoclonal antibodies (mAbs) against antigens of interest can be produced by techniques known in the art. Useful monoclonal antibodies include, but are not limited to, human monoclonal antibodies or chimeric human-mouse (or other animal species) monoclonal antibodies. Antibodies include full-length antibodies and antigen-binding fragments thereof. Human monoclonal antibodies can be made by any of a number of techniques known in the art (eg, Kozbor et al., 1983, Immunology Today 4:72-79). The antibodies may be functionally active fragments, derivatives or derivatives of antibodies that immunospecifically bind to target cells (e.g., cancer cell antigens, viral antigens, or microbial antigens), or other antibodies that bind to tumor cells or matrices. Can be analog. By "functionally active" herein is meant that the fragment, derivative or analog is capable of immunospecifically binding to a target cell. To determine whether a CDR sequence binds an antigen, a synthetic peptide containing the CDR sequence can be assayed for binding to the antigen by any binding assay method known in the art (e.g., BIA core assay). (For example, Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Fifth Edition, National Ins. position of Health, Bethesda, Md). Recombinant antibodies, such as chimeric monoclonal antibodies and humanized monoclonal antibodies that contain both human and non-human portions, are also useful antibodies. Chimeric antibodies are molecules in which different parts are derived from different animal species, such as those with variable regions derived from rat monoclonal antibodies and human immunoglobulin constant regions (e.g., U.S. Pat. No. 4,816,567; and No. 4,816,397). A humanized antibody is an antibody molecule derived from a non-human species that has one or more complementarity-determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule (e.g., as described in U.S. Pat. No. 5,585,089). Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example, using the methods described in (Berter et al., 1988, Science 240:1041-1043; Liu et al., 1987, Natl. Sci. 139:3521-3526; Sunet al., 1987 , Proc. Natl. Sci. USA 84:214-218; Nature 314:446-449; and Shaw et al. al., 1988, J. Natl. Cancer Inst. 80:1553-1559; Morrison, 1985, Science 229:1202-1207; es 4:214;; Jones et al., 1986, Nature 321:552-525; Verhoeyan et al., 1988, Science 239:1534; Beidler et al., 1988, J. Immunol. Fully human antibodies are particularly desirable and can be produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chain genes but are capable of expressing human heavy and light chain genes. can. Antibodies immunospecific for cancer cell antigens can be obtained commercially or produced by any method known to those skilled in the art, such as, for example, chemical synthesis or recombinant expression techniques. Nucleotide sequences encoding antibodies immunospecific for cancer cell antigens can be obtained, for example, from the GenBank or similar database, from the literature, or by conventional cloning and sequencing. In a specific embodiment, known antibodies for treating cancer can be used. Antibodies immunospecific for cancer cell antigens can be obtained commercially or produced by any method known to those skilled in the art, such as, for example, recombinant expression techniques. Nucleotide sequences encoding antibodies immunospecific for cancer cell antigens can be obtained, for example, from the GenBank or similar database, from the literature, or by conventional cloning and sequencing. In certain embodiments, useful antibodies are capable of binding to receptors or receptor complexes expressed on activated lymphocytes. The receptor or receptor complex includes a member of the immunoglobulin gene superfamily, a member of the TNF receptor superfamily, an integrin, a cytokine receptor, a chemokine receptor, a major histocompatibility protein, a lectin, or a complement control protein. be able to. In some embodiments, the antibody specifically binds to CD19, CD20, CD30, CD33, CD70, α-v-β-6, Liv-1 or Lewis Y antigen. Examples of antibodies that can be used for the treatment of cancer include, but are not limited to, the humanized anti-HER2 monoclonal antibody Herceptin® (trastuzumab; Genentech) for the treatment of patients with metastatic breast cancer. Rituxan® (rituximab; Genentech) (chimeric anti-CD20 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma); OvaRex (AltaRex Corporation, MA) (ovarian cancer Panorex (Glaxo Wellcome, NC) (mouse antibody / anti-EPCAM antibody for the treatment of colorectal cancer); Cetuximab Erbitux (Imclone) Systems Inc., NY) (IgG chimeric antibody / anti-EGFR antibody for the treatment of epidermal growth factor-positive cancers such as head and neck cancer); Vitaxin (MedImmune, Inc., MD) (for the treatment of breast cancer, lung cancer, etc.) Campath; Leukosite, MA; anti-CD52 antibody for the treatment of chronic lymphocytic leukemia (CLL); Smart M195; Protein Design Labs, Inc. .,CA)( Humanized anti-CD33 IgG antibody for the treatment of acute myeloid leukemia (AML); LymphoCide (Immunomedics, Inc., NJ) (humanized anti-CD22 IgG antibody for the treatment of non-Hodgkin's lymphoma); Smart ID10 ( Smart ID10; Protein Design Labs, Inc., CA) (humanized anti-HLA-DR antibody for the treatment of non-Hodgkin's lymphoma); Oncolym (Techniclone, Inc., CA) (for the treatment of non-Hodgkin's lymphoma) Radiolabeled murine anti-HLA-Dr10 antibody), Allomune (BioTransplant, CA) (humanized anti-CD2 mAb for the treatment of Hodgkin's disease or non-Hodgkin's lymphoma); Avastin (Genentech, Inc., CA) (lung cancer and anti-VEGF humanized antibodies for the treatment of colorectal cancer); Epratuzumab; Immunomedics, Inc. , NJ and Amgen, CA) (anti-CD22 antibody for the treatment of non-Hodgkin lymphoma); Patritumab (Daiichi Sankyo Co., Ltd.) (anti-HER3 humanized antibody for the treatment of lung and breast cancer cancers); and CEA-Cide (Labetuzumab Immunomedics, NJ) (humanized anti-CEA antibody for treatment of colorectal cancer), and the like. Other antibodies useful in the treatment of cancer include, but are not limited to, antibodies against the following antigens: For example, cancer / testis antigens such as MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, NY-ESO-1, PRAME, CT83, BAGE, XAGE, GAGE-1 and SSX2. Differentiation antigens such as , gp100, Melan A, Tyrosinase, CD20, CD22, CD33, CD79b, PSA and PAP, HER2, MUC-1, PSMA, CEA, survivin and WT- Overexpressed antigens such as 1 viral antigens such as HPV viral proteins (E6, E7, etc.) and Epstein-Barr virus (EBV) proteins (EBV-LMP2, etc.), mutant gene products such as p53, K-ras, and BCR-ABL. Examples include neo-antigens, CEA, α-fetoprotein (AFP), and oncofetal antigens. Specific examples of antibodies used in the present invention are listed below, but the present invention is not limited thereto. For example, anti-HER2 antibody, anti-EGFR antibody, anti-Lymphocyte Antigen 6E (Ly-6E) antibody, anti-Hepatocyte Growth Factor Receptor (HGFR) antibody, anti-CD22 antibody, anti-Folate Recept or alpha (FRα) antibody, anti-PSMA (FOLH1) antibody , anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-5T4 antibody, anti-Mesothelin antibody, anti-CD20 antibody, anti-CD33 antibody, anti-CDB7-H3 antibody, anti-CD269 (BCMA) antibody, anti-CD142 antibody , anti-CD70 antibody, anti-CD123 antibody, anti-TAG-72 antibody, anti-TFRC antibody, anti-EPHA2 antibody, anti-c-KIT antibody, anti-PD-L1 antibody, anti-Epithelial Cell Adhesion Molecule (EPCAM) antibody, anti-AXL antibody, anti- Interleukin-1 Receptor Accessory Protein antibody, anti-Mucin-16 (CA125) antibody, anti-MUC1 antibody, anti-GPC3 antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-Sodium- Dependent Phosphate Transport Protein 2B (SLC34A2 ) Antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-TweakR antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-CD147 antibody, anti-Sialyl-Tn antibody, anti-GCC antibody, anti-HER3 antibody, anti- Integrin antibody, anti-EGFR variant III antibody, anti-Claudin 6 antibody, Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 antibody, anti-PT K7 antibody, anti-LYPD3 antibody, anti-ASCT2 antibody, anti-ASPH antibody, anti-GPC1 antibody, anti-CD174 Antibodies, anti-CD38 antibodies, anti-ANGPT2 antibodies, CD44 antibodies, anti-DDL3 antibodies, anti-FGFR2 antibodies, anti-KAAG1 antibodies, anti-CD73 antibodies, anti-CLDN18.2 antibodies, anti-PRLR antibodies, anti-SEZ6 antibodies, anti-Neprilysin antibodies, anti-Neural Cell Adhesion Molecule 1 antibody, anti-CD166 (ALCAM) antibody, anti-CD24 antibody, anti-CD27 antibody, anti-CDH3 antibody, anti-EPHA4 antibody, anti-FGFR3 antibody, anti-GFRAL antibody, anti-Globo H antibody, anti-IL-13Ra2 antibody, anti-STEAP- 1 antibody, anti-TMCC3 antibody, anti-CD209 antibody, anti-CD37, anti-CD48 antibody, anti-CDCP1 antibody, anti-CD46 antibody, anti-CD200 antibody, anti-CTLA4 antibody, anti-CXCR5 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) antibody, anti CLDN6 / 9 antibody, anti-CEACAM6 antibody, anti-CA9 antibody, anti-EDNRB antibody, anti-GD3 Ganglioside antibody, anti-MICA / B antibody, anti-JAG1 / 2 antibody, anti-TM4SF1 antibody, anti-uPAR antibody, anti-Carbonic anhydrase IX antibody, anti-ALK1 Antibodies, anti-IGF-1R antibodies, anti-KDR antibodies, anti-CEACAM8 antibodies, anti-IL5R antibodies, anti-CD205 (Ly75) antibodies, anti-MSR1 antibodies, anti-KREMEN2 antibodies, anti-SSEA-4 antibodies, anti-CD228 antibodies, anti-CD5 antibodies, anti- DLL4 antibody, anti-FAP antibody, anti-Notch3 antibody, anti-AG7 antibody, anti-Guanylate Cyclases antibody, anti-Nectin-4 antibody, anti-CD226 (DNAM-1) antibody, anti-FcRL5 antibody, anti-HLA-DR antibody, anti-ITGB3 antibody, anti- DLK1 antibody, anti-CD157 (BST1) antibody, anti-CD56 (NCAM1) antibody, anti-MICA (MHC class I Polypeptide-Related Sequence A) antibody, anti-SSEA-1 antibody, anti-TRAIL-R2 (DR5) antibody , anti-GPNMB antibody, Anti-CCR5 antibody, anti-LAMP1 antibody, anti-LGALS3BP antibody, anti-ROR2 antibody, anti-DLL3 antibody, anti-ETBR antibody, anti-LIV-1 antibody, anti-Integrin αvβ6 antibody, anti-TIM-1 antibody, anti-AGS-16 (ENPP3) antibody, Anti-SLITRK6 antibody, anti-GD2 antibody, anti-CD52 antibody, anti-CCR4 antibody, anti-VEGFR2 antibody, anti-PDGFR antibody, anti-FGFR antibody, anti-SLAMF7 antibody, anti-GD2 Ganglioside antibody, anti-EPHA3 antibody, anti-Integrin αvβ3 antibody, anti-AGS-5 Antibodies, anti-CA19-9 antibodies, anti-PSA antibodies, anti-MAGE3 antibodies, anti-Transferrin receptor 1 (CD71) antibodies, anti-CEACAM1 antibodies, anti-CEACAM1 antibodies, anti-SLC3A2 (CD98) antibodies, anti-ACVR1 antibodies, anti-AG-7 antibodies, Anti-AMHR2 antibody, anti-ABCB1 antibody, anti-C16orf54 antibody, anti-CathepsinD antibody, anti-CCR7 antibody, anti-SLC44A4 antibody, anti-CD300LF antibody, anti-DPEP3 antibody, anti-FucGM1 antibody, anti-GPR20 antibody, anti-ITGB6 antibody, anti-Lewis-A-like Carbohydrate antibody, anti-prolactin receptor antibody, anti-Sialyl Tn antibody, anti-SLAMF6 antibody, anti-SLAMF7 antibody, anti-TRA-1-60 antibody, anti-matriptase antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-Can Ag antibody , anti-A33 antibody, anti-α10β1 integrin antibody, anti-ALPP antibody, anti-CD248 antibody, or anti-GPRC5D antibody. Antibodies expressed by generic names include, for example, trastuzumab, rituximab, palivizumab, infliximab, basiliximab, tocilizumab, bevacizumab, adalimumab, cetuximab, ranibizumab, omalizumab, eculizumab, ustekinumab, golimumab, canakinumab, denosumab, mogamulizumab, natalizumab, nivolumab. , secukinumab, ipilimumab, evolocumab, mepolizumab, alirocumab, ixekizumab, brodalumab, idarucizumab, pembrolizumab, sarilumab, bezlotoxumab, belimumab, avelumab, dupilumab, atezolizumab, benralizumab, emicizumab, guselkumab, durvalumab, vedolizumab, romosozumab, risankizumab, ravalizumab, bro Sumab, brolucizumab , tildrakizumab, satralizumab, galcanezumab, fremanezumab, erenumab, dinutuximab, anifrolumab, sotrovimab, bimekizumab, faricimab, nemolizumab, lanadelumab, ibritumomab, brentuximab, inotuzumab, polatuzumab, enfortumab, panitumumab, ofatumumab, pertuzumab, alemtuzumab, ramucirumab, elo tuzumab, daratumumab Otlertu zumab), rilotomab, teprotumumab, ganitumab, dalotuzumab ( dalotuzumab), cixutumumab, robatumumab, istiratumab, figitumumab, sibrotuzumab, mekubotamab, tilvestamab, mipacetamab, enapotamab, oregovomab, avagovomab, uba Matamab, Sofituzumab, Upifitamab, Rifastuzumab, Dacliximab ), daclizumab, inolimomab, camidanlumab, alsitumomab, artumomab, tusamitamab, labetuzumab, sibisatamab, patritumab, duligotumab, xenocutuzumab, seribantumab, barecetamab, rumletuzumab, ergemtumab, dicitamab, getuximab, zanidatamab, coprerotamab, inetetamab, gancotamab, Ambenitamab, Zenocutuzumab, Ertumaxomab, Runimotamab, Amivantamab, Nimotuzumab, Zaltumumab, Futuximab, Modotuximab, Depatuxizumab, Durigotumab, Tomzotuximab, Imgatuzumab, Matuzumab, Cercultamab, Petosemtamab, Rosatuxizumab, Etebritamab, Skiraslimab, Eplatuzumab, Vectuzumab momab, pinatuzumab, mirvetuximab, farletuzumab, rosopatamab, Capromab, Iratumumab, Sacituzumab, Datopotamab, Coltuximab, Denintuzumab, Duvortuxizumab, Roncastuximab, Obexelimab, Tafasitamab, Tapritumomab b), ubrituximab, tositumomab, ocrelizumab, ocaratuzumab ( Ocaratuzumab, Zuberitamab, Divozilimab, Imvotamab, Epcoritamab, Glofitamab, Odronextamab nexttamab), plamotamab, mosnetuzumab, amatuximab, Anetumab, Belantamab, Alnuctamab, Elranatamab, Linvoseltamab, Pacanalotamab, Pavurutam ab), Teclistamab, Vibecotamab, Talacotuzumab, Pibekimab, Flotetuzumab, Tucotuzumab, Catumaxomab, Solitomab, Oportuzumab, Edrecolomab, Citatuzumab ab), or Adecatumumab and one of these antibodies ~ Examples include antibodies having six (preferably six) complementarity determining regions (CDRs). The antibodies described herein also include modified antibodies. The modified form refers to an antibody that has been chemically or biologically modified. Chemical modifications include attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and the like. Biological modifications include post-translational modifications (e.g. N- or O-linked glycosylation, N- or C-terminal processing, deamidation, aspartic acid isomerization, methionine oxidation) These include those in which a methionine residue is added to the N-terminus by expression using a prokaryotic host cell. Also included in the meaning of such modifications are those labeled to enable detection or isolation of antibodies or antigens, such as enzyme labels, fluorescent labels, and affinity labels. Such modified antibodies of the present invention are useful for improving the stability and blood retention of the original antibodies, reducing antigenicity, and detecting or isolating such antibodies or antigens. Furthermore, by regulating the sugar chain modification (glycosylation, defucoselation, etc.) bound to the antibodies described herein, it is possible to enhance antibody-dependent cytotoxic activity. Techniques for regulating the sugar chain modification of antibodies include, but are not limited to, WO99 / 54342, WO00 / 61739, and WO02 / 31140. The antibodies of the present invention also include antibodies in which the sugar chain modification has been adjusted. When an antibody gene is once isolated and then introduced into an appropriate host to produce an antibody, a combination of an appropriate host and an expression vector can be used. Specific examples of antibody genes include a combination of a gene encoding a heavy chain sequence and a gene encoding a light chain sequence of the antibodies described herein. When transforming host cells, the heavy chain sequence gene and the light chain sequence gene can be inserted into the same expression vector or into separate expression vectors. be. When using eukaryotic cells as hosts, animal cells, plant cells, and eukaryotic microorganisms can be used. In particular, animal cells include mammalian cells such as monkey cells COS cells, mouse fibroblast NIH3T3 (ATCC No. CRL-1658), and Chinese hamster ovary cells (CHO cells, ATCC CCL-61) dihydrofolate. Examples include reductase-deficient strains. When using prokaryotic cells, examples include Escherichia coli and Bacillus subtilis. Antibodies can be obtained by introducing the desired antibody gene into these cells by transformation and culturing the transformed cells in vitro. In this culture, the yield may vary depending on the antibody sequence, and it is possible to select antibodies that are easy to produce as pharmaceuticals from among antibodies with equivalent binding activity using the yield as an indicator. Therefore, the antibody described herein includes a step of culturing the transformed host cell, and a step of collecting the antibody of interest or a functional fragment of the antibody from the culture obtained in the step. Also included are antibodies obtained by the method for producing antibodies characterized by the following. It is known that the lysine residue at the carboxyl terminus of the heavy chain of antibodies produced in cultured mammalian cells is deleted, and the two amino acid residues glycine and lysine at the carboxyl terminus of the heavy chain are also deleted. However, it is known that the proline residue located at the carboxyl terminus is newly amidated. However, these heavy chain sequence deletions and modifications do not affect the antigen binding ability and effector functions (complement activation, antibody-dependent cytotoxicity, etc.) of antibodies. Therefore, the antibodies described herein include the modified antibodies and functional fragments of the antibodies, including deletion forms in which one or two amino acids are deleted at the heavy carboxyl terminus, and amidated antibodies. Examples include deletions (for example, heavy chains in which the proline residue at the carboxyl terminal end is amidated). However, the deletion product of the carboxyl terminus of the heavy chain of the antibody according to the present invention is not limited to the above types, as long as the antigen binding ability and effector function are maintained. The two heavy chains constituting the antibody according to the present invention may be any one type of heavy chain selected from the group consisting of the full-length chain and the above-mentioned deletion form, or a combination of two types of heavy chains. It may be something. Although the amount ratio of each deletion product may be influenced by the type and culture conditions of the cultured mammalian cells producing the antibody according to the present invention, the main component of the antibody according to the present invention is carboxyl in both of the two heavy chains. Examples include cases where one terminal amino acid residue is deleted. The "antitumor drug molecule" described in this specification is a drug molecule that has an antitumor effect or cytotoxicity, regardless of its mechanism of action, and has a linker (L in general formula (I) above). １ or L ２ ) is not particularly limited as long as it has a substituent or partial structure that can be bonded to. The antitumor drug molecule preferably releases part or all of the linker within the tumor cell and exerts its antitumor effect. Examples of antitumor drug molecules include camptothecin; MMAE; maytansine; PBD (parabenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamicin ; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; dolastatin 10; superdox; ciprofloxacin; cardofloxacin (CS-940); or analogs or derivatives thereof Anti-tumor drug molecules independently selected from the group, etc. may be mentioned. An "analog" of "an anti-tumor drug molecule or an analog thereof, or a derivative thereof" as described herein means a chemical structure and activity similar to each anti-tumor drug molecule (i.e., an anti-tumor drug molecule or an analog thereof, or a derivative thereof). For example, "an analog of camptothecin" means a compound that has a chemical structure similar to camptothecin and has type I topoisomerase inhibitory activity like camptothecin. Analogs include, for example, anti-tumor drug molecules modified with solubilizing groups. As used herein, a "solubilizing group" is a group that increases the water solubility of a compound by ionizing or forming a hydrogen bond with a water molecule (i.e., increases the water solubility of a compound compared to one without the solubilizing group). It is a group that improves water solubility. Solubilizing groups include, for example, lactonyl groups (which may be, for example, β-propiolactone, γ-butyrolactone, or δ-valerolactone, preferably γ-butyrolactone), phosphoryl groups (-OPO ３ H ２ ), phosphonic acid group (-PO ３ H ２ ), dimethylaminobutyl group, carboxyl group, sulfonic acid group (-SO ３ H), nitrate group (-OSO ３ H), and C with one or more optionally substituted heteroatoms (e.g. O, S, or N) １ -C ６ Examples include alkyl groups. C with one or more heteroatoms (e.g. O, S, or N) １ -C ６ Examples of the alkyl group include an aminohexyl group, an aminopentyl group, an aminobutyl group, an aminopropyl group, an aminoethyl group, and an aminomethyl group. Also, C with one or more heteroatoms (e.g. O, S, or N) １ -C ６ Alkyl groups may be substituted, particularly with one, two, or three or more methyl groups. C with one or more optionally substituted heteroatoms (e.g. O, S, or N) １ -C ６ Examples of the alkyl group include aminohexyl, aminopentyl, aminobutyl, aminopropyl, aminoethyl, and aminomethyl groups substituted with one, two, or three or more methyl groups, such as , dimethylaminobutyl group. Substitutions for methyl groups include, for example, hydroxyl groups and halogens (eg, Cr, F, and Br). In certain preferred embodiments, the solubilizing group is a phosphoryl group (-OPO ３ H ２ ), or phosphonic acid group (-PO ３ H ２ ). The "derivative" of "antitumor drug molecules, analogs thereof, or derivatives thereof" as described herein refers to hydroxyl groups, sulfhydryl groups (-SH), amino groups present in the molecule of the antitumor drug. (-NH ２ , -NH- (including -NH- in the amide group and -NH- in the ring of the heteroaryl group or heterocyclyl group), a derivative in which a functional group such as a carboxyl group is protected with a "protecting group", or This shows a glycoside derivative produced when the group reacts with a saccharide. The protective groups of these derivatives are deprotected in vivo by various chemical, biochemical, or metabolic reactions (e.g., pH fluctuation, hydrolysis reaction, redox reaction, etc.) to form the parent compound (the original antitumor compound). In some cases, it is converted into a drug molecule) and exhibits antitumor activity, but in other cases, it is not deprotected and exhibits antitumor activity as it is. The "protective group" is described, for example, in Greene's Protective Groups in Organic Synthesis, 5th edition, P. G. M. Written by John Wiley & Sons Inc. (2014) and others. Examples of protective groups for the functional hydroxyl group include alkyloxyalkyl groups such as methyloxymethyl group, methoxyethyloxymethyl group, and ethoxy-2-ethyl group; arylalkyloxymethyl groups such as benzyloxymethyl group; phenyloxy Aryloxymethyl groups such as methyl groups; alkylthiomethyl groups such as methylthiomethyl groups; arylalkylthiomethyl groups such as benzylthiomethyl groups; arylthiomethyl groups such as phenylthiomethyl groups; Aminomethyl group which may be protected with a "protecting group"; Arylmethyl group such as benzyl group, 4-methoxybenzyl group, triphenylmethyl group; Alkylcarbonyl group such as methylcarbonyl group, ethylcarbonyl group; Allylcarbonyl group alkenylcarbonyl groups such as groups; alkynylcarbonyl groups such as propargylcarbonyl groups; arylcarbonyl groups such as phenylcarbonyl groups; heteroarylcarbonyl groups such as pyridin-2,3 or 4-ylcarbonyl groups; tetrahydrofuran-2 or 3-yl Heterocyclylcarbonyl groups such as carbonyl group and 5-oxotetrahydrofuran-2-ylcarbonyl group; Alkyloxycarbonyl groups such as tert-butyloxycarbonyl group, methyloxycarbonyl group, and ethyloxycarbonyl group; Allyloxycarbonyl group; Olenylmethyloxycarbonyl group, benzyloxycarbonyl group, 4-methoxybenzyloxycarbonyl group, 4(or 2)-nitrobenzyloxycarbonyl group, 4(or 2)-aminobenzyloxycarbonyl group or N-alkylcarbonyl derivative thereof or arylmethyloxycarbonyl group such as N-arylcarbonyl group, 4 (or 2)-hydroxybenzyloxycarbonyl group, or O-alkylcarbonyl group or O-arylcarbonyl group; tert-butylaminocarbonyl group, methylaminocarbonyl group , alkylaminocarbonyl groups such as ethylaminocarbonyl group; silyl groups such as trimethylsilyl group, trimethylsilylethoxymethyl group, tert-butyldimethylsilyl group, tert-butyldiphenylsilyl group; tetrahydropyranyl group, 2 (or 4)-methoxy A tetrahydropyranyl group such as a tetrahydropyranyl group can be mentioned. Further, the hydroxyl group may be protected as an ester with formic acid, boric acid, phosphoric acid, phosphonic acid, phosphinic acid, sulfuric acid, sulfonic acid, sulfinic acid, sulfenic acid, an amino acid, or a peptide. In one embodiment, the hydroxyl protecting group is an alkyloxyalkyl group; an arylalkyloxymethyl group; an aminomethyl group in which the N atom may be protected with an alkyl group or an "amino group protecting group" described below; an alkyl carbonyl group; alkenylcarbonyl group; alkynylcarbonyl group: arylcarbonyl group; alkyloxycarbonyl group; allyloxycarbonyl group; arylmethyloxycarbonyl group; alkylaminocarbonyl group; tetrahydropyranyl group; tetrahydrofuranyl group; ; lactonyl group; Nylalkyl group; lactonylcarbonyl group; lactonylalkylcarbonyl group; phosphoryl group; phosphorylalkyl group; or phosphorylalkylcarbonyl group. Examples of the protective group for the sulfhydryl group, which is a functional group, include the aforementioned protective groups for the hydroxyl group, but in addition to these, a disulfide bond (-S-S-) can also be used as a protective group. Examples of the protective group for the carboxy group which is a functional group include alkyl groups such as methyl group, ethyl group, and tert-butyl group; allyl group; arylmethyl group such as benzyl group; lactonyl group; trimethylsilyl group, trimethylsilylethoxymethyl group, Examples include silyl groups such as a tert-butyldimethylsilyl group and a tert-butyldiphenylsilyl group. In addition, the carboxyl group may be protected as an amide form (for example, an amide form with ammonia, alkylamine, dialkylamine, lactonylamine, amino acid ester, amino acid amide, etc.), and the amino group of the amide moiety is protected as a substituent. It may have a lactonyl group, a lactonylalkyl group, or a phosphorylalkyl group. In one embodiment, the protecting group for a carboxy group is an alkyl group; an allyl group; an arylmethyl group; a lactonyl group; a lactonylalkyl group; or a phosphorylalkyl group. For the functional groups sulfenic acid group, sulfinic acid group, sulfonic acid group, phosphinic acid group, phosphonic acid group, and boric acid group, the same protective groups as for the above-mentioned carboxy group can be used. Examples of protective groups for amino groups, which are functional groups, include alkyloxycarbonyl groups such as tert-butyloxycarbonyl group, methyloxycarbonyl group, and ethyloxycarbonyl group; allyloxycarbonyl group; 9-fluorenylmethyloxycarbonyl group , benzyloxycarbonyl group, 4-methoxybenzyloxycarbonyl group, 4(or 2)-nitrobenzyloxycarbonyl group, 4(or 2)-aminobenzyloxycarbonyl group or its N-alkylcarbonyl form or N-arylcarbonyl form , 4 (or 2)-hydroxybenzyloxycarbonyl group or an O-alkylcarbonyl or O-arylcarbonyl group thereof; an arylmethyl group such as a benzyl group or a triphenylmethyl group; a methyloxymethyl group , methoxyethyloxymethyl group, ethoxy-2-ethyl group, etc.; arylalkyloxymethyl group such as benzyloxymethyl group; aryloxymethyl group such as phenyloxymethyl group; alkylthiomethyl group such as methylthiomethyl group. group; arylalkylthiomethyl group such as benzylthiomethyl group; arylthiomethyl group such as phenyloxymethyl group; aminomethyl group whose N atom may be protected with an alkyl group or an amino protecting group; methylcarbonyl group, Alkylcarbonyl groups such as ethylcarbonyl groups; alkenylcarbonyl groups such as allylcarbonyl groups; alkynylcarbonyl groups such as propargylcarbonyl groups; arylcarbonyl groups such as phenylcarbonyl groups; heterocarbonyl groups such as pyridin-2,3 or 4-ylcarbonyl groups Arylcarbonyl group; heterocyclylcarbonyl group such as tetrahydrofuran-2 or 3-ylcarbonyl group, 5-oxotetrahydrofuran-2-ylcarbonyl group; or arylsulfonyl group such as 2,4-dinitrobenzenesulfonyl group, 4-nitrobenzenesulfonyl group ; and other amino group-protecting groups commonly used in peptide synthesis. Further, the amino group may be protected as an amide with formic acid, phosphoric acid, phosphonic acid, phosphinic acid, sulfuric acid, sulfonic acid, sulfinic acid, sulfenic acid, an amino acid, or a peptide. In one embodiment, the protecting group for the amino group is an alkyloxycarbonyl group; an allyloxycarbonyl group; an arylmethyloxycarbonyl group; an alkylcarbonyl group; an alkenylcarbonyl group; an arylcarbonyl group; a lactonyl group; a lactonylalkyl group; Nylcarbonyl group; lactonylalkylcarbonyl group; phosphoryl group; phosphorylalkyl group; or phosphorylalkylcarbonyl group. Attachment and removal of these protective groups is carried out according to commonly practiced methods (for example, Greene's Protective Groups in Organic Synthesis, 5th edition, written by P.G.M. Wuts, published by John Wiley & Sons Inc.) (2014) ). The above-mentioned functional groups can be protected as glycosides by reacting with various saccharides as described above. That is, it can be protected by a glycosyl group. Specific examples of the glycosyl group include D-glucosyl group, D-galactosyl group, D-mannosyl group, D-glucuronosyl group, etc., and the functional groups (-OH, -SH, -NH ２ , -NH-, -COOH groups, etc.) may also be protected as described above. These glycosides and their protected forms can be prepared using conventional methods commonly used in the field of glycochemistry (for example, Comprehensive Glycoscience From Chemistry to Systems Biology, Hans Kamerling (2007)). ). In addition, among the above functional groups, hydroxyl group, sulfhydryl group (-SH), amino group (-NH ２ , -NH- (including -NH- in the amide group and -NH- in the ring of the heteroaryl group or heterocyclyl group)) can be used with various sugar acids (gluconic acid, glucuronic acid, galacturonic acid, etc.), respectively. It may also be protected as an ester, thioester, amide or imide. The above describes the "protecting groups" for various functional groups in the "derivatives" of "antitumor drug molecules, analogs thereof, or derivatives thereof" described in this specification. It is also applicable to such functional groups in "oncologic drug molecules or analogs thereof", linkers, protecting groups or substituents. In one embodiment of the "protecting group" in the present invention, the protecting group is a polyetheralkyl-aminocarbonyl group, a glycosyl group, a lactonyl group; a lactonylalkyl group; a lactonylcarbonyl group; a lactonylalkylcarbonyl group; a phosphoryl group ; a phosphorylalkyl group; or a phosphorylalkylcarbonyl group. Note that the above-mentioned selection of a protecting group and its attachment / detachment method are also applied to the production of the compound (conjugate precursor) of general formula (II) described below. A specific example of the "antitumor drug molecule, an analog thereof, or a derivative thereof" described herein is shown in Example 1 below, and a specific example of the structure of the general formula (II): linker / multiple drug unit (LMDU) is shown in Example 2 below, and a specific example of the precursor of the antibody / multi-drug complex of general formula (III) is shown in Example 3 below, but the present invention is not limited thereto. Example 1. Examples of “antitumor drug molecules, analogs thereof, or derivatives thereof” camptothecin topotecan root tecan Exatecan SN-38 DB-67 BNP-1350 ST-1481 CKD-602 Dxd (N-(2-hydroxyacetyl)exatecan) U-001 U-002 U-003 U-004 U-005 U-006 U-007 MMAE (monomethyl auristatin E) MMAF (monomethyl auristatin F) MMAQ (monomethyl auristatin Q) MMAD (monomethyldolastatin 10) Dolastatin 10 U-008 U-009 U-010 U-011 U-012 U-013 U-014 U-015 U-016 U-017 U-018 U-019 U-020 U-021 U-022 U-023 U-024 U-025 U-026 U-027 U-028 U-029 U-030 U-031 U-032 U-033 U-034 U-035 U-036 U-037 U-038 U-039 U-040 U-041 U-042 U-043 U-044 U-045 maytansin DM-1 (Mertansine) DM-3 DM-4 PBD dimer Eribulin 5-FU PD-318088 AS-703026 TAK-733 LY-3023414 calicheamicin gamma 1 Paclitaxel docetaxel Mitomycin C Bleomycin A2 cyclocytidine vincristine Vinblastine Daunomycin Doxorubicin Superdox Ciprofloxacin Cardofloxacin (CS-940) U-046 U-047 U-048 U-049 U-050 U-051 U-052 U-053 U-054 U-055 U-056 U-057 U-058 U-059 U-060 U-061 U-062 U-063 U-064 U-065 U-066 U-067 U-068 U-069 U-070 U-071 U-072 U-073 U-074 U-075 U-076 U-077 U-078 U-079 U-080 U-081 U-082 U-083 U-084 U-085 U-086 U-087 U-088 U-089 U-090 U-091 U-092 U-093 U-094 U-095 U-096 U-097 U-098 U-099 U-100 U-101 U-102 U-103 U-104 The "residue of an anti-tumor drug molecule" described herein means one hydrogen atom or one hydrogen atom from any position of the "anti-tumor drug molecule, its analog, or its derivative". This is a residue produced by removing the hydroxyl group of The atoms or residues to be removed can be appropriately selected by those skilled in the art. The "alkyl group" described in this specification is a group obtained by removing one hydrogen atom from a linear or branched saturated hydrocarbon having 1 to 10 carbon atoms (ie, an alkane). Note that even if not specified, the alkyl group also includes an "optionally substituted alkyl group." As the substituent of the alkyl group which may be substituted, one or more substituents independently selected from Group A below can be mentioned. Group A Halogen atom (fluorine atom, chlorine atom, bromine atom, or iodine atom); Alkyloxy group; Hydroxyl group; Sulfhydryl group; Amino group; Alkylamino group; dialkylamino group (two alkyl groups may be taken together to form a heterocyclyl group containing an N atom); Carboxy group; Cyano group; Nitro group; Alkylcarbonyl group; Alkenylcarbonyl group; Alkynylcarbonyl group; Arylcarbonyl group; heteroarylcarbonyl group; heterocyclylcarbonyl group; Lactonylcarbonyl group; phosphorylalkylcarbonyl group; Alkyloxycarbonyl group; Aryloxycarbonyl group; heteroaryloxycarbonyl group; Aminocarbonyl group; an aminocarbonyl group in which the amino moiety is an amino group of any amino acid or peptide; N-alkylaminocarbonyl group; N,N-dialkylaminocarbonyl group (two alkyl groups may be taken together to form a heterocyclyl group containing an N atom); Aminocarbonyloxy group; N-alkylaminocarbonyloxy group; N,N-dialkylaminocarbonyloxy group (two alkyl groups may be taken together to form a heterocyclyl group containing an N atom); Alkyloxycarbonyloxy group; Aryloxycarbonyloxy group; heteroaryloxycarbonyloxy group; Ureido group; N-alkylureido group; N,N-dialkylureido group (two alkyl groups may be taken together to form a heterocyclyl group containing an N atom); N,N,N'-trialkylureido group (two alkyl groups on the same N atom may be taken together to form a heterocyclyl group containing an N atom); Guanidino group; Amidino group; hydrazino group; Alkylhydrazino group; N,N-dialkylhydrazino group; N,N'-dialkylhydrazino group; Alkylthio group; Alkylsulfinyl group; Alkylsulfonyl group; Arylthio group; Arylsulfinyl group; Arylsulfonyl group; heteroarylthio group; heteroarylsulfinyl group; heteroarylsulfonyl group; Sulfenic acid group; Sulfinic acid group; Sulfonic acid group; Sulfate group; Sulfinamide group; Sulfonamide group; Phosphine oxide group; Phosphinic acid group; Phosphoryl group (phosphonic acid group: -P(=O)(OH) ２ ); Phosphoric acid group (phosphate group: -O-P(=O)(OH) ２ ); Boric acid group; Alkenyl group; Alkynyl group; Cycloalkyl group; Cycloalkenyl group; Aryl group; heteroaryl group; heterocyclyl group; Lactonyl group; and -(OCH ２ CH ２ ) ｘ -Y group (x is an integer from 1 to 30, Y is hydrogen atom; Alkyl group; Halogen atom (fluorine atom, chlorine atom, bromine atom, or iodine atom); Alkyloxy group; Alkylthio group; Hydroxyl group; Sulfhydryl group; Amino group; Alkylamino group; dialkylamino group (two alkyl groups may be taken together to form a heterocyclyl group containing an N atom); Carboxy group; Cyano group; Nitro group; Alkylcarbonyl group; Alkenylcarbonyl group; Alkynylcarbonyl group; Arylcarbonyl group; heteroarylcarbonyl group; heterocyclylcarbonyl group; Lactonylcarbonyl group; phosphorylalkylcarbonyl group; Alkyloxycarbonyl group; Aryloxycarbonyl group; heteroaryloxycarbonyl group; Aminocarbonyl group; An aminocarbonyl group in which the amino group moiety is an amino group of any amino acid or peptide; N-alkylaminocarbonyl group; N,N-dialkylaminocarbonyl group (two alkyl groups may be taken together to form a heterocyclyl group containing an N atom); Aminocarbonyloxy group; N-alkylaminocarbonyloxy group; N,N-dialkylaminocarbonyloxy group (two alkyl groups may be taken together to form a heterocyclyl group containing an N atom); Alkyloxycarbonyloxy group; Aryloxycarbonyloxy group; heteroaryloxycarbonyloxy group; Ureido group; N-alkylureido group; N,N-dialkylureido group (two alkyl groups may be taken together to form a heterocyclyl group containing an N atom); N,N,N'-trialkylureido group (two alkyl groups on the same N atom may be taken together to form a heterocyclyl group containing an N atom); Guanidino group; Amidino group; hydrazino group; Alkylhydrazino group; N,N-dialkylhydrazino group; N,N'-dialkylhydrazino group; Alkylthio group; Alkylsulfinyl group; Alkylsulfonyl group; Arylthio group; Arylsulfinyl group; Arylsulfonyl group; heteroarylthio group; heteroarylsulfinyl group; heteroarylsulfonyl group; Sulfenic acid group; Sulfinic acid group; Sulfonic acid group; Sulfate group; Sulfinamide group; Sulfonamide group; Phosphine oxide group; Phosphinic acid group; Phosphoryl group (phosphonic acid group: -P(=O)(OH) ２ ); Phosphoric acid group (phosphate group: -O-P(=O)(OH) ２ ); Boric acid group; Alkyl group; Alkenyl group; Alkynyl group; Cycloalkyl group; Cycloalkenyl group; Aryl group; heteroaryl group; heterocyclyl group; or lactonyl group); A group consisting of Specific examples of the alkyl group include methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, Examples include n-hexyl group, n-heptyl group, n-octyl group, n-nonyl group, n-decyl group, and the like. In addition, when the term "alkane" is used in this specification, the alkane is a "linear chain having 1 to 10 carbon atoms," or "branched saturated hydrocarbon". The "alkenyl group" described in this specification refers to a linear or branched unsaturated hydrocarbon containing one or more double bonds (-C=C-) in the chain of the alkyl group defined above. It is the basis. As the substituent for the optionally substituted alkenyl group, one or more substituents independently selected from Group A can be mentioned. Specifically, the alkenyl group is, for example, a methylidene group (=CH ２ group), ethenyl group, 1-propenyl group, 2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1,3-butadienyl group, 1-methyl-2-propenyl group, 1,1 -dimethyl-2-propenyl group, 1-pentenyl group, 2-pentenyl group, 3-pentenyl group, 4-pentenyl group, 1-methyl-2-butenyl group, 3-methyl-1-butenyl group, 1-hexenyl group , 2-hexenyl group, 3-hexenyl group, 4-hexenyl group, 5-hexenyl group, 1-methyl-2-pentenyl group, 3-methyl-1-pentenyl group, 2-heptenyl group, 4-octenyl group, 1 -nonenyl group, 2-decenyl group, etc. The "alkynyl group" described in this specification refers to a linear alkyl group as defined above (with a carbon number of 2 to 10) containing one or more triple bonds (C triple bond C) in the chain; Or a branched unsaturated hydrocarbon group. As the substituent of the alkynyl group which may be substituted, one or more substituents independently selected from Group A can be mentioned. Specifically, the alkynyl group includes, for example, ethynyl group, 1-propynyl group, 2-propynyl group, 1-butynyl group, 2-butynyl group, 3-butynyl group, 1-methyl-2-propynyl group, 1,1-dimethyl-2-propynyl group, 1-pentynyl group, 2-pentynyl group, 3-pentynyl group, 4-pentynyl group, 1-methyl-2-butynyl group, 3-methyl-1-butynyl group, 1 -hexynyl group, 2-hexynyl group, 3-hexynyl group, 4-hexynyl group, 5-hexynyl group, 1-methyl-2-pentynyl group, 3-methyl-1-pentynyl group, 2-heptynyl group, 4-octynyl group group, 1-nonynyl group, 2-decynyl group, etc. The "alkyloxy group" described in this specification is a monovalent group (alkyl-O- group) in which the alkyl group having 1 to 10 carbon atoms as defined above is bonded to an oxy group. Specific examples of the alkyloxy group include methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butyloxy group, isobutyloxy group, sec-butyloxy group, tert-butyloxy group, n- Examples include pentyloxy group, n-hexyloxy group, n-heptyloxy group, n-octyloxy group, n-nonyloxy group, and n-decyloxy group. The "alkylthio group" described in this specification is a monovalent group (alkyl-S- group) in which the alkyl group having 1 to 10 carbon atoms as defined above is bonded to a thio group. Specific examples of the alkylthio group include methylthio group, ethylthio group, n-propylthio group, isopropylthio group, n-butylthio group, isobutylthio group, sec-butylthio group, tert-butylthio group, and n-pentylthio group. group, n-hexylthio group, n-heptylthio group, n-octylthio group, n-nonylthio group, n-decylthio group and the like. As the substituent for the optionally substituted alkyloxy group and alkylthio group, one or more substituents independently selected from Group A can be mentioned. The "cycloalkyl group" described in this specification refers to a group obtained by removing one hydrogen atom from a monocyclic cyclic hydrocarbon having 3 to 10 carbon atoms (i.e., cycloalkane), and a group having 4 to 10 carbon atoms. It is a group obtained by removing one hydrogen atom from a bicyclic cyclic hydrocarbon (that is, a bicyclic cycloalkane). . Examples of substituents for the cycloalkyl group that may be substituted include oxo group (=O); thioxo group (=S); imino group (=N(R８ )); Oxime group (=N-OR ９ ); hydrazono group (=N-N(R １０ )(R １１ )); alkyl group; and group A (hereinafter, the group consisting of oxo group; thioxo group; imino group; oxime group; hydrazono group; alkyl group; and group A is referred to as group B) One or more substituents may be mentioned (in the foregoing R ８ ,R ９ ,R １０ , and R １１ are each independently a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, a cycloalkenyl group, an aryl group, a heteroaryl group, or a heterocyclyl group). Specifically, the cycloalkyl group includes a unit having 3 to 10 carbon atoms, such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group, and a cyclodecyl group. Cyclic cycloalkyl group; bicyclo[1.1.0]butyl group, bicyclo[2.1.0]pentyl group, bicyclo[3.1.0]hexyl group, bicyclo[3.2.0]heptyl group , bicyclo[2.2.1]heptyl group, bicyclo[3.3.0]octyl group, bicyclo[3.2.1]octyl group, bicyclo[2.2.2]octyl group, bicyclo[6.1] 0]nonyl group, bicyclo[4.4.0]decyl group, and other bicyclic cycloalkyl groups having 4 to 10 carbon atoms. In addition, when the term "cycloalkane" is used in this specification, the cycloalkane is a "monocyclic ring having 3 to 10 carbon atoms" which is a "cycloalkyl group" defined above with one hydrogen atom attached. and bicyclic cyclic hydrocarbons having 4 to 10 carbon atoms. The "cycloalkenyl group" described in this specification refers to a monocyclic and bicyclic cyclic group containing one or more double bonds (-C=C-) in the ring of the cycloalkyl group defined above. It is a saturated hydrocarbon group. As the substituent of the optionally substituted cycloalkenyl group, one or more substituents independently selected from Group B can be mentioned. Specifically, the cycloalkenyl group includes, for example, 1-cyclopropenyl group, 1-cyclobutenyl group, 1-cyclopentenyl group, 2-cyclopentenyl group, 1-cyclohexenyl group, 2-cyclohexenyl group, 3 -Cyclohexenyl group, 1,3-cyclohexadienyl group, 1,4-cyclohexadienyl group, 1-cycloheptenyl group, 2-cyclooctenyl group, 3-cyclooctenyl group, 4-cyclooctenyl group, 1-cyclononenyl group, 1- Monocyclic cycloalkenyl group having 3 to 10 carbon atoms such as cyclodecenyl group; bicyclo[1.1.0]but-1-enyl group, bicyclo[2.1.0]pent-2-enyl group, bicyclo [3.1.0] hex-2-enyl group, bicyclo[3.2.0]hept-3-enyl group, bicyclo[2.2.1]hept-2-enyl group, bicyclo[3.3. 0] oct-2-enyl group, bicyclo[3.2.1]oct-2-enyl group, bicyclo[2.2.2]oct-2-enyl group, bicyclo[6.1.0]nona-4 -enyl group, bicyclo[4.4.0]dec-3-enyl group, and other bicyclic cycloalkenyl groups having 4 to 10 carbon atoms. The "aryl group" described in this specification is a group obtained by removing one hydrogen atom from a monocyclic or bicyclic aromatic hydrocarbon having 6 to 11 ring carbon atoms (i.e., arene). . As the substituent of the aryl group which may be substituted, one or more substituents independently selected from an alkyl group and Group A (hereinafter, the group consisting of an alkyl group and Group A is referred to as Group C) can be used. can be mentioned. Specifically, the aryl group includes, for example, a monocyclic aryl group such as a phenyl group; a partially saturated ring-constituting carbon group such as a naphthyl group, a tetrahydronaphthyl group, an indenyl group, and an indanyl group. Numbers 9 to 11 (C ９ ~C １１ ) bicyclic aryl groups, etc. In addition, when the term "arene" is used in this specification, the arene refers to a "monocyclic ring having 6 to 11 carbon atoms" which is the "aryl group" defined above with one hydrogen atom attached. A bicyclic aromatic hydrocarbon having 9 to 11 carbon atoms or a ring having 9 to 11 carbon atoms. The "heteroaryl group" described in this specification refers to a 5- to 14-membered monocyclic, bicyclic, or It is a group obtained by removing one hydrogen atom from a tricyclic aromatic heterocycle (ie, heteroarene). As the substituent of the optionally substituted heteroaryl group, one or more substituents independently selected from Group C can be mentioned. Specifically, the heteroaryl group includes, for example, a pyrrolyl group, a furyl group, a thienyl group, a pyrazolyl group, an imidazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, a pyridyl group, a pyrazinyl group, A 5- to 6-membered monocyclic heteroaryl group containing 1 to 4 heteroatoms selected from oxygen, sulfur, and nitrogen atoms in addition to carbon atoms, such as pyrimidinyl, pyridazinyl, and triazinyl groups; indolyl group, isoindolyl group, indazolyl group, tetrahydroindazolyl group, benzofuranyl group, dihydrobenzofuranyl group, dihydroisobenzofuranyl group, benzothiophenyl group, dihydrobenzothiophenyl group, dihydroisobenzothiophenyl group, benzoxa Zolyl group, dihydrobenzoxazolyl group, benzothiazolyl group, dihydrobenzothiazolyl group, quinolyl group, tetrahydroquinolyl group, isoquinolyl group, tetrahydroisoquinolyl group, naphthyridinyl group, tetrahydronaphthyridinyl group, quinoxalinyl group, 8- to 11-membered bicyclic heteroaryl groups containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms in addition to carbon atoms, such as tetrahydroquinoxalinyl groups and quinazolinyl groups; 11- to 14-membered tricyclic heteroaryl groups containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms in addition to carbon atoms, such as dibenzofuran, dibenzopyrrole, dibenzothiophene, dibenzopyridine, etc. can be mentioned. In addition, when the term "heteroarene" is used in this specification, the heteroarene is defined as a "heteroaryl group" defined above with one hydrogen atom attached to it, "an oxygen atom, a sulfur atom, etc. in addition to a carbon atom". 5- to 14-membered monocyclic, bicyclic, or tricyclic aromatic heterocycle containing 1 to 4 heteroatoms selected from atoms and nitrogen atoms. The "heterocyclyl group" described in this specification refers to a 3- to 12-membered monocyclic non-aromatic heterocycle containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms in addition to carbon atoms ( That is, it is a monovalent group obtained by removing one hydrogen atom from (heterocyclone). As substituents of the heterocyclyl group which may be substituted, oxo group (=O); thioxo group (=S); imino group (=NR ９ ;R ９ is the same as above); hydrazono group (=N-N(R １０ )(R １１ );R １０ and R １１ (same meaning as above); alkyl group; and group A (hereinafter, the group consisting of oxo group; thioxo group; imino group; hydrazono group; More than one substituent may be mentioned. Specifically, the heterocyclyl group includes, for example, an azetidinyl group, an oxetanyl group, a thietanyl group, a pyrrolidinyl group, a piperidinyl group, a piperidinyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, a tetrahydrothienyl group, a piperazinyl group, a morpholinyl group, Perhydroazepinyl group, azacyclooctyl group, azacyclooct-3-enyl group, azacyclooct-4-enyl group, azacyclononyl group, azacyclodecyl group, 6- to 12-membered azabicycloalkyl group (e.g. azabicyclohexyl group, azabicycloheptyl group, azabicyclooctyl group, azabicyclononyl group, azabicyclodecyl group, azabicycloundecyl group, or azabicyclododecyl group), a 6- to 12-membered azabicycloalkenyl group (e.g. azabicyclohexenyl group, azabicycloheptenyl group, azabicyclooctenyl group, azabicyclononenyl group, azabicyclodecenyl group, azabicycloundecenyl group, or azabicyclododecenyl group), 6-membered ~ Examples include 12-membered azaspiroalkyl groups (eg, azaspirohexyl group, azaspiroheptyl group, azaspirooctyl group, azaspirononyl group, azaspirodecyl group, azaspiroundecyl group, or azaspirododecyl group). In addition, when the term "heterocyclane" is used in this specification, the heterocyclane is defined as a "heterocyclyl group" defined above with one hydrogen atom attached, "an oxygen atom in addition to a carbon atom, 4- to 12-membered monocyclic non-aromatic heterocycle containing 1 to 4 heteroatoms selected from sulfur atoms and nitrogen atoms. The above-mentioned cyclic compounds cycloalkanes, arenes, heteroarenes, and heterocyclones may be condensed with any other cyclic compound to form a 2- to 4-ring cyclic compound; A monovalent or divalent group can be produced by removing one or two hydrogen atoms from a cyclic compound. The "lactonyl group" described in this specification is a type of the above-mentioned heterocyclyl group, and the heterocyclyl group has an oxygen atom as a heteroatom in the ring, and the carbon atom adjacent to the oxygen atom is substituted with an oxo group. The lactonyl group includes α-acetolactonyl group, β-propiolactonyl group, γ-butyrolactonyl group, δ-valerolactonyl group, ε-caprolactonyl group, γ-nonalactonyl group, γ-decalactonyl group. , γ-undecalactonyl group, glucono-δ-lactonyl group, or pantolactonyl group (monovalent residue of pantolactone), and may be substituted in the same manner as the above-mentioned heterocyclyl group. The lactonyl group is D in the antibody / multiple drug conjugate of the present invention represented by general formula (I). １ ,D ２ , L １ , L ２ or L ３ can be a substituent bonded to a carbon atom or a heteroatom (N, O, S, Se, P, etc.) present in Further, the lactonyl group may be a substituent bonded as a lactonylalkyl group, a lactonylcarbonyl group, or a lactonylalkylcarbonyl group. The "alkylene group" described in this specification means a divalent group obtained by removing one arbitrary hydrogen atom from the "alkyl group" defined above. Furthermore, when the alkyl group has a substituent, it means a divalent group obtained by removing one more arbitrary hydrogen atom from a carbon atom constituting the alkyl chain that is not a substituent. Furthermore, in the general formula (I) of the present invention, L １ and L ２ are each independently an optionally substituted alkylene group, One or more methylene groups in the chain of the alkylene group are -C(R １ )(R ２ )-;-O-;-N(R ３ )-;-N(R ３ )-N(R ３ )-;-S-;-Se-;-Si(R ４ )(R ５ )-;-S-S-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R ６ )(R ７ ))-;-C(=O)-;-C(=S)-;-C(=N(R ８ ))-;-C(=N-OR ９ )-;-C(=N-N(R １０ )(R １１ ))-;-P(=O)(R １２ )-;-P(=O)(OR １３ )-;-O-P(=O)(R １２ )-O-;-O-P(=O)(OR １３ )-O-;-C(R １４ )=;=C(R １４ )-;-C(R １４ )=C(R １４ )−;−N=;=N−;−C≡C−;−(O−C(R １ )(R ２ )-C(R １ )(R ２ )) １−３０ -;-(C(R １ )(R ２ )-C(R １ )(R ２ )−0) １−３０ -(In the above R １ ,R ２ ,R ３ ,R ４ ,R ５ ,R ６ ,R ７ ,R ８ ,R ９ ,R １０ ,R １１ ,R １２ ,R １３ , and R １４ are independently selected from a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, an aryl group, a heteroaryl group, and a heterocyclyl group; ３ is an alkyl group, the alkyl group may form a cyclic structure together with the alkyl group on the adjacent methylene group, m and n are independently integers from 0 to 2); an optionally substituted alkenylene group, an optionally substituted alkynylene group, an optionally substituted cycloalkylene group; an optionally substituted cycloalkenylene group; an optionally substituted arylene group; an optionally substituted arylene group; and optionally substituted heterocyclylene groups. As the substituent of the alkylene group which may be substituted, one or more substituents independently selected from Group A can be mentioned. Specifically, the alkylene group includes, for example, a methylene group, an ethylene group, a methylmethylene group, a trimethylene group, an ethylmethylene group, a dimethylmethylene group, an n-propylene group, an n-butylene group, an n-pentylene group, and an n-pentylene group. -hexylene group, n-heptylene group, n-octylene group, n-nonylene group, n-decylene group, n-undecylene group, n-dodecylene group, n-tridecylene group, n-tetradecylene group, n-pentadecylene group, n Examples include -hexadecylene group, n-heptadecylene group, n-octadecylene group, n-nonadecylene group, n-icosenylene group, n-triacontylene group, n-tetracontylene group, and n-pentacontylene group. The "alkenylene group" described in this specification means L in the general formula (I) １ and L ２ It is a group constituting a linker chain represented by, and means a divalent group obtained by removing one arbitrary hydrogen atom from the "alkenyl group" defined above. Further, when the alkenyl group has a substituent, it means a divalent group obtained by removing one more arbitrary hydrogen atom from a carbon atom constituting the alkenyl chain that is not a substituent. As the substituent of the optionally substituted alkenylene group, one or more substituents independently selected from Group A can be mentioned. Specifically, the alkenylene group includes, for example, ethenylene group, 1-propenylene group, 2-propenylene group, 1-butenylene group, 2-butenylene group, 3-butenylene group, 1,3-butadienylene group, 1- Methyl-2-propenylene group, 1,1-dimethyl-2-propenylene group, 1-pentenylene group, 2-pentenylene group, 3-pentenylene group, 4-pentenylene group, 1-methyl-2-butenylene group, 3-methyl -1-butenylene group, 1-hexenylene group, 2-hexenylene group, 3-hexenylene group, 4-hexenylene group, 5-hexenylene group, 1-methyl-2-pentenylene group, 3-methyl-1-pentenylene group, 2 -heptenylene group, 4-octenylene group, 1-nonenylene group, 2-decenylene group, 1-undecenylene group, 3-dodecenylene group, 2-tridecenylene group, 4-tetradecenylene group, 1-pentadecenylene group, 2-hexadecenylene group, 3 -Heptadecenylene group, 2-octadecenylene group, 1-nonadecenylene group, 1-icosenylene group, etc. The "alkynylene group" described in this specification means L in the general formula (I) １ and L ２ It is a group constituting a linker chain represented by, and means a divalent group obtained by removing one arbitrary hydrogen atom from the "alkynyl group" defined above. Furthermore, when the alkynyl group has a substituent, it means a divalent group obtained by removing one more arbitrary hydrogen atom from a carbon atom constituting the alkynyl chain that is not a substituent. As the substituent of the alkynylene group which may be substituted, one or more substituents independently selected from Group A can be mentioned. Specifically, the alkynylene group includes, for example, ethynylene group, 1-propynylene group, 2-propynylene group, 1-butynylene group, 2-butynylene group, 3-butynylene group, 1-methyl-2-propynylene group, 1,1-dimethyl-2-propynylene group, 1-pentynylene group, 2-pentynylene group, 3-pentynylene group, 4-pentynylene group, 1-methyl-2-butynylene group, 3-methyl-1-butynylene group, 1 -Hexynylene group, 2-hexynylene group, 3-hexynylene group, 4-hexynylene group, 5-hexynylene group, 1-methyl-2-pentynylene group, 3-methyl-1-pentynylene group, 2-heptynylene group, 4-octynylene group group, 1-nonynylene group, 2-decynylene group, 1-undecynylene group, 3-dodecynylene group, 2-tridecynylene group, 4-tetradecynylene group, 1-pentadecynylene group, 2-hexadecynylene group, 3-heptadecynylene group, 2-octadecynylene group , 1-nonadecynylene group, 1-icocynylene group, and the like. The "cycloalkylene group" described in this specification means L in the general formula (I) １ and L ２ It is a group constituting a linker chain represented by, and means a divalent group obtained by removing one arbitrary hydrogen atom from the "cycloalkyl group" defined above. Furthermore, when the cycloalkyl group has a substituent, it means a divalent group obtained by removing one more arbitrary hydrogen atom from a carbon atom constituting the cycloalkyl ring that is not a substituent. As the substituent of the optionally substituted cycloalkylene group, one or more substituents independently selected from Group B can be mentioned. Specifically, the cycloalkylene group includes a group having 3 carbon atoms, such as a cyclopropylene group, a cyclobutylene group, a cyclopentylene group, a cyclohexylene group, a cycloheptylene group, a cyclooctylene group, a cyclononylene group, and a cyclodecylene group. ~10 monocyclic cycloalkylene groups; bicyclo[1.1.0]butylene group, bicyclo[2.1.0]pentylene group, bicyclo[3.1.0]hexylene group, bicyclo[3.2. 0] heptylene group, bicyclo[2.2.1]heptylene group, bicyclo[3.3.0]octylene group, bicyclo[3.2.1]octylene group, bicyclo[2.2.2]octylene group, bicyclo Examples include bicyclic cycloalkylene groups having 4 to 10 carbon atoms, such as [6.1.0] nonylene group and bicyclo[4.4.0] decylene group. The "cycloalkenylene group" described in this specification means L in the general formula (I) １ and L ２ It is a group constituting a linker chain represented by, and means a divalent group obtained by removing one arbitrary hydrogen atom from the "cycloalkenyl group" defined above. Furthermore, when the cycloalkenyl group has a substituent, it means a divalent group obtained by removing one more arbitrary hydrogen atom from a carbon atom constituting the cycloalkenyl ring that is not a substituent. As the substituent of the optionally substituted cycloalkenylene group, one or more substituents independently selected from Group B can be mentioned. Specifically, the cycloalkenylene group includes, for example, 1-cyclopropenylene group, 1-cyclobutenylene group, 1-cyclopentenylene group, 2-cyclopentenylene group, 1-cyclohexenylene group, 2 -Cyclohexenylene group, 3-cyclohexenylene group, 1,3-cyclohexadienylene group, 1,4-cyclohexadienylene group, 1-cycloheptenylene group, 2-cyclooctenylene group, 3- Monocyclic cycloalkenylene group having 3 to 10 carbon atoms, such as cyclooctenylene group, 4-cyclooctenylene group, 1-cyclononenenylene group, 1-cyclodecenylene group; bicyclo[1.1.0]buta-1- enylene group, bicyclo[2.1.0]pent-2-enylene group, bicyclo[3.1.0]hex-2-enylene group, bicyclo[3.2.0]hept-3-enylene group, bicyclo[ 2.2.1] hept-2-enylene group, bicyclo[3.3.0]oct-2-enylene group, bicyclo[3.2.1]oct-2-enylene group, bicyclo[2.2.2 ] Oct-2-enylene group, bicyclo[6.1.0]non-4-enylene group, bicyclo[4.4.0]deca-3-nylene group, etc., bicyclic groups having 4 to 10 carbon atoms; Examples include cycloalkenyl groups. The "arylene group" described in this specification means L in the general formula (I) １ and L ２ It is a group constituting a linker chain represented by , and means a divalent group obtained by removing one arbitrary hydrogen atom from the "aryl group" defined above. Furthermore, when the aryl group has a substituent, it means a divalent group obtained by removing one more arbitrary hydrogen atom from a carbon atom constituting the aryl ring that is not a substituent. As the substituent of the optionally substituted arylene group, one or more substituents independently selected from Group C can be mentioned. Specifically, the arylene group includes, for example, a monocyclic arylene group having 6 to 11 ring carbon atoms such as a phenylene group; a naphthylene group, a tetrahydronaphthylene group, an indenylene group, and an indanilene group; Examples include bicyclic arylene groups having 9 to 11 ring carbon atoms that may be partially saturated. The "heteroarylene group" described herein means L in the general formula (I) １ and L ２ It is a group constituting a linker chain represented by, and means a divalent group obtained by removing one arbitrary hydrogen atom from the "heteroaryl group" defined above. Furthermore, when the heteroarylene group has a substituent, it means a divalent group obtained by removing one more arbitrary hydrogen atom from the heteroaryl ring constituent atom that is not a substituent. As the substituent of the optionally substituted heteroarylene group, one or more substituents independently selected from Group C can be mentioned. Specifically, the heteroarylene group includes, for example, a pyrrolilene group, a furylene group, a thienylene group, a pyrazolylene group, an imidazolylene group, an oxazorylene group, an isoxazorylene group, a thiazorylene group, an isothiazolylene group, a thiadiazolylene group, a pyridylene group, A 5- to 6-membered monocyclic heteroarylene containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms in addition to carbon atoms, such as pyrazinylene group, pyrimidinylene group, pyridazinylene group, and triazinylene group. Group; indolylene group, isoindolylene group, indazolylene group, tetrahydroindazolylene group, benzofuranylene group, dihydrobenzofuranylene group, dihydroisobenzofuranylene group, benzothiophenylene group, dihydrobenzothiophenylene group, dihydroisobenzothio Phenylene group, benzoxazorylene group, dihydrobenzoxazorylene group, benzothiazolylene group, dihydrobenzothiazolylene group, quinorylene group, tetrahydroquinolylene group, isoquinorylene group, tetrahydroisoquinolylene group, naphthyridinylene group, tetrahydro 8- to 11-membered groups containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms in addition to carbon atoms, such as naphthyridinylene group, quinoxalynylene group, tetrahydroquinoxalynylene group, and quinazolinylene group. Bicyclic heteroarylene groups can be mentioned. The "heterocyclylene group" described in this specification refers to a 4- to 12-membered monocyclic non-aromatic hetero atom containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms, and nitrogen atoms in addition to carbon atoms. It is a ring group. As the substituent of the optionally substituted heterocyclylene group, one or more substituents independently selected from Group D can be mentioned. Specifically, the heterocyclylene group includes, for example, an azetidinylene group, an oxetanylene group, a thietanylene group, a pyrrolidinylene group, a piperidinylene group, a piperidinylene group, a tetrahydrofylene group, a tetrahydropyranylene group, a tetrahydrothienylene group, and a piperazinylene group. , morpholinylene group, perhydroazepinylene group, azacyclooctylene group, azacyclooct-3-enylene group, azacyclooct-4-enylene group, azacyclononylene group, azacyclodecylene group, 6-membered ~ A 12-membered azabicycloalkylene group (e.g., azabicyclohexylene group, azabicycloheptylene group, azabicyclooctylene group, azabicyclononylene group, azabicyclodecylene group, azabicycloundecylene group, or azabicyclodo) decylene group), 6- to 12-membered azabicycloalkenylene group (e.g., azabicyclohexenylene group, azabicycloheptenylene group, azabicyclooctenylene group, azabicyclononenenylene group, azabicyclodecenylene group) , azabicycloundecenylene group, or azabicyclododecenylene group), a 6- to 12-membered azaspiroalkylene group (e.g., azaspirohexylene group, azaspiroheptylene group, azaspirooctylene group, azaspirononylene group, azaspirodecylene group, azaspiroundecylene group, or azaspirododecylene group). The heterocyclylene group may be condensed with one or more of the aryl rings and / or the heteroaryl rings to form a 2-4 ring heterocyclylene group. In addition, the above-mentioned alkyl group, alkenyl group, alkynyl group, cycloalkyl group, cycloalkenyl group, aryl group, heteroaryl group, heterocyclyl group, alkylene group, alkenylene group, alkynylene group, cycloalkylene group, cycloalkenylene group, arylene group , heteroarylene group, and heterocyclylene group have a hydroxyl group, a sulfhydryl group, an amino group (-NH ２ , -NH- (including -NH- in the ring of heteroaryl group and heterocyclyl group)), carboxy group, sulfenic acid group, sulfinic acid group, sulfonic acid group, phosphinic acid group, phosphonic acid group, or boric acid group, etc. When the functional group has a functional group, those groups may be protected with the protecting group described above for "antitumor drug molecules, analogs thereof, or derivatives thereof." The "pharmacologically acceptable salts" described herein include salts of alkali metals such as lithium, sodium, and potassium; salts of Group 2 metals such as magnesium and calcium; salts with aluminum or zinc; ammonia, choline, etc. , diethanolamine, lysine, ethylenediamine, tert-butylamine, tert-octylamine, tris(hydroxymethyl)aminomethane, N-methyl-glucosamine, triethanolamine, and salts with amines such as dehydroabiethylamine; hydrogen chloride, bromide Salts with inorganic acids such as hydrogen, hydrogen iodide, sulfuric acid, nitric acid, and phosphoric acid; formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, apple acid salts with organic acids such as tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, and benzenesulfonic acid; or salts with acidic amino acids such as aspartic acid and glutamic acid. Furthermore, "pharmacologically acceptable salts" also include inner salts. Note that the antibody / multi-drug conjugate of the present invention and its pharmacologically acceptable salts may be obtained as hydrates or solvates, and the present invention includes any of them. In the antibody / multi-drug conjugate of the present invention (general formula (I)), the portion other than "A(antibody)-B-", that is, the linker / multi-drugs unit: hereinafter referred to in the present specification. The structure of the linker / multiple drug unit (LMDU) is shown below as general formula (II) (sometimes abbreviated as LMDU). １ , L ２ , L ３ ,D １ and D ２ configured by any combination of Linker / multiple drug unit; structure of LMDU General formula (II): In the general formula (II) above, L １ , L ２ , L ３ ,D １ and D ２ has the same meaning as above. Specific examples of the linker / multiple drug unit (LMDU) represented by the above general formula (II) are illustrated below, but the present invention is not limited thereto. Example 2. Example of linker / multiple drug unit (LMDU) Example 2-1 Example 2-2 Example 2-3 Example 2-4 Example 2-5 Example 2-6 Example 2-7 Example 2-8 Example 2-9 Example 2-10 Example 2-11 Example 2-12 Example 2-13 Example 2-14 Example 2-15 [Production method] Next, a general manufacturing method for the antibody / multi-drug conjugate of the present invention and its intermediates will be explained. The antibody / multi-drug conjugate of the present invention is produced by reacting an antibody with a compound of general formula (III) (hereinafter referred to as a reactive precursor). General formula (III): [In the formula, Z is a sulfhydryl group (-SH) or an amino group (-NH ２ ) to form a covalent bond, such as Hal-CH ２ -C(=O)- group (Hal is Cl, Br or I), maleimidyl group, ethynylphosphonamidate group (Hackenberger C.P.R. et.al., Angew. Chem. Int. Ed. 58, 11631 -11636 (2019)), carboxy group, N-hydroxysuccinimidyl ester group, etc. The maleimidyl group has the following formula: [In the formula, * is “L” ４ ] The ethynylphosphonamidate group has the following formula: (R １６ is a methyl group, an ethyl group, -CH ２ CH ２ OCH ２ CH ２ (OH group, etc.) [In the formula, * is “L” ４ ] The N-hydroxysuccinimidyl ester group has the following formula: [In the formula, * is “L” ４ ] It is expressed as L ４ is L defined above ３ is a linker that constitutes a part of the structure, and MDU is a linker that forms part of the structure of L ３ is a residue (multiple drug units) from which is removed, and is represented by the following general formula (IV)] General formula (IV): Structure of MDU [In the formula, L １ , L ２ ,D １ ,D ２ , and G have the same meanings as above] Examples of general formula (III) are shown below. Example 3. Compound of general formula (III) (Z-L ４ -MDU) example Example 3-1 Example 3-2 Example 3-3 Example 3-4 Example 3-5 Example 3-6 Example 3-7 Example 3-8 Example 3-9 Example 3-10 Example 3-11 Example 3-12 Example 3-13 Example 3-14 Example 3-15 Example A3. Example A3-1 Example A3-2 Example A3-3 Example A3-4 Example A3-5 Example A3-6 Example A3-7 Example A3-8 Example A3-9 Example A3-10 Example A3-11 Example A3-12 Example A3-13 Example A3-14 Example A3-15 Example A3-16 Example A3-17 Example A3-18 Example A3-19 Example A3-20 Example A3-21 Example A3-22 Example A3-23 Example A3-24 Further example three compounds (exemplary precursor compounds) may be represented by formula (X). {here, Z is Z in the table below, L １ Ha, L １−ａ ~L １−ｂ is one selected from the group consisting of; L ２ Ha, L ２−ａ ~L ２−ｄ is one selected from the group consisting of; L ３ Ha, L ３−ａ ~L ３−ｉ is one selected from the group consisting of; D １ D. １−ａ ~D １−ｂ is one selected from the group consisting of; D ２ D. ２−ａａ ~D ２−ａｔ is one selected from the group consisting of; *1 is connected to *1, *1' is connected to *1', *2 is connected to *2, *2' is connected to *2', *3 is connected to *3, * 3' is connected to *3'. } Further exemplary precursor compounds may be represented by formula (XI). {here, Z is Z in the table below, L １ Ha, L １−ａ ~L １−ｂ is one selected from the group consisting of; L ２ Ha, L ２−ｂ ~L ２−ｈ is one selected from the group consisting of; L ３ Ha, L ３−ａ ~L ３−ｉ is one selected from the group consisting of; D １ D. １−ａ ~D １−ｂ is one selected from the group consisting of; D ２ D. ２−ｂａ ~D ２−ｂｇ is one selected from the group consisting of; *1 is connected to *1, *1' is connected to *1', *2 is connected to *2, *2' is connected to *2', *3 is connected to *3, * 3' is connected to *3'. } Further exemplary precursor compounds may be represented by formula (XII). {here, Z is Z in the table below, L １ Ha, L １−ａ ~L １−ｂ is one selected from the group consisting of; L ２ Ha, L ２−ｂ , L ２−ｂ , L ２−ｉ ~L ２−ｎ is one selected from the group consisting of; L ３ Ha, L ３−ａ ~L ３−ｉ is one selected from the group consisting of; D １ D. １−ａ ~D １−ｂ is one selected from the group consisting of; D ２ D. ２−ｃａ ~D ２−ｃｈ is one selected from the group consisting of; *1 is connected to *1, *1' is connected to *1', *2 is connected to *2, *2' is connected to *2', *3 is connected to *3, * 3' is connected to *3'. } Further exemplary precursor compounds may be represented by formula (XIII). {here, Z is Z in the table below, L １ Ha, L １−ａ ~L １−ｂ is one selected from the group consisting of; L ２ Ha, L ２−ｏ ~L ２−ｒ is one selected from the group consisting of; L ３ Ha, L ３−ａ ~L ３−ｅ , and L ３−ｊ ~L ３−ｍ is one selected from the group consisting of; D １ D. １−ａ ~D １−ｂ is one selected from the group consisting of; D ２ D. ２−ｄａ and *1 is connected to *1, *1' is connected to *1', *2 is connected to *2, *2' is connected to *2', *3 is connected to *3, * 3' is connected to *3'. } The present invention also provides exemplary precursor compounds (Examples 4-1 to 4-1440) {in the following formulas, Z, L １−ａ ~L １−ｂ , L ２−ａ ~L ２−ｄ , L ３−ａ ~L ３−ｉ ,D １−ａ ~D １−ｂ , and D ２−ａａ ~D ２−ａｔ is as defined above} may be provided. Example 4-1: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-2: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-3: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-4: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-5: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-6: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-7: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-8: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-9: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-10: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-11: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-12: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-13: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-14: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-15: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-16: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-17: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-18: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-19: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-20: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-21: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-22: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-23: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-24: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-25: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-26: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-27: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-28: Z-L ３−ａ -N(-L １−ａ-D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-29: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-30: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-31: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-32: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-33: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-34: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-35: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-36: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-37: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-38: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-39: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-40: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-41: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-42: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-43: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-44: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-45: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-46: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-47: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-48: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-49: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-50: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-51: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-52: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-53: Z-L ３−ａ -N(-L １−ｂ− D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-54: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-55: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-56: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-57: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-58: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-59: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-60: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-61: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-62: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-63: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-64: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-65: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-66: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-67: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-68: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-69: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-70: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-71: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-72: Z-L３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-73: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-74: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-75: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-76: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-77: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-78: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-79: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-80: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-81: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-82: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-83: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-84: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-85: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-86: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-87: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-88: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-89: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-90: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-91: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-92: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-93: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-94: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-95: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-96: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-97: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-98: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-99: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-100: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-101: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-102: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-103: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-104: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-105: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-106: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-107: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-108: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-109: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-110: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-111: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-112: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-113: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-114: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-115: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L２−ｃ -D ２−ａｏ ), Example 4-116: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-117: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-118: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-119: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-120: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-121: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-122: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-123: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-124: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-125: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-126: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-127: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-128: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-129: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-130: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-131: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-132: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-133: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-134: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-135: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-136: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-137: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-138: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-139: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-140: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-141: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-142: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-143: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-144: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-145: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-146: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-147: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-148: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-149: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-150: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-151: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-152: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-153: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-154: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-155: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-156: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-157: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-158: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-159: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-160: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-161: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-162: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-163: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-164: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-165: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-166: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-167: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-168: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-169: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-170: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-171: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-172: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-173: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-174: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-175: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-176: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-177: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-178: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-179: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-180: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-181: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-182: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-183: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-184: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-185: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-186: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-187: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-188: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-189: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-190: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-191: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-192: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-193: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-194: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-195: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-196: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-197: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-198: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-199: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-200: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-201: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-202: Z-L３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-203: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-204: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-205: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-206: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-207: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-208: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-209: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-210: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-211: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-212: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-213: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-214: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-215: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-216: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-217: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-218: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-219: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-220: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-221: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-222: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-223: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-224: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-225: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-226: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-227: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-228: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-229: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-230: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-231: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-232: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-233: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-234: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-235: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-236: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-237: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-238: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-239: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-240: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-241: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-242: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-243: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-244: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-245: Z-L ３−ｂ -N(-L １−ａ-D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-246: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-247: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-248: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-249: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-250: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-251: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-252: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-253: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-254: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-255: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-256: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-257: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-258: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-259: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-260: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-261: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-262: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-263: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-264: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-265: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-266: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-267: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-268: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-269: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-270: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-271: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-272: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-273: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-274: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-275: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-276: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-277: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-278: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-279: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-280: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-281: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-282: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-283: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-284: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-285: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-286: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-287: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-288: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L２−ａ -D ２−ａｈ ), Example 4-289: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-290: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-291: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-292: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-293: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-294: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-295: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-296: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-297: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-298: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-299: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-300: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-301: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-302: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-303: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-304: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-305: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-306: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-307: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-308: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-309: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-310: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-311: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-312: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-313: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-314: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-315: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-316: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-317: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-318: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-319: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-320: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-321: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-322: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-323: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-324: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-325: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-326: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-327: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-328: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-329: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-330: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-331: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-332: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-333: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-334: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-335: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-336: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-337: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-338: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-339: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-340: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-341: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-342: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-343: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-344: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-345: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-346: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-347: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-348: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-349: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-350: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-351: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-352: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-353: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-354: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-355: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-356: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-357: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-358: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-359: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-360: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-361: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-362: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-363: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-364: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-365: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-366: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-367: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-368: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-369: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-370: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-371: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-372: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-373: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-374: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-375: Z-L３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-376: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-377: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-378: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-379: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-380: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-381: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-382: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-383: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-384: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-385: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-386: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-387: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-388: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-389: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-390: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-391: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-392: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-393: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-394: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-395: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-396: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-397: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-398: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-399: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-400: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-401: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-402: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-403: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-404: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-405: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-406: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-407: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-408: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-409: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-410: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-411: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-412: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-413: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-414: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-415: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-416: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-417: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-418: Z-L ３−ｃ -N(-L １−ａ-D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-419: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-420: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-421: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-422: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-423: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-424: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-425: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-426: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-427: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-428: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-429: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-430: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-431: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-432: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-433: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-434: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-435: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-436: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-437: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-438: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-439: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-440: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-441: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-442: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-443: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-444: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-445: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-446: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-447: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-448: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-449: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-450: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-451: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-452: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-453: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-454: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-455: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-456: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-457: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-458: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-459: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-460: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-461: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L２−ｃ -D ２−ａａ ), Example 4-462: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-463: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-464: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-465: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-466: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-467: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-468: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-469: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-470: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-471: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-472: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-473: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-474: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-475: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-476: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-477: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-478: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-479: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-480: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-481: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-482: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-483: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-484: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-485: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-486: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-487: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-488: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-489: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-490: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-491: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-492: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-493: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-494: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-495: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-496: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-497: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-498: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-499: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-500: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-501: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-502: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-503: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-504: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-505: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-506: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-507: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-508: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-509: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-510: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-511: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-512: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-513: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-514: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-515: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-516: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-517: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-518: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-519: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-520: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-521: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-522: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-523: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-524: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-525: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-526: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-527: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-528: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-529: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-530: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-531: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-532: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-533: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-534: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-535: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-536: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-537: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-538: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-539: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-540: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-541: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-542: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-543: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-544: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-545: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-546: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-547: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-548: Z-L３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-549: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-550: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-551: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-552: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-553: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-554: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-555: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-556: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-557: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-558: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-559: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-560: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-561: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-562: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-563: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-564: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-565: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-566: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-567: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-568: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-569: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-570: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-571: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-572: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-573: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-574: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-575: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-576: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-577: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-578: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-579: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-580: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-581: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-582: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-583: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-584: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-585: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-586: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-587: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-588: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-589: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-590: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-591: Z-L ３−ｄ -N(-L １−ａ-D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-592: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-593: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-594: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-595: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-596: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-597: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-598: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-599: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-600: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-601: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-602: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-603: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-604: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-605: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-606: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-607: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-608: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-609: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-610: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-611: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-612: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-613: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-614: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-615: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-616: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-617: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-618: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-619: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-620: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-621: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-622: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-623: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-624: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-625: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-626: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-627: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-628: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-629: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-630: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-631: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-632: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-633: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-634: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L２−ｃ -D ２−ａｎ ), Example 4-635: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-636: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-637: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-638: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-639: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-640: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-641: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-642: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-643: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-644: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-645: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-646: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-647: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-648: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-649: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-650: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-651: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-652: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-653: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-654: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-655: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-656: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-657: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-658: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-659: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-660: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-661: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-662: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-663: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-664: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-665: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-666: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-667: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-668: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-669: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-670: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-671: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-672: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-673: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-674: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-675: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-676: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-677: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-678: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-679: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-680: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-681: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-682: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-683: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-684: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-685: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-686: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-687: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-688: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-689: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-690: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-691: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-692: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-693: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-694: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-695: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-696: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-697: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-698: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-699: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-700: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-701: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-702: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-703: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-704: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-705: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-706: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-707: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-708: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-709: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-710: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-711: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-712: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-713: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-714: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-715: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-716: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-717: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-718: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-719: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-720: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-721: Z-L３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-722: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-723: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-724: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-725: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-726: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-727: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-728: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-729: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-730: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-731: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-732: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-733: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-734: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-735: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-736: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-737: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-738: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-739: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-740: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-741: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-742: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-743: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-744: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-745: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-746: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-747: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-748: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-749: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-750: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-751: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-752: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-753: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-754: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-755: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-756: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-757: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-758: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-759: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-760: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-761: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-762: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-763: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-764: Z-L ３−ｅ -N(-L １−ｂ-D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-765: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-766: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-767: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-768: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-769: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-770: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-771: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-772: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-773: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-774: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-775: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-776: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-777: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-778: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-779: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-780: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-781: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-782: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-783: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-784: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-785: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-786: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-787: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-788: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-789: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-790: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-791: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-792: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-793: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-794: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-795: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-796: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-797: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-798: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-799: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-800: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-801: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-802: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-803: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-804: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-805: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-806: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-807: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L２−ａ -D ２−ａｇ ), Example 4-808: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-809: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-810: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-811: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-812: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-813: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-814: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-815: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-816: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-817: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-818: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-819: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-820: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-821: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-822: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-823: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-824: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-825: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-826: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-827: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-828: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-829: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-830: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-831: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-832: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-833: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-834: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-835: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-836: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-837: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-838: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-839: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-840: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-841: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-842: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-843: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-844: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-845: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-846: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-847: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-848: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-849: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-850: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-851: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-852: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-853: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-854: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-855: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-856: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-857: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-858: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-859: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-860: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-861: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-862: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-863: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-864: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-865: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-866: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-867: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-868: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-869: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-870: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-871: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-872: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-873: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-874: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-875: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-876: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-877: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-878: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-879: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-880: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-881: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-882: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-883: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-884: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-885: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-886: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-887: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-888: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-889: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-890: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-891: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-892: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-893: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-894: Z-L３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-895: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-896: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-897: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-898: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-899: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-900: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-901: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-902: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-903: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-904: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-905: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-906: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-907: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-908: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-909: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-910: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-911: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-912: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-913: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-914: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-915: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-916: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-917: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-918: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-919: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-920: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-921: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-922: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-923: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-924: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-925: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-926: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-927: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-928: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-929: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-930: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-931: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-932: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-933: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-934: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-935: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-936: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-937: Z-L ３−ｆ -N(-L １−ｂ-D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-938: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-939: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-940: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-941: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-942: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-943: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-944: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-945: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-946: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-947: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-948: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-949: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-950: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-951: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-952: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-953: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-954: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-955: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-956: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-957: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-958: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-959: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-960: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-961: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-962: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-963: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-964: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-965: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-966: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-967: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-968: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-969: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-970: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-971: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-972: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-973: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-974: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-975: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-976: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-977: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-978: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-979: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-980: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L２−ｂ -D ２−ａｔ ), Example 4-981: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-982: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-983: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-984: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-985: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-986: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-987: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-988: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-989: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-990: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-991: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-992: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-993: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-994: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-995: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-996: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-997: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-998: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-999: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1000: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-1001: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-1002: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-1003: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-1004: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-1005: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-1006: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-1007: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-1008: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-1009: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-1010: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-1011: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-1012: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-1013: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-1014: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-1015: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-1016: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-1017: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-1018: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-1019: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-1020: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-1021: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-1022: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-1023: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L２−ｃ -D ２−ａｃ ), Example 4-1024: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-1025: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-1026: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-1027: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-1028: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-1029: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-1030: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-1031: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-1032: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-1033: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-1034: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-1035: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-1036: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-1037: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-1038: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-1039: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1040: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-1041: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-1042: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-1043: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-1044: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-1045: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-1046: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-1047: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-1048: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-1049: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-1050: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-1051: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-1052: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-1053: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-1054: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-1055: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-1056: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-1057: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-1058: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-1059: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-1060: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-1061: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-1062: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-1063: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-1064: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-1065: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-1066: Z-L ３−ｇ -N(-L １−ａ -D１−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-1067: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-1068: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-1069: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-1070: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-1071: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-1072: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-1073: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-1074: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-1075: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-1076: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-1077: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-1078: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-1079: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1080: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-1081: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-1082: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-1083: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-1084: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-1085: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-1086: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-1087: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-1088: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-1089: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-1090: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-1091: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-1092: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-1093: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-1094: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-1095: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-1096: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-1097: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-1098: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-1099: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-1100: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-1101: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-1102: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-1103: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-1104: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-1105: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-1106: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-1107: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-1108: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-1109: Z-L ３−ｇ -N(-L１−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-1110: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-1111: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-1112: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-1113: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-1114: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-1115: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-1116: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-1117: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-1118: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-1119: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1120: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-1121: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-1122: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-1123: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-1124: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-1125: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-1126: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-1127: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-1128: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-1129: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-1130: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-1131: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-1132: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-1133: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-1134: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-1135: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-1136: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-1137: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-1138: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-1139: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-1140: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-1141: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-1142: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-1143: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-1144: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-1145: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-1146: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-1147: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-1148: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-1149: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-1150: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-1151: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-1152: Z-L３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-1153: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-1154: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-1155: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-1156: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-1157: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-1158: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-1159: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1160: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-1161: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-1162: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-1163: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-1164: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-1165: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-1166: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-1167: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-1168: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-1169: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-1170: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-1171: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-1172: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-1173: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-1174: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-1175: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-1176: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-1177: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-1178: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-1179: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-1180: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-1181: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-1182: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-1183: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-1184: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-1185: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-1186: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-1187: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-1188: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-1189: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-1190: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-1191: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-1192: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-1193: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-1194: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-1195: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-1196: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-1197: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-1198: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-1199: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1200: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-1201: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-1202: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-1203: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-1204: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-1205: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-1206: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-1207: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-1208: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-1209: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-1210: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-1211: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-1212: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-1213: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-1214: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-1215: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-1216: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-1217: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-1218: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-1219: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-1220: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-1221: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-1222: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-1223: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-1224: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-1225: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-1226: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-1227: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-1228: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-1229: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-1230: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-1231: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-1232: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-1233: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-1234: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-1235: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-1236: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-1237: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ), Example 4-1238: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-1239: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1240: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-1241: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-1242: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-1243: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-1244: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-1245: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-1246: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-1247: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-1248: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-1249: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-1250: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-1251: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-1252: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-1253: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-1254: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-1255: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-1256: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-1257: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-1258: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-1259: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-1260: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-1261: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-1262: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-1263: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-1264: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-1265: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-1266: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-1267: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-1268: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-1269: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-1270: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-1271: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-1272: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-1273: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-1274: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-1275: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-1276: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-1277: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-1278: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-1279: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1280: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ-D ２−ａｔ ), Example 4-1281: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-1282: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-1283: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｃ ), Example 4-1284: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-1285: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-1286: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-1287: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-1288: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-1289: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-1290: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-1291: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-1292: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-1293: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-1294: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-1295: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-1296: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-1297: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-1298: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-1299: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-1300: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-1301: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-1302: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-1303: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-1304: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-1305: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-1306: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-1307: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-1308: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-1309: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-1310: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-1311: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-1312: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-1313: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-1314: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-1315: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-1316: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-1317: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-1318: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-1319: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1320: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-1321: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａａ ), Example 4-1322: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｂ ), Example 4-1323: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ)(-L ２−ａ -D ２−ａｃ ), Example 4-1324: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｄ ), Example 4-1325: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｅ ), Example 4-1326: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｆ ), Example 4-1327: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｇ ), Example 4-1328: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｈ ), Example 4-1329: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｉ ), Example 4-1330: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｊ ), Example 4-1331: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｋ ), Example 4-1332: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｌ ), Example 4-1333: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｍ ), Example 4-1334: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｎ ), Example 4-1335: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｏ ), Example 4-1336: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ａ -D ２−ａｐ ), Example 4-1337: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｑ ), Example 4-1338: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｒ ), Example 4-1339: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｓ ), Example 4-1340: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｂ -D ２−ａｔ ), Example 4-1341: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａａ ), Example 4-1342: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｂ ), Example 4-1343: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｃ ), Example 4-1344: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｄ ), Example 4-1345: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｅ ), Example 4-1346: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｆ ), Example 4-1347: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｇ ), Example 4-1348: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｈ ), Example 4-1349: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｉ ), Example 4-1350: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｊ ), Example 4-1351: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｋ ), Example 4-1352: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｌ ), Example 4-1353: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｍ ), Example 4-1354: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｎ ), Example 4-1355: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｏ ), Example 4-1356: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｃ -D ２−ａｐ ), Example 4-1357: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｑ ), Example 4-1358: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｒ ), Example 4-1359: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1360: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(-L ２−ｄ -D ２−ａｔ ), Example 4-1361: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-1362: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-1363: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-1364: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-1365: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-1366: Z-L ３−ｉ -N(-L １−ａ-D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-1367: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-1368: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-1369: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-1370: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-1371: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-1372: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-1373: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-1374: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-1375: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-1376: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-1377: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-1378: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-1379: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-1380: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-1381: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-1382: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-1383: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-1384: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-1385: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-1386: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-1387: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-1388: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-1389: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-1390: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-1391: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-1392: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-1393: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-1394: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-1395: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-1396: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-1397: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-1398: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-1399: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1400: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ), Example 4-1401: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａａ ), Example 4-1402: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｂ ), Example 4-1403: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｃ ), Example 4-1404: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｄ ), Example 4-1405: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｅ ), Example 4-1406: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｆ ), Example 4-1407: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｇ ), Example 4-1408: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｈ ), Example 4-1409: Z-L ３−ｉ-N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｉ ), Example 4-1410: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｊ ), Example 4-1411: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｋ ), Example 4-1412: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｌ ), Example 4-1413: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｍ ), Example 4-1414: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｎ ), Example 4-1415: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｏ ), Example 4-1416: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ａ -D ２−ａｐ ), Example 4-1417: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｑ ), Example 4-1418: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｒ ), Example 4-1419: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｓ ), Example 4-1420: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｂ -D ２−ａｔ ), Example 4-1421: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａａ ), Example 4-1422: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｂ ), Example 4-1423: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｃ ), Example 4-1424: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｄ ), Example 4-1425: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｅ ), Example 4-1426: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｆ ), Example 4-1427: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｇ ), Example 4-1428: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｈ ), Example 4-1429: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｉ ), Example 4-1430: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｊ ), Example 4-1431: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｋ ), Example 4-1432: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｌ ), Example 4-1433: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｍ ), Example 4-1434: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｎ ), Example 4-1435: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｏ ), Example 4-1436: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｃ -D ２−ａｐ ), Example 4-1437: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｑ ), Example 4-1438: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｒ ), Example 4-1439: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｓ ), Example 4-1440: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(-L ２−ｄ -D ２−ａｔ ). When Z in the above compounds (Examples 4-1 to 4-1440) is linked to an antibody, the Z portion becomes the following structure. [In the formula, * is the bonding point with "antibody-S-", and ** is L ３ (For example, L in the above compound ３−ａ ~L ３−ｉ ] The present invention also provides AMDC represented by such a chemical formula. The present invention also provides exemplary precursor compounds (Examples 5-1 to 5-504) {in the following formulas, Z, L １−ａ ~L １−ｂ , L ２−ｂ , L ２−ｄ ~L ２−ｈ , L ３−ａ ~L ３−ｉ ,D １−ａ ~D １−ｂ , and D ２−ｂａ ~D ２−ｂｇ is as defined above} may be provided. Example 5-1: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-2: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-3: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-4: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-5: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-6: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-7: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｇ), Example 5-8: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-9: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-10: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-11: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-12: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-13: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-14: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-15: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-16: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-17: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-18: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-19: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-20: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-21: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-22: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-23: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-24: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-25: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-26: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-27: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-28: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-29: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-30: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-31: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-32: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-33: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-34: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-35: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-36: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-37: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-38: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-39: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-40: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-41: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-42: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-43: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-44: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-45: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-46: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-47: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-48: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-49: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-50: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-51: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-52: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-53: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-54: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-55: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-56: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-57: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-58: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-59: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-60: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-61: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-62: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-63: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-64: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-65: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-66: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-67: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-68: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-69: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-70: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-71: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-72: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-73: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-74: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-75: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-76: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-77: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-78: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-79: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-80: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-81: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-82: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-83: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-84: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-85: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-86: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-87: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-88: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-89: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-90: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-91: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-92: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-93: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-94: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-95: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-96: Z-L３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-97: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-98: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-99: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-100: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-101: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-102: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-103: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-104: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-105: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-106: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-107: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-108: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-109: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-110: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-111: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-112: Z-L ３−ｂ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-113: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-114: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-115: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-116: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-117: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-118: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-119: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-120: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-121: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-122: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-123: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-124: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-125: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-126: Z-L ３−ｃ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-127: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-128: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-129: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-130: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-131: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-132: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-133: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-134: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-135: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-136: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-137: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-138: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-139: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ), Example 5-140: Z-L ３−ｃ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-141: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-142: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-143: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-144: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-145: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-146: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-147: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-148: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-149: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-150: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-151: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-152: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-153: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-154: Z-L ３−ｃ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-155: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-156: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-157: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-158: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-159: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-160: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-161: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-162: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-163: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-164: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-165: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-166: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-167: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-168: Z-L ３−ｃ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-169: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-170: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-171: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-172: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-173: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-174: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-175: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-176: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-177: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-178: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-179: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-180: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-181: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-182: Z-L ３−ｄ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-183: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ)(L ２−ｅ -D ２−ｂａ ), Example 5-184: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-185: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-186: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-187: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-188: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-189: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-190: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-191: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-192: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-193: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-194: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-195: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-196: Z-L ３−ｄ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-197: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-198: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-199: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-200: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-201: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-202: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-203: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-204: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-205: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-206: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-207: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-208: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-209: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-210: Z-L ３−ｄ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-211: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-212: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-213: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-214: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-215: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-216: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-217: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-218: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-219: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-220: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-221: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-222: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-223: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-224: Z-L ３−ｄ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-225: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-226: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-227: Z-L ３−ｅ-N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-228: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-229: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-230: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-231: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-232: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-233: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-234: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-235: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-236: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-237: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-238: Z-L ３−ｅ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-239: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-240: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-241: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-242: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-243: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-244: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-245: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-246: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-247: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-248: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-249: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-250: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-251: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-252: Z-L ３−ｅ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-253: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-254: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-255: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-256: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-257: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-258: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-259: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-260: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-261: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-262: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-263: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-264: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-265: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-266: Z-L ３−ｅ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-267: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-268: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-269: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-270: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-271: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-272: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-273: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-274: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-275: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-276: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-277: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-278: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-279: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-280: Z-L ３−ｅ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-281: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-282: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-283: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-284: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-285: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-286: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-287: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-288: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-289: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-290: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-291: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-292: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-293: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-294: Z-L ３−ｆ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-295: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-296: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-297: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-298: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-299: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-300: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-301: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-302: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-303: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-304: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-305: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-306: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-307: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-308: Z-L ３−ｆ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-309: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-310: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-311: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-312: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-313: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-314: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L２−ｂ -D ２−ｂｆ ), Example 5-315: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-316: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-317: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-318: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-319: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-320: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-321: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-322: Z-L ３−ｆ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-323: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-324: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-325: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-326: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-327: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-328: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-329: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-330: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-331: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-332: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-333: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-334: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-335: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-336: Z-L ３−ｆ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-337: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-338: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-339: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-340: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-341: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-342: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-343: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-344: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-345: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-346: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-347: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-348: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-349: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-350: Z-L ３−ｇ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-351: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-352: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-353: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-354: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-355: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-356: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-357: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-358: Z-L ３−ｇ -N(-L１−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-359: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-360: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-361: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-362: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-363: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-364: Z-L ３−ｇ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-365: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-366: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-367: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-368: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-369: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-370: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-371: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-372: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-373: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-374: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-375: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-376: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-377: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-378: Z-L ３−ｇ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-379: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-380: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-381: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-382: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-383: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-384: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-385: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-386: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-387: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-388: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-389: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-390: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-391: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-392: Z-L ３−ｇ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-393: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-394: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-395: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-396: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-397: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-398: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-399: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-400: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-401: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-402: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-403: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-404: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-405: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-406: Z-L ３−ｈ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-407: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-408: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-409: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-410: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-411: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-412: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-413: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-414: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-415: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-416: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-417: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-418: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-419: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-420: Z-L ３−ｈ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-421: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-422: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-423: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-424: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-425: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-426: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-427: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-428: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-429: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-430: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-431: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-432: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-433: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-434: Z-L ３−ｈ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-435: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-436: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-437: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-438: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-439: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-440: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-441: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-442: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-443: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-444: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-445: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ-D ２−ｂｄ ), Example 5-446: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-447: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-448: Z-L ３−ｈ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-449: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-450: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-451: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-452: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-453: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-454: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-455: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-456: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-457: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-458: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-459: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-460: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-461: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-462: Z-L ３−ｉ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-463: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-464: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-465: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-466: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-467: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-468: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-469: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-470: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-471: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-472: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-473: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-474: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-475: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-476: Z-L ３−ｉ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ), Example 5-477: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂａ ), Example 5-478: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｂ ), Example 5-479: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｃ ), Example 5-480: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｅ -D ２−ｂｄ ), Example 5-481: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｇ -D ２−ｂｅ ), Example 5-482: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｆ ), Example 5-483: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｂｇ ), Example 5-484: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂａ ), Example 5-485: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｂ ), Example 5-486: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｃ ), Example 5-487: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｆ -D ２−ｂｄ ), Example 5-488: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｈ -D ２−ｂｅ ), Example 5-489: Z-L ３−ｉ -N(-L １−ｂ-D １−ａ )(L ２−ｄ -D ２−ｂｆ ), Example 5-490: Z-L ３−ｉ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｂｇ ), Example 5-491: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂａ ), Example 5-492: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｂ ), Example 5-493: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｃ ), Example 5-494: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｅ -D ２−ｂｄ ), Example 5-495: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｇ -D ２−ｂｅ ), Example 5-496: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｆ ), Example 5-497: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｂｇ ), Example 5-498: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂａ ), Example 5-499: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｂ ), Example 5-500: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｃ ), Example 5-501: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｆ -D ２−ｂｄ ), Example 5-502: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｈ -D ２−ｂｅ ), Example 5-503: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｆ ), Example 5-504: Z-L ３−ｉ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｂｇ ). When Z in the above compounds (Examples 5-1 to 5-504) is linked to an antibody, the Z portion becomes the following structure. [In the formula, * is the bonding point with "antibody-S-", and ** is L ３ (For example, L in the above compound ３−ａ ~L ３−ｉ ] The present invention also provides AMDC represented by such a chemical formula. The present invention also provides exemplary precursor compounds (Examples 6-1 to 6-936) {in the following formulas, Z, L １−ａ ~L １−ｂ , L ２−ｂ , L ２−ｄ , L ２−ｉ ~L ２−ｎ , L ３−ａ ~L ３−ｉ ,D １−ａ ~D １−ｂ , and D ２−ｃａ ~D ２−ｃｈ is as defined above} may be provided. Example 6-1: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｉ -D ２−ｃａ ), Example 6-2: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｉ -D ２−ｃｃ ), Example 6-3: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｉ -D ２−ｃｄ ), Example 6-4: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｉ -D ２−ｃｅ ), Example 6-5: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｉ -D ２−ｃｆ ), Example 6-6: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｊ -D ２−ｃａ ), Example 6-7: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｊ -D ２−ｃｃ ), Example 6-8: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｊ -D ２−ｃｄ ), Example 6-9: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｊ -D ２−ｃｅ ), Example 6-10: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｊ -D ２−ｃｆ ), Example 6-11: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｋ -D ２−ｃｂ ), Example 6-12: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｌ -D ２−ｃａ ), Example 6-13: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｌ -D ２−ｃｃ ), Example 6-14: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｌ -D ２−ｃｄ ), Example 6-15: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｌ -D ２−ｃｅ ), Example 6-16: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｌ -D ２−ｃｆ ), Example 6-17: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｍ -D ２−ｃａ ), Example 6-18: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｍ -D ２−ｃｃ ), Example 6-19: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｍ -D ２−ｃｄ ), Example 6-20: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｍ -D ２−ｃｅ ), Example 6-21: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｍ -D ２−ｃｆ ), Example 6-22: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｎ -D ２−ｃｂ ), Example 6-23: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｃｇ ), Example 6-24: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｂ-D ２−ｃｈ ), Example 6-25: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｃｇ ), Example 6-26: Z-L ３−ａ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｃｈ ), Example 6-27: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｉ -D ２−ｃａ ), Example 6-28: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｉ -D ２−ｃｃ ), Example 6-29: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｉ -D ２−ｃｄ ), Example 6-30: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｉ -D ２−ｃｅ ), Example 6-31: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｉ -D ２−ｃｆ ), Example 6-32: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｊ -D ２−ｃａ ), Example 6-33: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｊ -D ２−ｃｃ ), Example 6-34: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｊ -D ２−ｃｄ ), Example 6-35: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｊ -D ２−ｃｅ ), Example 6-36: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｊ -D ２−ｃｆ ), Example 6-37: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｋ -D ２−ｃｂ ), Example 6-38: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｌ -D ２−ｃａ ), Example 6-39: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｌ -D ２−ｃｃ ), Example 6-40: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｌ -D ２−ｃｄ ), Example 6-41: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｌ -D ２−ｃｅ ), Example 6-42: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｌ -D ２−ｃｆ ), Example 6-43: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｍ -D ２−ｃａ ), Example 6-44: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｍ -D ２−ｃｃ ), Example 6-45: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｍ -D ２−ｃｄ ), Example 6-46: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｍ -D ２−ｃｅ ), Example 6-47: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｍ -D ２−ｃｆ ), Example 6-48: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｎ -D ２−ｃｂ ), Example 6-49: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｃｇ ), Example 6-50: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｃｈ ), Example 6-51: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｃｇ ), Example 6-52: Z-L ３−ａ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｃｈ ), Example 6-53: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｉ -D ２−ｃａ ), Example 6-54: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｉ -D ２−ｃｃ ), Example 6-55: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｉ -D ２−ｃｄ ), Example 6-56: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｉ -D ２−ｃｅ ), Example 6-57: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｉ -D ２−ｃｆ ), Example 6-58: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｊ -D ２−ｃａ ), Example 6-59: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｊ -D ２−ｃｃ ), Example 6-60: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｊ -D ２−ｃｄ ), Example 6-61: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｊ -D ２−ｃｅ ), Example 6-62: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｊ -D ２−ｃｆ ), Example 6-63: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｋ -D ２−ｃｂ ), Example 6-64: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｌ -D ２−ｃａ ), Example 6-65: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｌ -D ２−ｃｃ ), Example 6-66: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｌ -D ２−ｃｄ ), Example 6-67: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｌ -D ２−ｃｅ ), Example 6-68: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｌ -D ２−ｃｆ), Example 6-69: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｍ -D ２−ｃａ ), Example 6-70: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｍ -D ２−ｃｃ ), Example 6-71: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｍ -D ２−ｃｄ ), Example 6-72: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｍ -D ２−ｃｅ ), Example 6-73: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｍ -D ２−ｃｆ ), Example 6-74: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｎ -D ２−ｃｂ ), Example 6-75: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｃｇ ), Example 6-76: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｂ -D ２−ｃｈ ), Example 6-77: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｃｇ ), Example 6-78: Z-L ３−ａ -N(-L １−ｂ -D １−ａ )(L ２−ｄ -D ２−ｃｈ ), Example 6-79: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｉ -D ２−ｃａ ), Example 6-80: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｉ -D ２−ｃｃ ), Example 6-81: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｉ -D ２−ｃｄ ), Example 6-82: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｉ -D ２−ｃｅ ), Example 6-83: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｉ -D ２−ｃｆ ), Example 6-84: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｊ -D ２−ｃａ ), Example 6-85: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｊ -D ２−ｃｃ ), Example 6-86: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｊ -D ２−ｃｄ ), Example 6-87: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｊ -D ２−ｃｅ ), Example 6-88: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｊ -D ２−ｃｆ ), Example 6-89: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｋ -D ２−ｃｂ ), Example 6-90: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｌ -D ２−ｃａ ), Example 6-91: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｌ -D ２−ｃｃ ), Example 6-92: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｌ -D ２−ｃｄ ), Example 6-93: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｌ -D ２−ｃｅ ), Example 6-94: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｌ -D ２−ｃｆ ), Example 6-95: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｍ -D ２−ｃａ ), Example 6-96: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｍ -D ２−ｃｃ ), Example 6-97: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｍ -D ２−ｃｄ ), Example 6-98: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｍ -D ２−ｃｅ ), Example 6-99: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｍ -D ２−ｃｆ ), Example 6-100: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｎ -D ２−ｃｂ ), Example 6-101: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｃｇ ), Example 6-102: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｂ -D ２−ｃｈ ), Example 6-103: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｃｇ ), Example 6-104: Z-L ３−ａ -N(-L １−ｂ -D １−ｂ )(L ２−ｄ -D ２−ｃｈ ), Example 6-105: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｉ -D ２−ｃａ ), Example 6-106: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｉ -D ２−ｃｃ ), Example 6-107: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｉ -D ２−ｃｄ ), Example 6-108: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｉ -D ２−ｃｅ ), Example 6-109: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｉ -D ２−ｃｆ ), Example 6-110: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｊ -D ２−ｃａ ), Example 6-111: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｊ -D ２−ｃｃ ), Example 6-112: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｊ -D ２−ｃｄ), Example 6-113: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｊ -D ２−ｃｅ ), Example 6-114: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｊ -D ２−ｃｆ ), Example 6-115: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｋ -D ２−ｃｂ ), Example 6-116: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｌ -D ２−ｃａ ), Example 6-117: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｌ -D ２−ｃｃ ), Example 6-118: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｌ -D ２−ｃｄ ), Example 6-119: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｌ -D ２−ｃｅ ), Example 6-120: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｌ -D ２−ｃｆ ), Example 6-121: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｍ -D ２−ｃａ ), Example 6-122: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｍ -D ２−ｃｃ ), Example 6-123: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｍ -D ２−ｃｄ ), Example 6-124: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｍ -D ２−ｃｅ ), Example 6-125: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｍ -D ２−ｃｆ ), Example 6-126: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｎ -D ２−ｃｂ ), Example 6-127: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｃｇ ), Example 6-128: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｂ -D ２−ｃｈ ), Example 6-129: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｃｇ ), Example 6-130: Z-L ３−ｂ -N(-L １−ａ -D １−ａ )(L ２−ｄ -D ２−ｃｈ ), Example 6-131: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｉ -D ２−ｃａ ), Example 6-132: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｉ -D ２−ｃｃ ), Example 6-133: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｉ -D ２−ｃｄ ), Example 6-134: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｉ -D ２−ｃｅ ), Example 6-135: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｉ -D ２−ｃｆ ), Example 6-136: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｊ -D ２−ｃａ ), Example 6-137: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｊ -D ２−ｃｃ ), Example 6-138: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｊ -D ２−ｃｄ ), Example 6-139: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｊ -D ２−ｃｅ ), Example 6-140: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｊ -D ２−ｃｆ ), Example 6-141: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｋ -D ２−ｃｂ ), Example 6-142: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｌ -D ２−ｃａ ), Example 6-143: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｌ -D ２−ｃｃ ), Example 6-144: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｌ -D ２−ｃｄ ), Example 6-145: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｌ -D ２−ｃｅ ), Example 6-146: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｌ -D ２−ｃｆ ), Example 6-147: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｍ -D ２−ｃａ ), Example 6-148: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｍ -D ２−ｃｃ ), Example 6-149: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｍ -D ２−ｃｄ ), Example 6-150: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｍ -D ２−ｃｅ ), Example 6-151: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｍ -D ２−ｃｆ ), Example 6-152: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｎ -D ２−ｃｂ ), Example 6-153: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｃｇ ), Example 6-154: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｂ -D ２−ｃｈ ), Example 6-155: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ )(L ２−ｄ -D ２−ｃｇ ), Example 6-156: Z-L ３−ｂ -N(-L １−ａ -D １−ｂ)(L ２−ｄ -D ２−ｃｈ ), Example 6-157: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｉ -D ２−ｃａ ), Example 6-158: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｉ -D ２−ｃｃ ), Example 6-159: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ２−ｉ -D ２−ｃｄ ), Example 6-160: Z-L ３−ｂ -N(-L １−ｂ -D １−ａ )(L ...

Claims

1. Formula (I): [Chemical formula 1] [In the formula, A is an antibody residue obtained by removing the sulfhydryl group or amino group present in the antibody. B is a -S- or -NH- derived from a sulfhydryl group or amino group present in the antibody, G is, [Case 2] [Chemical 3] [C4] or [C5] It is a base represented by the formula, in R is a hydrogen atom, a hydroxyl group, an amino group, an alkyl group, or an alkyloxy group. Cy is a cycloalkyl ring, cycloalkenyl ring, aryl ring, heteroaryl ring, or heterocyclyl ring. a is an integer between 1 and 10. D １ and D ２ These are residues obtained by removing one hydrogen atom or one hydroxyl group from any position in an antitumor drug molecule or its analogues, or derivatives thereof, and these residues may be the same or different. L １ G and D １ It is a linker that connects them, L ２ G and D ２ It is a linker that connects them, L ３ This is a linker that connects G and B. L １ 、 L ２ 、 and L ３ may be the same or different, D １ , D ２ , L １ , L ２ , and L ３ At least one of these is a substituent or protecting group consisting of one or more phosphoryl groups (-P(=O)(OH) ２ ) has, The total number of phosphoryl groups is 1 to 10. L １ , L ２ , and L ３ At least one of them has one or more lactonyl groups as substituents, The total number of lactonyl groups is 1 to 10, and if the total number of lactonyl groups is 2 or more, the lactonyl groups may be the same or different. An antibody / multi-drug conjugate, or a pharmacokinetically acceptable salt thereof, represented by [formula].

2. The antibody-multiple drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, wherein A is an antibody residue derived from an antibody having properties selected from the group consisting of being able to bind to target cells, being able to be internalized in the target cells, and being able to damage the target cells.

3. A is an antibody residue obtained by removing a sulfhydryl group or an amino group present in an antibody capable of targeting tumor cells, wherein the sulfhydryl group is generated by a reduction reaction of disulfide bonds in the antibody, as described in claim 1, or a pharmaceutically acceptable salt thereof.

4. A, anti-HER2 antibody, anti-EGFR antibody, anti-Lymphacytite Antigen 6E (Ly-6E) antibody, anti-Hepatocytite Growth Factor Receptor (HGFR) antibody, anti-CD22 antibody, anti-Folate Receptor Anti-alpha (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-5T4 antibody, anti-Mesothelin antibody, anti-CD20 antibody, anti-CD33 antibody, anti-CDB7-H3 antibody, anti-CD269 (BCMA) antibody, anti-CD142 antibody, anti-CD70 antibody, anti-CD123 antibody, anti-TAG-72 antibody, anti-TFRC antibody, anti-EPHA2 antibody, anti-c-KIT antibody, anti-PD-L1 antibody, anti-Epithelial Cell Adhesion Molecule (EPCAM) antibody, anti-AXL antibody, anti-Interleukin-1 receptor access protein antibody, anti-Mucin-16 (CA125) antibody, anti-MUC1 antibody, anti-GPC3 antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-Sodium-Dependent Phototransport Protein Antibody 2B (SLC34A2), anti-CD25, anti-ROR1, anti-TweakR, anti-CD74, anti-CEACAM5, anti-CD105, anti-CD79b, anti-CD147, anti-Sialilyl-Tn, anti-GCC, anti-HER3, anti-Integrin, anti-EGFR variant III, anti-Claudin 6, anti-Leucine-Rich Repeat-Containing G-Protein Co-opted Receptor 5 antibodies, anti-PTK7 antibody, anti-LYPD3 antibody, anti-ASTT2 antibody, anti-ASPH antibody, anti-GPC1 antibody, anti-CD174 antibody, anti-CD38 antibody, anti-ANGPT2 antibody, anti-CD44 antibody, anti-DDL3 antibody, anti-FGFR2 antibody, anti-KAAG1 antibody, anti-CD73 antibody, anti-CLDN18.2 antibody, anti-PRLR antibody, anti-SEZ6 antibody, anti-Neprysin antibody, anti-Neural Cell Adhesion MolecularAntibodies, including anti-CD166 (ALCAM) antibody, anti-CD24 antibody, anti-CD27 antibody, anti-CDH3 antibody, anti-EPHA4 antibody, anti-FGFR3 antibody, anti-GFRAL antibody, anti-Globo H antibody, anti-IL-13Ra2 antibody, anti-STEP-1 antibody, anti-TMCC3 antibody, anti-CD209 antibody, anti-CD37, anti-CD48 antibody, anti-CDCP1 antibody, anti-CD46 antibody, anti-CD200 antibody, anti-CTLA4 antibody, anti-CXCR5 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) antibody, anti-CLDN6 / 9 antibody, anti-CEACAM6 antibody, anti-CA9 antibody, anti-EDNRB antibody, and anti-GD3 antibody. Ganglioside antibody, anti-MICA / B antibody, anti-JAG1 / 2 antibody, anti-TM4SF1 antibody, anti-UPAR antibody, anti-Carbonic anhydrase IX antibody, anti-ALK1 antibody, anti-IGF-1R antibody, anti-KDR antibody, anti-CEACAM8 antibody, anti-IL5R antibody, anti-CD205 (Ly75) antibody, anti-MSR1 antibody, anti-KREMEN2 antibody, anti-SSEA-4 antibody, anti-CD228 antibody, anti-CD5 antibody, anti-DLL4 antibody, anti-FAP antibody, anti-Notch3 antibody, anti-AG7 antibody, anti-Guanylate Cycles antibodies, anti-Nectuin-4 antibody, anti-CD226 (DNA-1) antibody, anti-FcRL5 antibody, anti-HLA-DR antibody, anti-ITGB3 antibody, anti-DLK1 antibody, anti-CD157 (BST1) antibody, anti-CD56 (NCAM1) antibody, anti-MICA (MHC class I Polypeptide-Related Sequence) A) Antibodies, including anti-SSEA-1 antibody, anti-TRAIL-R2 (DR5) antibody, anti-GPNMB antibody, anti-CCR5 antibody, anti-LAMP1 antibody, anti-LGALS3BP antibody, anti-ROR2 antibody, anti-DLL3 antibody, anti-ETBR antibody, anti-LIV-1 antibody, anti-Integrin αvβ6 antibody, anti-TIM-1 antibody, anti-AGS-16 (ENPP3) antibody, anti-SLITRK6 antibody, anti-GD2 antibody, anti-CD52 antibody, anti-CCR4 antibody, anti-VEGFR2 antibody, anti-PDGFR antibody, anti-FGFR antibody, anti-SLAMF7 antibody, anti-GD2 ganglioid antibody, anti-EPHA3 antibody, and anti-Integrin. αvβ3 antibody, anti-AGS-5 antibody, anti-CA19-9 antibody, anti-PSA antibody, anti-MAGE3 antibody, anti-Transferrin receptor 1 (CD71) antibody, anti-CEACAM1 antibody, anti-SLC3A2 (CD98)Antibodies, anti-ACVR1 antibodies, anti-AG-7 antibodies, anti-AMHR2 antibodies, anti-ABCB1 antibodies, anti-C16orf54 antibodies, anti-CathepsinD antibodies, anti-CCR7 antibodies, Anti-SLC44A4 antibody, anti-CD300LF antibody, anti-DPEP3 antibody, anti-FucGM1 antibody, anti-GPR20 antibody, anti-ITGB6 antibody, anti-Lewis-A-like Carbohydrate antibody, anti-prolactin receptor antibody, anti-Sialyl An antibody / multiple drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, comprising an antibody residue derived from Tn antibody, anti-SLAMF6 antibody, anti-SLAMF7 antibody, anti-TRA-1-60 antibody, anti-matriptase antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-CanAg antibody, anti-A33 antibody, anti-α10β1 integrin antibody, anti-ALPP antibody, anti-CD248 antibody, or anti-GPRC5D antibody.

5. A, anti-HER2 antibody, anti-EGFR antibody, anti-Lymphacytite Antigen 6E (Ly-6E) antibody, anti-Hepatocytite Growth Factor Receptor (HGFR) antibody, anti-CD22 antibody, anti-Folate Receptor Anti-alpha (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-5T4 antibody, anti-Mesothelin antibody, anti-CD20 antibody, anti-CD269 (BCMA) antibody, anti-CD142 antibody, anti-CD123 antibody, anti-TAG-72 antibody, anti-TFRC antibody, anti-c-KIT antibody, anti-Epithelial Cell Adhesion Molecule (EPCAM) antibody, anti-AXL antibody, anti-Mucin-16 (CA125) antibody, anti-CLEC12A (CLL1) antibody, anti-LRRC15 antibody, anti-ADAM9 antibody, anti-Sodium-Dependent Phototransport Protein 2B (SLC34A2) antibody, anti-CD25 antibody, anti-ROR1 antibody, anti-CD74 antibody, anti-CEACAM5 antibody, anti-CD105 antibody, anti-CD79b antibody, anti-HER3 antibody, anti-EGFR variant III antibodies, anti-PTK7 antibody, anti-GPC1 antibody, anti-CD38 antibody, anti-DDL3 antibody, anti-SEZ6 antibody, anti-CD166 (ALCAM) antibody, anti-CDH3 antibody, anti-FGFR3 antibody, anti-Globo antibody H antibody, anti-CD37 antibody, anti-CD48 antibody, anti-CD46 antibody, anti-FLT3 antibody, anti-SDC1 (CD138) antibody, anti-TM4SF1 antibody, anti-IGF-1R antibody, anti-CEACAM8 antibody, anti-CD205 (Ly75) antibody, anti-CD228 antibody, anti-FAP antibody, anti-AG7 antibody, anti-Nectin-4 antibody, anti-CD226 (DNAM-1) antibody, anti-HLA-DR antibody, anti-DLK1 antibody, anti-CD157 (BST1) antibody, anti-CD56 (NCAM1) antibody, anti-CR5 antibody, anti-ROR2 antibody, anti-LIV-1 antibody, anti-TIM-1 antibody, anti-CA19-9 antibody, anti-CEACAM1 antibody, anti-SLC3A2 (CD98)Antibodies, anti-ACVR1 antibodies, anti-AG-7 antibodies, anti-AMHR2 antibodies, anti-ABCB1 antibodies, anti-C16orf54 antibodies, anti-CathepsinD antibodies, anti-CCR7 antibodies, Anti-SLC44A4 antibody, anti-CD300LF antibody, anti-DPEP3 antibody, anti-FucGM1 antibody, anti-GPR20 antibody, anti-ITGB6 antibody, anti-Lewis-A-like Carbohydrate antibody, anti-prolactin receptor antibody, anti-Sialyl Tn antibody, anti-SLAMF6 antibody, anti-SLAMF7 antibody, anti-TRA-1-60 antibody, anti-matriptase antibody, anti-B7-H4 antibody, anti-Cripto antibody, anti-CD99 antibody, anti-CanAg antibody, anti-α10β1 The antibody / multiple drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the antibody residue is derived from an integrin antibody, an anti-ALPP antibody, an anti-CD248 antibody, or an anti-GPRC5D antibody.

6. A is anti-HER2 antibody, anti-EGFR antibody, anti-Lymphocyte Antigen 6E (Ly-6E) antibody, anti-CD22 antibody, anti-Folate Receptor alpha (FRα) antibody, anti-PSMA (FOLH1) antibody, anti-CD30 (TNFRSF8) antibody, anti-TROP-2 antibody, anti-CD19 antibody, anti-Meso thelin antibody, anti-CD20 antibody, anti-CD269 (BCMA) antibody, anti-CD123 antibody, anti-TFRC antibody, anti-c-KIT antibody, anti-Epithelial Cell Adhesion Molecule (EPCAM) antibody, anti-AXL antibody, anti-Mucin-16 (CA125) antibody, anti-Sodium-Dependent An antibody / multi-drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, comprising an antibody residue derived from Phosphatate Transport Protein 2B (SLC34A2) antibody, anti-CD25 antibody, anti-CEACAM5 antibody, anti-CD79b antibody, anti-HER3 antibody, anti-PTK7 antibody, anti-CD38 antibody, anti-CD37 antibody, anti-FLT3 antibody, anti-IGF-1R antibody, anti-FAP antibody, anti-Nectin-4 antibody, anti-CD56 (NCAM1) antibody, anti-AG-7 antibody, anti-CCR7 antibody, anti-DPEP3 antibody, anti-ITGB6 antibody, anti-matriptase antibody, anti-Cripto antibody, anti-ALPP antibody, or anti-GPRC5D antibody.

7. An antibody / multiple drug conjugate according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein a is an integer from 1 to 8.

8. An antibody / multiple drug conjugate according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein a is an integer from 1 to 7.

9. An antibody / multiple drug conjugate according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by formula (i), formula (ii), or formula (iii).

10. An antibody / multiple drug conjugate according to any one of claims 1 to 6, wherein G is a group represented by formula (i), or a pharmaceutically acceptable salt thereof.

11. D １ and D ２ However, each of these independently is a residue of an antitumor drug molecule selected from the group consisting of camptothecin; MMAE; meitansine; PBD (parabenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamycin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; dorastatin 10; superdox; ciprofloxacin; cardofloxacin (CS-940); auristatin E; seco-DUBA; or analogs or derivatives thereof; or derivatives of the said analogs. An antibody / multiple drug conjugate according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.

12. D １ and D ２ However, the residues are those of an antitumor drug molecule independently selected from the group consisting of camptothecin; MMAE; meitansine; PBD (parabenzodiazepine) dimer; eribulin; 5-FU; PD-318088; AS-703026; TAK-733; LY-3023414; calicheamycin; paclitaxel; docetaxel; mitomycin C; bleomycin; cyclocytidine; vincristine; vinblastine; daunomycin; doxorubicin; dorastatin 10; superdox; auristatin E; seco-DUBA; or analogs or derivatives thereof; or derivatives of the said analogs. An antibody / multiple drug conjugate according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.

13. D １ and D ２ However, the residue is an antitumor drug molecule independently selected from the group consisting of camptothecin; MMAE; meitansine; PBD (parabenzodiazepine) dimer; eribulin; auristatin E; seco-DUBA; or analogs or derivatives thereof; or derivatives of the said analogs. An antibody / multiple drug conjugate according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.

14. D １ and D ２ However, each is independently a residue of the same antitumor drug or an analog or derivative of the same antitumor drug; or a derivative of the said analog. An antibody / multiple drug conjugate according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.

15. D １ and D ２ However, each is a residue of a different antitumor drug or an analog or derivative of a different antitumor drug; or a derivative of the said analog. An antibody / multiple drug conjugate according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.

16. D １ , D ２ , L １ , L ２ , and L ３ At least one of these is a substituent or protecting group consisting of one or more phosphoryl groups (-P(=O)(OH) ２ ) has, The total number of phosphoryl groups is 1 to 4. L １ , L ２ , and L ３ At least one of them has one or more lactonyl groups as substituents, The total number of lactonyl groups is 1 to 8. If the total number of lactonyl groups is two or more, those lactonyl groups may be the same or different. An antibody / multiple drug conjugate according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.

17. L １ , L ２ , and L ３ However, each of these is an alkylene group that may be substituted; One or more methylene groups in the alkylene chain, -C(R １ )(R ２ )-;-O-;-N(R ３ )-;-N(R ３ )-N(R ３ )-;-S-;-Se-;-Si(R ４ )(R ５ )-;-S-S-;-Se-Se-;-SOm-;-SeOn-;-C(=C(R ６ )(R ７ ))-;-C(=O)-;-C(=S)-;-C(=N(R ８ ))-;-C(=N-OR ９ )-;-C(=N-N(R １０ )(R １１ ))-;-P(=O)(R １２ )-;-P(=O)(OR １３ )-;-O-P(=O)(R １２ )-O-;-O-P(=O)(OR １３ )-O-;-C(R １４ )=; =C(R １４ )-;-C(R １４ )=C(R １４ )-;-N=; =N-;-C≡C-;-(OC(R １ ) (Caution ２ )-C(R １ ) (Caution ２ )) １－３０ -;-(C(R １ ) (Caution ２ )-C(R １ ) (Caution ２ )-0) １－３０ -; may be replaced by one or more divalent groups independently selected from the group consisting of an optionally substituted alkenylene group; an optionally substituted alkylylene group; an optionally substituted cycloalkylene group; an optionally substituted cycloalkenylene group; an optionally substituted arylene group; an optionally substituted heteroarylene group; and an optionally substituted heterocyclylene group. R １ , R ２ , R ３ , R ４ , R ５ , R ６ , R ７ , R ８ , R ９ , R １０ , R １１ , R １２ , R １３ , and R １４ However, each is independently selected from the group consisting of a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclyl group, R ３ If the alkyl group is an alkyl group, it may form a cyclic structure together with the alkyl group in the adjacent methylene group. m and n are independent integers between 0 and 2. An antibody / multiple drug conjugate according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.

18. L １ 、 L ２ 、 and L ３ are each independently an alkylene group which may be substituted; One or more methylene groups in the alkylene chain, -C(R １ ) (alkyl) -; -C(R １４ )=; -O-; -N(R ３ )-; -N=; -N(R ３ )-C(R １ )(R ２ )-(wherein, when R ３ , and R １ or R ２ is an alkyl group, R ３ and R １ or R ２ may together form a cyclic structure)); -N(R) ３ )-C(R １ ) (Caution ２ )-C(=O)-(wherein, R ３ , and R １ or R ２ When R is an alkyl group, ３ and R １ or R ２ (They may be together forming a ring structure); -O-C(R １ )(R ２ )-; -S-C(R １ )(R ２ )-; -N(R ３ )-N(R ３ )-; -N(R ３ )-O-C(R １ )(R ２ )-; -S-; -Si(R ４ )(R ５ )-; -S-S-; -SOm-; -C (=O)-; -C(R １ )(R ２ )-C(=O)-; -C(=C(R ６ )(R ７ ))-; -C(=N(R ８ ))-; -C(=N-OR ９ )-; -C(=N-N(R １０ )(R １１ )-; -P(=O)(R １２ )- -P(=O)(R １２ )-O-; -O-P(=O)(R １２ )-O-; -P(=O)(OR １３ )-O-; -P(=O)(OR １３ )-N(R ３ )-; -O-P(=O)(OR １３ )-O-; -C(R １４ )=C(R １４ )-; -C(R １４ )=C(R １４ )-P(=O)(OR １３ )-N(R ３ )-; -C(R １４ )=N-; -C(R １４ )=N-N(R ３ )-; -C≡C-; -O-C(R １ )(R ２ )-C(R １ )(R ２ )-; -O-C(R １ )(R ２ )-C(R １ )(R ２ )-O-; -(O-C(R １ )(R ２ )-C(R １ )(R ２ )) １－３０ -; -C(=O)-O-; -C(=O)-S-; -C(=O)-N(R ３ )-; -C(=O)-N(R ３ )-O-; -C(=O)-N(R ３ )-C(R １ ) (Caution ２ )-(wherein, R ３ , and R １ or R ２ When R is an alkyl group, ３ and R １ or R ２ (They may be together forming a ring structure); -C(=S)-O-; -C(=S)-S-; -O-C(=O)-O-; -O-C(=O)-N(R ３ )-; -S-C(=O)-N(R ３ )-; -N(R ３ )-C(=O)-N(R ３ )-; Arylene groups that may be substituted; A heteroarylene group which may be substituted; and Optionally substituted heterocyclylene groups It is replaced by one or more divalent groups that are independently selected from it. The antibody / multiple drug conjugate according to claim 17, or a pharmaceutically acceptable salt thereof.

19. L １ , L ２ , and L ３ However, each alkylene group may be substituted independently; One or more methylene groups in the alkylene chain, -C(R １４ )=; -O-; -N(R ３ )-; -N=; -S-; -C (=O)-; -O-Si(CH ３ (CH) ３ )-O-; -CH ２ -C(=O)-; -C(=O)-NH-; -C(=O)-O-; -C(=O)-S-; -O-C(=O)-O-: -N(H or CH) ３ )-C(=O)-O-; -NH-NH-; -N(CH) ３ )-O-CH ２ -; -C(=O)-(CH ２ ) １－２０ -C(=O)-; -C(=O)-(CH ２ ) １－１０ -O-(CH ２ ) １－１０ -C(=O)-; -C(=O)-CH ２ -(O-CH ２ CH ２ ) １－２０ -O-CH ２ -C(=O)-; -(O-CH ２ CH ２ ) １－２０ -; -C(=O)-N(H or CH) ３ ) - CH ２ CH ２ -N(H or CH) ３ ) - C (= O) -; [Case 6] [In the formula, * represents a bond point with an adjacent group.] -C(=O)-N(H or CH) ３ ) - CH ２ -; -P(=O)(OH)-O-; -O-P(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-O-; -OP(=O)(OH)-OP(=O)(OH)-OP(=O)(OH)-O-; -CH(CH ２ -NH ２ )-; -CH(CH ２ -NHH-C(=O)-; -CH(CH ２ -NHH-C(=O)-(CH ２ CH ２ -O-) １－２０ -CH ３ )-; -CH(CH ２ -NH-C(=O)-(CH ２ ) ０－２０ -Lactonyl)-; -CH(CH ２ -NH-C(=O)-(CH ２ CH ２ -O-) １－２０ -CH ２ -Lactonyl)-; -CH(CH ２ -NH-C(=O)-(CH ２ ) １－２０ (Phosphoryl) -CH(CH ２ -NH-C(=O)-(CH ２ CH ２ -O-) １－２０ -CH ２ (Phosphoryl) -CH(CH ２ -NH-(CH ２ ) １－２０ (Phosphoryl) -(cis)-CH=CH-P(=O)(O-CH ２ CH ３ or O-CH ２ CH ２ -OH)-NH-(phenylene)-C(=O)-; -C(=O)-(cyclohexylene)-; - (Sukushinimijiren) -; -Gly-; -Ala-; -Val-; -Leu-; -Ile-; -Phe-; -Ser-; -Cys-; -Asp-; -Glu-; -Orn-; -Lys-; -Cit-; -Arg-; -His-; -Pro-; -GlyGly-; -PheLys-; -ValLys-; -ValCit-; -ValAla-; -AspValCit-; -GluValCit-; -LysValCit-; -SerValCit-; -AspValAla-; -GluValAla-; -LysValAla-; -SerValAla-; -GlyGlyPheGly-; -AspGlyGlyPheGly-; -GluGlyGlyPheGly-; -LysGlyGlyPheGly-; -SerGlyGlyPheGly-; -AspAspAspAspAsp-; -N(H or CH) ３ )-(phenylene which may be substituted)-CH ２ -O-C(=O)-; -O-(substituted phenylene)-CH ２ -O-C(=O)-; -N(H or CH) ３ )-(pyridylene which may be substituted)-CH ２ -O-C(=O)-; [C7] [Chem.8] [Chem.9] [Chemical formula 10] and [Chemical formula 11] [In the formula, * represents a bond point with an adjacent group.] (In the above-mentioned amino acids and amino acid residues in the peptide, The carboxyl groups of the side chains of Asp and Glu may be lactonyl esters, lactonyl alkyl esters, or phosphoryl alkyl esters; or they may be unsubstituted amides, monoalkylamides, or dialkylamides, and the amino group of the amide portion may have a lactonyl group, a lactonyl alkyl group, or a phosphoryl alkyl group as a substituent: The amino groups in the side chains of Lys and Orn may have substituents such as a lactonyl group, a lactonyl alkyl group, a lactonyl carbonyl group, a lactonyl alkylcarbonyl group, a phosphoryl group, a phosphoryl alkyl group, or a phosphoryl alkylcarbonyl group: The hydroxyl group of the Ser side chain and the sulfhydryl group of the Cys side chain may have a lactonyl group, lactonyl alkyl group, lactonyl carbonyl group, lactonyl alkylcarbonyl group, phosphoryl group, phosphoryl alkyl group, or phosphoryl alkylcarbonyl group as substituents. It is replaced by one or more divalent groups that are independently selected from it. The antibody / multiple drug conjugate according to claim 17, or a pharmaceutically acceptable salt thereof.

20. [Chemical formula 12] [Chem.13] [Chem.14] [Chem.15] [Chem.16] [Chem.17] [Chem.18] [In the formula, A ＨＥＲ２ [where a is an antibody residue obtained by removing the sulfhydryl group present in the anti-HER2 antibody, and a is an integer from 1 to 10] An antibody / multiple drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the above.

21. [Chem.19] and [C20] [In the formula, A ＨＥＲ２ [a is an antibody residue obtained by removing the sulfhydryl group present in the anti-HER2 antibody from the anti-HER2 antibody, and a is an integer from 1 to 10.] An antibody / multiple drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the above.

22. The following formula [chemical formula 21] [In the formula, A ＨＥＲ２ [a is an antibody residue obtained by removing the sulfhydryl group present in the anti-HER2 antibody from the anti-HER2 antibody, and a is an integer from 1 to 10.] An antibody / multiple drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof.

23. [Chem.22] [In the formula, A ＨＥＲ２ [ is an antibody residue obtained by removing the sulfhydryl group present in the anti-HER2 antibody, and a is the same as above.] An antibody / multiple drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition comprising one or more antibody / multiple drug conjugates according to any one of claims 1 to 6 and 20 to 23, or a pharmaceutically acceptable salt thereof.

25. An antibody-drug conjugate (ADC) comprising an antibody and a drug, wherein the drug is linked to the antibody via a linker modified with a solubilizing group.

26. The following formula: [chemical 1] [chemical 2] [C3] {In the formula, the succinimidyl group is linked to the S or N atom of the antibody side chain at the location of the asterisk symbol, the phosphonic acid group is linked to an antitumor drug molecule, its analogue, derivative, or derivative of the analogue at the location of the asterisk symbol, and the carboxyl group is linked to an antitumor drug molecule, its analogue, derivative, or derivative of the analogue at the location of the asterisk symbol.} An ADC with a linker represented as such.

27. ​​The following compounds, ZL 3-a -N(-L 1-a -D 1-b )(L 2-e -D 2-ba ), ZL 3-a -N(-L 1-a -D 1-a )(L 2-e -D 2-ba ), ZL 3-a -N(-L 1-a -D 1-b )(L 2-e -D 2-bd ), ZL 3-a -N(-L 1-a -D 1-a )(L 2-e -D 2-bd ), ZL 3-a -N(-L 1-a -D 1-b )(L 2-b -D 2-bf ), and ZL 3-a -N(-L 1-a -D 1-a )(L 2-b -D 2-bf ) A compound selected from the group.

28. A compound of ZL 3-a-N(-L 1-a-D 1-b)(L 2-b-D 2-bf).

Images